[
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_0",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "[Section: General]\nView All Guidelines\nPIDS/IDSA 2023\nGuidelines for\nDiagnosing and\nManaging Acute\nBacterial Arthritis in\nPediatrics\nPublished December 13, 2023\nCharles R Woods, John S Bradley, Archana Chatterjee, Matthew P Kronman, Sandra R Arnol\nd, Joan Robinson, Lawson A Copley, Antonio Arrieta, Sandra L Fowler, Christopher Harriso\nn, Stephen C Eppes, C Buddy Creech, Laura P Stadler, Samir S Shah, Lynnette J Mazur, Mar\nia A Carrillo-Marquez, Coburn H Allen, Valéry Lavergne\nCURRENT\nDownload PDF\nView Citation\nCopy Link\nIDSA\nFoundation\n\nIDWeek\n\nHIVMA\n\n\n\nJournal of the Pediatric Infectious Diseases Society, Volume 13, Issue 1, January 2024, Pag\nes 1–59, https://doi.org/10.1093/jpids/piad089 \nPublished: 06 November 2023",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 0,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_1",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "es 1–59, https://doi.org/10.1093/jpids/piad089 \nPublished: 06 November 2023\nA correction has been published: Journal of the Pediatric Infectious Diseases Society, piae\n065, https://doi.org/10.1093/jpids/piae065 \nPublished: 13 July 2024\nAbstract\nThis clinical practice guideline for the diagnosis and treatment of acute bacterial arthritis (ABA) in\nchildren was developed by a multidisciplinary panel representing the Pediatric Infectious Diseases\nSociety (PIDS) and the Infectious Diseases Society of America (IDSA). This guideline is intended for\nuse by healthcare professionals who care for children with ABA, including specialists in pediatric\ninfectious diseases and orthopedics. The panel’s recommendations for the diagnosis and treatment",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 1,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_2",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "infectious diseases and orthopedics. The panel’s recommendations for the diagnosis and treatment\nof ABA are based upon evidence derived from topic-specific systematic literature reviews.\nSummarized below are the recommendations for the diagnosis and treatment of ABA in children.\nThe panel followed a systematic process used in the development of other IDSA and PIDS clinical\npractice guidelines, which included a standardized methodology for rating the certainty of the\nevidence and strength of recommendation using the GRADE approach (Grading of\nRecommendations Assessment, Development and Evaluation) (see Figure 1 ). A detailed\ndescription of background, methods, evidence summary and rationale that support each\nrecommendation, and knowledge gaps can be found online  in the full text.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 2,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_3",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "recommendation, and knowledge gaps can be found online  in the full text.\nExecutive Summary\nI. What non-invasive diagnostic laboratory tests should be performed in children with suspected\nABA? \nRecommendations:\n1. In children with suspected ABA, we recommend performing blood culture prior to administration\nof antimicrobial therapy (strong recommendation, moderate certainty of evidence).\n2. In children with suspected ABA, we suggest measuring serum C-reactive protein (CRP) on initial\nevaluation (conditional recommendation, very low certainty of evidence). Comment: Serum\nCRP has a low accuracy to establish the diagnosis of ABA given the variability between\npathogens, but in situations where the initial CRP is elevated, this result can serve as the",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 3,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_4",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "pathogens, but in situations where the initial CRP is elevated, this result can serve as the\nbaseline value for sequential monitoring that may guide decision-making regarding duration of\nantimicrobial therapy.\n3. In children with suspected ABA, we suggest against measuring serum procalcitonin (conditional\nrecommendation, low certainty of evidence).\nII. What imaging studies should be performed in children with suspected ABA?\nRecommendations:\n1. In children with suspected ABA, we recommend obtaining plain radiography of the affected joint\nand adjacent bones rather than not performing plain radiographs (strong recommendation,\nmoderate certainty of evidence). Comment: Despite the low sensitivity of plain radiography for",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 4,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_5",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "moderate certainty of evidence). Comment: Despite the low sensitivity of plain radiography for\ndetecting presence of joint effusion or adjacent osteomyelitis on initial presentation, other\nimportant etiologies of acute musculoskeletal pain may be identified.\n2. In children with suspected ABA in whom further imaging studies are required to detect the\npresence of joint effusion, particularly of the hip or the shoulder, we recommend performing\nultrasonography of the affected joint before performing more complex and less widely available\nimaging tests (strong recommendation, moderate certainty of evidence). Comment:\nUltrasonography documenting the absence of joint effusion suggests that ABA is not present.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 5,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_6",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Ultrasonography documenting the absence of joint effusion suggests that ABA is not present.\n3. In children with suspected ABA in whom further imaging studies are required to assess the\nextent of inflammation and infection, including adjacent osteomyelitis and pyomyositis, we\nsuggest performing a magnetic resonance imaging (MRI) study rather than other imaging\nmodalities (e.g., computerized tomography (CT) or bone scintigraphy) (conditional\nrecommendation, very low certainty of evidence). Comment: Children with ABA at high risk of\nadjacent osteomyelitis include those with more than 3 or 4 days of symptoms prior to\npresentation, S. aureus infection, and marked elevation of CRP, but these risk factors require\nfurther validation.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 6,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_7",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "further validation.\nIII. For children with suspected ABA, when should diagnostic invasive procedures be performed\nto collect synovial fluid from affected joint(s) and which diagnostic tests should be performed on\nthe collected joint fluid?\nRecommendations:\n1. In children with suspected ABA, we suggest collecting synovial fluid from the affected joint by\narthrocentesis prior to starting empiric antimicrobial therapy (conditional recommendation,\nmoderate certainty of evidence).\n2. On joint fluid obtained by arthrocentesis, we recommend performing white blood cell count and\ndifferential and routine microbiological cultures (aerobic bacterial culture and Gram stain)\n(strong recommendation, moderate certainty of evidence). Comment: Further diagnostic",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 7,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_8",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "(strong recommendation, moderate certainty of evidence). Comment: Further diagnostic\ntesting may be beneficial in certain situations: 1) molecular testing for specimens from which no\npathogen has been identified by Gram stain and aerobic bacterial culture, (particularly in\npreschool-aged children at higher risk of K. kingae infection); and 2) more extensive scope of\nmicrobial testing, beyond aerobic bacterial culture (e.g., anaerobic, fungal, and/or mycobacterial\ncultures and stains; molecular testing, which may include metagenomic next-generation\nsequencing), in children who are immunocompromised or who have a history of penetrating\ninjury. Additional molecular tests may be performed on synovial samples held in the laboratory,",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 8,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_9",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "injury. Additional molecular tests may be performed on synovial samples held in the laboratory,\nor for additional cultures, a repeat arthrocentesis may be required.\nIV. At the time of presentation, can parenteral antimicrobial agent administration be delayed until\njoint specimens have been obtained?\nRecommendations:\n1. In children with presumed ABA who are ill-appearing or have rapidly progressive infection, we\nrecommend immediately starting empiric antimicrobial therapy (after blood cultures are\nobtained if possible) rather than withholding antibiotics until invasive diagnostic procedures are\nperformed (strong recommendation, moderate certainty of evidence). Comment: Invasive\ndiagnostic procedures should occur as soon as feasible, even if antibiotics have already been\nadministered.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 9,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_10",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "administered.\n2. In children with presumed ABA who do not appear clinically ill, we suggest withholding\nantimicrobial therapy, while under careful observation, until an initial joint aspirate is collected\nfor diagnostic purposes (conditional recommendation, very low certainty of evidence).\nComment: The decision to initiate antimicrobials prior to invasive diagnostic procedures\ndepends on the severity of the clinical presentation, local accessibility to experts and resources\nor, if appropriate, the time required for transport to a higher level of care for additional\ndiagnostic or debridement procedures. The ability to diagnose pathogens by molecular\ndiagnostic techniques suggests that critical information on pathogen identity is now less",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 10,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_11",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "diagnostic techniques suggests that critical information on pathogen identity is now less\ndependent on obtaining bacterial cultures prior to starting antimicrobial therapy.\nV. Which empiric antimicrobial agent(s) should be provided for children with suspected ABA?\nRecommendations:\n1. In children with suspected ABA, we recommend using empiric antimicrobial therapy active\nagainst S. aureus (strong recommendation, moderate certainty of evidence). Comment:\nAntimicrobials with activity against community-acquired MRSA (CA-MRSA) should be\nconsidered based on local susceptibility data and severity of disease. Adding empiric\nantimicrobial coverage for pathogens in addition to coverage for S. aureus may be warranted",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 11,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_12",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "antimicrobial coverage for pathogens in addition to coverage for S. aureus may be warranted\nwhen other pathogens are suspected based on relevant aspects of immunization, exposure\nhistory, clinical presentation, or physical examination.\n2. In infants and preschool aged children (6 to 48 months of age) with suspected ABA, we suggest\nselecting empiric therapy to include activity against K. kingae rather than only targeting S.\naureus (conditional recommendation, very low certainty of evidence). Comment: With K. kingae\nreported as the most frequent pathogen in this age group in recent studies, additional therapy is\nsuggested if empiric therapy used for S. aureus is not active against K. kingae.\nVI. When should advanced imaging be performed and/or invasive procedures be repeated in the",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 12,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_13",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "VI. When should advanced imaging be performed and/or invasive procedures be repeated in the\nmanagement of presumed or confirmed bacterial arthritis in children?\nRecommendations:\n1. In children with presumed or confirmed ABA who demonstrate a poor clinical and laboratory\nresponse within 48-96 hours (continued fever, persistent bacteremia and/or rising CRP) after\ninitial invasive procedures (open or arthroscopic) and initiation of appropriate antimicrobial\ntherapy, we suggest performing MRI if not previously obtained (conditional recommendation,\nvery low certainty of evidence). Comment: MRI is performed to evaluate for adjacent AHO,\npyomyositis, or abscess as potential indications of ineffective source control to provide a basis",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 13,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_14",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "pyomyositis, or abscess as potential indications of ineffective source control to provide a basis\nto determine whether additional invasive procedures should be considered.\n2. In children with presumed or confirmed primary ABA who demonstrate a poor clinical and\nlaboratory response within 48-96 hours (continued fever, persistent bacteremia and/or rising\nCRP) after initial invasive procedures, and evidence to suggest persisting foci of infection\n(ineffective source control), we suggest additional invasive procedures to ensure adequate\nsource control (conditional recommendation, very low certainty of evidence). Comment: When\nABA is associated with adjacent osteomyelitis, management should follow the osteomyelitis\nguideline.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 14,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_15",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "guideline.\nVII. In children with presumed or confirmed ABA who require a surgical procedure, should\nsurgically administered (intra-articular) antimicrobial agents be routinely used in addition to\nsystemic antimicrobial therapy?\nRecommendation:\nIn children with presumed or confirmed ABA who require a surgical procedure, we recommend\nagainst the routine use of intra-articular antimicrobial agents (strong recommendation, very low\ncertainty of evidence). Comment: This recommendation places a high value on avoiding\nunnecessary harms and costs associated with this intervention.\nVIII. What is the role for adjuvant corticosteroids in children with presumed or confirmed ABA?\nRecommendation:\nIn children with presumed or confirmed ABA, we suggest against using adjunctive corticosteroid",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 15,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_16",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "In children with presumed or confirmed ABA, we suggest against using adjunctive corticosteroid\ntherapy (conditional recommendation, very low certainty of evidence). Comment: This\nrecommendation places a high value on avoiding potential serious harms despite providing potential\nminimal beneficial effects.\nIX. In children with presumed or confirmed ABA who respond to initial empiric therapy, how\nshould selection of agents be made for definitive parenteral and oral therapy? (See Section XI for\ndiscussion of oral versus parenteral therapy.)\nRecommendations:\n1. In children with confirmed ABA, selection of a definitive antimicrobial regimen should be based\non the principles of selecting an effective agent against the identified pathogen, with the",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 16,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_17",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "on the principles of selecting an effective agent against the identified pathogen, with the\nnarrowest spectrum, lowest adverse effect profile and most favorable patient tolerability (Good\nPractice Statement).\n2. In children with presumed ABA with no pathogen identified, selection of a definitive\nantimicrobial regimen should be based on the principles of selecting an effective agent based\non the most likely causative organism(s), with an antimicrobial spectrum comparable to that of\nempiric therapy to which the patient initially responded, with the lowest adverse effect profile\nand most favorable patient tolerability (Good Practice Statement).\nX. In children with presumed or confirmed ABA, what clinical and laboratory criteria should be\nused to assess the response to therapy?",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 17,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_18",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "used to assess the response to therapy?\nRecommendation:\nIn children with presumed or confirmed ABA receiving antimicrobial therapy with or without surgical\nintervention, in addition to serial clinical evaluation, we suggest performing CRP at initial evaluation\nfollowed by sequential monitoring of CRP to assess response to therapy, rather than relying solely\non clinical evaluation (conditional recommendation, low certainty of evidence). Comment: Serial\nclinical examinations that assess the febrile response, pain and musculoskeletal function remain the\nprimary means of monitoring response to treatment.\nXI. Should hospitalized children with presumed or confirmed ABA who are responding well to\ninitial intravenous therapy, no longer requiring skilled nursing care and deemed ready for",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 18,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_19",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "initial intravenous therapy, no longer requiring skilled nursing care and deemed ready for\nhospital discharge be transitioned to a) oral therapy or b) outpatient parenteral antibiotic therapy\n(OPAT)?\nRecommendations:\n1. For children with presumed or confirmed ABA who respond to initial intravenous antibiotic\ntherapy, we recommend transition to an oral antibiotic regimen rather than OPAT when an\nappropriate, well-tolerated oral antibiotic option is available, and that antibiotic is active against\nthe confirmed or presumed pathogen(s) (strong recommendation; low certainty of evidence).\nComment: This recommendation places a high value on avoidance of harms and costs, as well\nas on considerations of patient’s values and preferences, feasibility, acceptability, and equity.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 19,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_20",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "as on considerations of patient’s values and preferences, feasibility, acceptability, and equity.\n2. For children with presumed or confirmed ABA who respond to initial parenteral antibiotic\ntherapy but for whom oral antimicrobial therapy is not feasible, we suggest transition from the\nacute-care hospital to OPAT, rather than remaining in the hospital for the total duration of\ntherapy (conditional recommendation, very low certainty of evidence). Comment: This\nrecommendation places a high value on avoiding harms and costs associated with unnecessary\nand prolonged hospital stay. The decision to implement this recommendation and the selection\nof the type of OPAT (home, intermediate care facility, clinic) may be influenced by availability of\nlocal resources.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 20,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_21",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "local resources.\nXII. For children with presumed or confirmed ABA, what duration of therapy with antimicrobial\nagents is recommended?\nRecommendations:\n1. In children with confirmed primary ABA without adjacent osteomyelitis with rapid clinical\nimprovement and consistent, progressive decrease in CRP by the end of the first week of\ntreatment, we suggest treating for a total duration of antimicrobial therapy (parenteral plus oral)\nas short as 10 to 14 days for common pathogens (S. aureus, S. pyogenes, S. pneumoniae, and\nH. influenzae type b), rather than for longer courses of 21 to 28 days (conditional\nrecommendation, low certainty of evidence). Comment: For children with slower clinical\nresponse, inadequate source control, or persistently elevated CRP, courses of therapy of 21 to",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 21,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_22",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "response, inadequate source control, or persistently elevated CRP, courses of therapy of 21 to\n28 days may be preferred. Such longer durations may be more commonly required when\ninfection is caused by pathogens with relatively less antibiotic susceptibility or greater\nvirulence, particularly enteric or non-fermenting Gram-negative bacilli and some S. aureus\nstrains (e.g., USA300 or similarly virulent strains, whether MSSA or MRSA). Children with ABA\nwith adjacent osteomyelitis should be treated according to the osteomyelitis guideline.\n2. In children with presumed primary ABA without adjacent osteomyelitis with rapid clinical\nimprovement and consistent, progressive decrease in CRP by the end of the first week of",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 22,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_23",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "improvement and consistent, progressive decrease in CRP by the end of the first week of\ntreatment, we suggest treating for a total duration of antimicrobial therapy (parenteral plus oral)\nas short as 10 to 14 days rather than for longer courses (conditional recommendation, very low\ncertainty of evidence). Comment: For children with slower clinical and laboratory responses,\nlonger courses of therapy may be preferred, as noted above.\nXIII. Are follow-up imaging studies needed to assess the response to and duration of therapy for\nprimary ABA?\nRecommendation:\nIn children with primary ABA with expected improvement during medical management with or\nwithout surgical intervention, associated with full clinical recovery, we suggest against routine",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 23,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_24",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "without surgical intervention, associated with full clinical recovery, we suggest against routine\nfollow-up imaging (conditional recommendation, very low certainty of evidence). Comment: In\nsituations where there is any clinical concern for previously undetected adjacent osteomyelitis, a\nplain film may be considered just prior to cessation of antimicrobial therapy if osteomyelitis was not\nreasonably excluded by advanced imaging studies (e.g., MRI) earlier in the course.\nXIV. For children with presumed or confirmed ABA who do not respond to therapy, or relapse\nfollowing completion of therapy, which interventions are appropriate to optimize outcomes?\nRecommendation:\nFor children with presumed or confirmed ABA either experiencing primary treatment failure, or early\nor late recurrence:",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 24,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_25",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "or late recurrence:\na. Clinicians should assess adequacy of the antimicrobial regimen (spectrum of activity, dosage, and\nantibiotic exposure at the site of infection, adherence) and of joint debridement and irrigation before\ndeciding on the need to broaden the spectrum or to restart antimicrobials (Good Practice\nStatement).\nb. Clinicians should assess the need for additional diagnostic evaluation for possible adjacent\nosteomyelitis, along with any need for surgical intervention for therapeutic and/or diagnostic\npurposes (Good Practice Statement). Comment: The initial diagnosis of primary ABA may need to\nbe reconsidered.\nXV. How long do children with primary ABA require follow-up examinations to address sequelae\n(e.g., joint contractures, potential growth arrest) due to the infection?",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 25,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_26",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "(e.g., joint contractures, potential growth arrest) due to the infection?\nRecommendation:\nIn children with primary ABA, we suggest close follow-up by providers with expertise in\nmanagement of musculoskeletal infections until the completion of antibiotic therapy and return of\nfunction in the infected joint (conditional recommendation, very low certainty of evidence).\nComment: For primary ABA that responds promptly to treatment, follow-up is not routinely required\nbeyond 2-3 weeks from the start of treatment. For children with ABA with adjacent osteomyelitis,\nsee 2021 PIDS/IDSA Guideline on Diagnosis and Management of Acute Hematogenous\nOsteomyelitis in Pediatrics.\nIntroduction\nAcute bacterial arthritis (ABA) is the result of bacterial pathogens entering a joint in the developing",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 26,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_27",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "infant or child, most often in the context of bacteremia. Many terms have been used to describe this\ninfection including “suppurative” [1-3], “purulent” [4-6], and “pyogenic” [7-9] arthritis. The panel\nelected to use ABA to be more precise regarding the scope of diagnosis and management outlined\nin this guideline (see Table 1  for definitions). These guidelines use the term “suspected” ABA for\npatients prior to the confirmation of the diagnosis by traditional microbiologic methods and/or\nmolecular studies, after which the term “confirmed” is used. The term “presumed” is employed\nwhen all testing to identify a bacterial etiology has been negative, but the patient is treated as\nthough they have ABA. Finally, the term “excluded” is used when this diagnosis is considered\nunlikely.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 27,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_28",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "unlikely.\nThere are over 200 joints in the human body, with a great diversity in structure and function [10].\nThe reported incidence of ABA in children from resource-rich Western countries is approximately 2-\n10/100,000 children annually, but varies by pathogen, age, immunization status, joint involved, sex,\nand race/ethnicity [11-13]. Some differences in the epidemiology of pediatric ABA have been\ndocumented in resource-rich countries in Asia, with no clear basis for observed differences [14, 15].\nABA in children most often involves the highly flexible diarthrodial joints that contain synovial fluid,\ntypically the hip (in approximately 25-40% of reported arthritis), knee (13- 56%), ankle (9-23%),",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 28,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_29",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "typically the hip (in approximately 25-40% of reported arthritis), knee (13- 56%), ankle (9-23%),\nelbow (5-20%), and shoulder (4-10%) [11, 16-18]. Fibrocartilaginous joints that do not contain\nsynovial fluid are less commonly infected and often are more difficult to diagnose clinically\n(intervertebral joints [e.g., discitis], pubic symphysis joints and the sacroiliac joints) [19-22].\nPathogens identified in ABA are often age-specific, reflecting maturation of host immunity and\nexposures to microorganisms from individuals, pets, animals, and the environment. Most commonly,\nbacteremia in an otherwise healthy child leads to translocation of a pathogen into the joint synovial\nfluid, despite the lack of a recognized preceding risk factor (“primary arthritis”). Less commonly,",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 29,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_30",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "fluid, despite the lack of a recognized preceding risk factor (“primary arthritis”). Less commonly,\norganisms gain access to the joint space by direct inoculation from trauma (accidental or\niatrogenic). Recent data suggest changes in the pathogens detected over the past several decades,\nparticularly with decreases in vaccine-preventable infections caused by Streptococcus pneumoniae\nand Haemophilus influenzae type b (Hib) and increases in methicillin-resistant Staphylococcus\naureus (MRSA) [9, 17, 23]. S. aureus is the most commonly identified pathogen among highly\nimmunized populations of children in reports that relied on traditional bacterial culture-based\ndiagnostic techniques [16, 17, 24]. Of note, the reported incidence of certain pathogens has",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 30,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_31",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "diagnostic techniques [16, 17, 24]. Of note, the reported incidence of certain pathogens has\nincreased substantially over the past decade. This is likely the result of enhanced methods used to\ndetect pathogens, including molecular techniques, that have demonstrated a higher yield of Kingella\nkingae [25-29]. S. pyogenes continues to cause a small portion of ABA cases, similar to S.\npneumoniae [16, 23, 25, 28, 29]. Although K. kingae is reported as the most common pathogen\ndetected in recent studies of young children, S. aureus appears to be associated with the greatest\nrisk of long-term complications of infection [30, 31].\nThe clinical presentation is dependent on the pathogen, the age of the child, and the joint involved.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 31,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_32",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Many pathogens incite a brisk inflammatory response following infection of the joint space. This\nresponse can include prominent local signs (e.g., pain, swelling, erythema) and symptoms of\ninfection in the involved joint, often accompanied by systemic signs/symptoms and laboratory\nmarkers of inflammation that are characteristic of serious invasive bacterial infection. Tenderness of\nthe joint and associated tissues usually increases with movement of the joint (or in the case of\nfibrocartilaginous non-mobile joints, particularly in infants with sacroiliitis, pain with weight-bearing\nor sitting). Due to the deeper anatomic location of some infected joints, swelling and erythema may\nnot be clinically detected. However, for less virulent bacterial pathogens, the diagnosis of ABA can",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 32,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_33",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "be difficult, as the degree of inflammation in the joint may only be mild to moderate, with a\ncorresponding lack of significant systemic symptoms, and perhaps evidenced by non-use of a limb\nor holding the involved joint in a position of comfort (i.e., pseudo-paralysis). Laboratory markers of\ninflammation may be minimally elevated in these cases of ABA, adding to the difficulty of making the\ncorrect diagnosis.\nAlthough prospective, controlled studies reporting a consistent clinical and laboratory dataset\ncollected from infected children have not been published, multiple retrospective reviews suggest\ndifferences in the clinical and laboratory presentation, clinical course, and outcomes between the",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 33,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_34",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "differences in the clinical and laboratory presentation, clinical course, and outcomes between the\ntwo most common bacterial pathogens, S. aureus and K. kingae [16, 31, 32]. A history of relatively\nacute onset of symptoms and more rapid progression of joint pain over 24-48 hours is more\ncharacteristic of S. aureus infection and is consistent across all age groups. In contrast, the onset of\nsymptoms for K. kingae infection in infants and preschool-aged children, the most common age\ngroups for this pathogen, appears in many cases to be more indolent, less well-defined, with less\nsevere symptoms and often without the rapid progression to severe pain and systemic symptoms\nusually seen with S. aureus. In addition, most children with K. kingae infection are young (infants or",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 34,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_35",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "preschool-aged), with limited ability to share specific localizing symptoms [32, 33].\nABA occurring with associated contiguous osteomyelitis, particularly with S. aureus, is common.\nMetastatic sites of infection (distal or contiguous), appearing simultaneously with ABA are\nuncommon despite a presumed or confirmed preceding bacteremia. Notably, there is a lack of\nassociation of S. aureus ABA with endocarditis. Rare complications of K. kingae infection beyond\njoint disease have been described, including endocarditis [32]. Multiple concurrently infected joints\nare uncommon in ABA caused by S. aureus or K. kingae. Less common ABA pathogens, also\nassociated with bacteremia, such as Streptobacillus moniliformis (Rat Bite Fever), Fusobacterium",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 35,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_36",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "associated with bacteremia, such as Streptobacillus moniliformis (Rat Bite Fever), Fusobacterium\nnecrophorum (Lemierre’s syndrome) and Neisseria gonorrhoeae (gonorrhea) may be associated\nwith concurrent infection of multiple joints as well as other distinct anatomic sites of infection.\nMany conditions other than ABA (both infectious and non-infectious) may be associated with\ninflammation of joints, often accompanied by systemic symptoms. These include various\nnonpyogenic bacterial infection (e.g., Lyme arthritis, mycobacterial), non-bacterial infections (viral,\nfungal), as well as post-infectious, autoinflammatory, autoimmune (juvenile idiopathic arthritis [JIA]),\nhematologic, oncologic, chemical, and traumatic arthritis. Infection adjacent to a joint may also",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 36,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_37",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "hematologic, oncologic, chemical, and traumatic arthritis. Infection adjacent to a joint may also\ncause inflammation in the joint or a perception of inflammation in the joint [13, 24, 34, 35].\nThe term “culture-negative” ABA has been used for many years to label clinical presentations\nconsistent with ABA for which bacterial cultures of synovial fluid and blood are negative. Molecular\ntesting methods developed over the past 15 years now allow identification of causative microbes in\na high proportion of cases where cultures are negative, and the frequency of pathogen identification\nin such cases is likely to increase over time. The panel suggests the use of “presumed ABA with no\nidentified pathogen” for culture-negative cases with clinical signs of arthritis, elevated white blood",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 37,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_38",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "cell count with neutrophil predominance in synovial fluid, and a clinical course consistent with ABA\n(i.e., temporal improvement and resolution after drainage and initiation of antimicrobial therapy).\nGuideline Focus\nThis clinical practice guideline focuses on ABA in otherwise healthy children 1 month to 17 years old\nin North America. Uncommon bacterial causes of ABA are not discussed in this document, as\nadequate, controlled data are not available to support recommendations. Treatment\nrecommendations for these uncommon pathogens may be found in other organism-specific or\ndisease-specific texts and publications. The clinical presentations of osteomyelitis and ABA can\noverlap substantially in children [36]; these entities may occur concurrently. For additional",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 38,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_39",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "overlap substantially in children [36]; these entities may occur concurrently. For additional\nrecommendations on acute hematogenous osteomyelitis, a companion guideline was recently\npublished [37]. Neonates are excluded due to important differences in bacterial pathogens [38],\ncomplications of infection, immunologic immaturity, as well as lack of adequate antimicrobial\npharmacokinetic data for neonates of various gestational and postnatal ages.\nMethodology \nClinical Practice Guidelines\nClinical Practice Guidelines are statements that include recommendations intended to optimize\npatient care by assisting practitioners and patients in making shared decisions about appropriate\nhealth care for specific clinical circumstances. These are informed by a systematic review of",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 39,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_40",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "health care for specific clinical circumstances. These are informed by a systematic review of\nevidence and an assessment of the benefits and harms of alternative care options. The “IDSA\nHandbook on Clinical Practice Guideline Development” provides more detailed information on the\nprocesses followed throughout the development of this guideline [39].\nGuideline Panel Composition\nThe Chair of the guideline panel was selected by the leadership of the Pediatric Infectious Diseases\nSociety (PIDS) in conjunction with IDSA leadership. (C.W.). Two co-chairs were selected by the chair\nto assist in leading the panel (A.C. and J.B). A total of 20 panelists comprised the full panel. The\npanel included physicians with expertise in pediatric infectious diseases, pediatric hospital",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 40,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_41",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "panel included physicians with expertise in pediatric infectious diseases, pediatric hospital\nmedicine, general pediatrics, pediatric emergency medicine, pediatric orthopedic surgery, and\nepidemiology. Panelists also were diverse in gender, geographic distribution, and years of clinical\nexperience. A guideline methodologist (V.L.) oversaw all methodological aspects of the guideline\ndevelopment and identified and summarized the scientific evidence using the “PICO” format\n(Patient/Population [P]; Intervention/Indicator [I]; Comparator/Control [C]; Outcome [O]) questions.\nIDSA staff (G.D.) oversaw all administrative and logistical issues related to the guideline panel. Panel\nmembers writing this Guideline also co-authored the Pediatric Osteomyelitis Guideline [37].",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 41,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_42",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "members writing this Guideline also co-authored the Pediatric Osteomyelitis Guideline [37].\nDisclosure and Management of Potential Conflict of Interest\nAll members of the expert panel complied with the IDSA policy on conflict of interest (COI), which\nrequires disclosure of any financial, intellectual, or other interest that might be construed as\nconstituting an actual, potential, or apparent conflict. Evaluation of such relationships as potential\nconflicts of interest was determined by a review process which included assessment by the\nStandards and Practice Guideline Committee (SPGC) Chair, the SPGC liaison to the Guideline panel\nand the Board of Directors liaison to the SPGC, and if necessary, the Conflicts of Interests Task",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 42,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_43",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "and the Board of Directors liaison to the SPGC, and if necessary, the Conflicts of Interests Task\nForce of the Board. This assessment of disclosed relationships for possible COI was based on the\nrelative weight of the financial relationship (i.e., monetary amount) and the relevance of the\nrelationship (i.e., the degree to which an independent observer might reasonably interpret an\nassociation as related to the topic or recommendation of consideration). The reader of these\nguidelines should be mindful of this when the list of disclosures is reviewed. See the Notes section\nat the end of this guideline for the disclosures reported to IDSA.\nClinical Questions and Evidence Review\nThe clinical practice guideline development started in 2011. A first iteration was nearly completed by",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 43,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_44",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "2017 at which point a decision was made to revisit the methodology to fulfill the National Academy\nof Medicine standards on trustworthy guidelines [40]. In line with these standards, the GRADE\napproach for the assessment of the certainty of evidence and strength of recommendation was\nintegrated in the process. Consequently, a new set of clinical questions was developed and\napproved. All outcomes of interest were identified a priori and explicitly rated for their relative\nimportance for decision making. Each clinical question was assigned to a subgroup of panelists.\nThe Health Sciences Library System at the University of Pittsburgh designed the literature searches\nand MeSH terms for Ovid Medline, and the William H. Welch Medical Library of Johns Hopkins",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 44,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_45",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "and MeSH terms for Ovid Medline, and the William H. Welch Medical Library of Johns Hopkins\nUniversity designed the literature searches and MeSH terms for EMBASE and Cochrane Reviews.\nSearches were limited to studies published in English and restricted to year of publication (from\nJanuary 2005 to January 2022). The initial formal literature search was performed in August 2017\nand updates of the review of the literature were conducted again in May 2019, February 2021, and\nJanuary 2022. To supplement the electronic searches, the panelists had the option of manually\nsearching journals, conference proceedings’ reference lists, and regulatory agency websites for\nrelevant articles through 2022.\nA subgroup of panelists (A.C.A., S.F., C.J.H., M.P.K., and J.R.) screened titles and abstracts of all",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 45,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_46",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "identified citations. All potentially relevant citations were subjected to a full-text review, using\npredefined inclusion and exclusion criteria that were tailored to meet the specific population,\nintervention, and comparator of each clinical question. Abstracts and conference proceedings,\nletters to the editor, editorials, review articles, and unpublished data were excluded. A minimum of\n10 reported confirmed ABA cases were required for published manuscripts to be included in the\npooled analysis. The results of the literature search were supervised and thoroughly reviewed by\nthe guideline methodologist for the final selection of the relevant articles. Panel members reviewed\nthe final set of included articles for accuracy. Once the articles were selected, the guideline",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 46,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_47",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "the final set of included articles for accuracy. Once the articles were selected, the guideline\nmethodologist in conjunction with panelists extracted the data for surrogates and predetermined\npatient-important outcomes. Where applicable, data were pooled using random effects model (fixed\neffects model for pooling of rates) using RevMan [41].\nThe guideline methodologist prepared the evidence summaries for each question and assessed the\nrisk of bias and the certainty of evidence. The risk of bias was assessed by using the Cochrane risk\nof bias tool for randomized controlled trials [42], the ROBINS-I [43] for observational studies and the\nQUADAS-2 tool for diagnostic test accuracy studies [44]. The certainty in the evidence was",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 47,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_48",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "QUADAS-2 tool for diagnostic test accuracy studies [44]. The certainty in the evidence was\ndetermined for each critical and important outcome, and then for each recommendation using the\nGRADE approach for rating the confidence in the evidence [45, 46]. The summaries of evidence\nwere developed in the GRADEpro Guideline Development Tool [47] and reviewed by panel members\nresponsible for each PICO and edited as appropriate. The final evidence summaries were presented\nto the whole panel for deliberation and drafting of recommendations. Literature search strategies,\nPRISMA flow diagram detailing the search results, evidence profiles tables, and additional data, such\nas meta-analysis results when appropriate, can be found in the Supplementary Material .",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 48,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_49",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "as meta-analysis results when appropriate, can be found in the Supplementary Material .\nRanking of the outcomes by importance for decision-making was determined by consensus for\neach PICO question. In situations where a PICO question compared the use of one specific antibiotic\nregimen to another (e.g., comparing spectrum of activity, route of administration, or duration of\ntherapy) and the beneficial effects of the two regimens were similar, then the undesirable outcomes\ncould be ranked as critical for decision-making, but several other considerations might have also\nbeen taken into account, such as antimicrobial stewardship issues for appropriate use, tolerability,\nas well as costs.\nDevelopment of Clinical Recommendations",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 49,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_50",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "as well as costs.\nDevelopment of Clinical Recommendations\nAll recommendations were labeled as either “strong” or “conditional” according to the GRADE\napproach [39]. The words “we recommend” indicate strong recommendations and “we suggest”\nindicate conditional recommendations. Figure 1  provides the suggested interpretation of strong\nand conditional recommendations for patients, clinicians, and healthcare policymakers. For\nrecommendations where the comparator treatment or tests are not formally stated, the comparison\nof interest is implicitly referred to as “not using the intervention” (not using either a specific\ntreatment or a diagnostic test).\nHigh certainty of evidence was lacking for many recommendations. According to GRADE guidance",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 50,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_51",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "High certainty of evidence was lacking for many recommendations. According to GRADE guidance\non discordant recommendations, strong recommendations in the setting of lower certainty of\nevidence were only assigned when the panelists believed they conformed to one of the five\naccepted paradigmatic conditions [48]. For recommendations pertaining to good practice\nstatements, appropriate identification and wording choices were followed according to the GRADE\nworking group [49]. A good practice statement represents a message perceived by the guideline\npanel as necessary in regard to actual current health care practice, is supported by a large body of\nindirect evidence difficult to summarize and indicates that implementing this recommendation would",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 51,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_52",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "indirect evidence difficult to summarize and indicates that implementing this recommendation would\nclearly result in large net positive consequences. “Research Needs” were noted for\nrecommendations as deemed appropriate by the panel.\nFinal presentation of evidence summaries and the development of the recommendations was\npartially performed by a face-to-face meeting of the whole expert panel in San Francisco, CA in\nOctober 2018, which was followed by a series of video teleconferences by the whole panel, or by\nspecific members of the panel for completion (from November 2018 to May 2023). All members of\nthe panel participated in the preparation of the draft guideline and approved the recommendations.\nRevision Process",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 52,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_53",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Revision Process\nFeedback was obtained from three external peer expert reviewers, the Pediatric Orthopaedic\nSociety of North America (POSNA), the IDSA Standards and Practice Guidelines Committee (SPGC)\nand Board of Directors and the PIDS Board of Directors. The guideline also was reviewed by\nappropriate sections and committees of the American Academy of Pediatrics.\nRevision for Currency Schedule\nApproximately every two years and more frequently if needed, IDSA and PIDS will determine the\nneed for revisions to the guideline by an examination of the current literature and the likelihood that\nany new data will have an impact on the recommendations. Any revision to the guideline will be\nsubmitted for review and approval to the appropriate Committees and Boards of IDSA and PIDS.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 53,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_54",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "submitted for review and approval to the appropriate Committees and Boards of IDSA and PIDS.\nRecommendations for the Diagnosis and\nManagement of ABA in Pediatrics\nI. What non-invasive diagnostic laboratory tests should be performed in children with suspected\nABA?\nRecommendations:\n1. In children with suspected ABA, we recommend performing blood culture prior to administration\nof antimicrobial therapy (strong recommendation, moderate certainty of evidence).\n2. In children with suspected ABA, we suggest measuring serum C-reactive protein (CRP) on initial\nevaluation (conditional recommendation, very low certainty of evidence) Comment: Serum CRP\nhas a low accuracy to establish the diagnosis of ABA given the variability between pathogens,",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 54,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_55",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "has a low accuracy to establish the diagnosis of ABA given the variability between pathogens,\nbut in situations where the initial CRP is elevated, this result can serve as the baseline value for\nsequential monitoring that may guide decision-making regarding duration of antimicrobial\ntherapy.\n3. In children with suspected ABA, we suggest against measuring serum procalcitonin (conditional\nrecommendation, low certainty of evidence).\nBlood Culture\nSummary of Evidence\nBlood culture is recommended for children with suspected ABA to aid in identification of the etiology\nof infection. Our systematic review of the literature identified one meta-analysis along with several\nrecent case series that provided data on the yield of blood culture in pediatric ABA. This study",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 55,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_56",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "recent case series that provided data on the yield of blood culture in pediatric ABA. This study\nreviewed the literature up to 2014 and reported a pooled rate of blood culture positivity in children\nwith ABA of 23.9% (95% CI: 8.4 to 44.2%) from four European studies plus their local data [50].\nOur updated systematic review included 22 studies reporting the positivity rate of blood culture in\npediatric ABA from 2005 to 2022. These studies collectively included 2,172 children with presumed\nor confirmed ABA (ranging from 18 to 239 patients per study) [12, 24, 28, 50-68]. In our analysis, we\naddressed two cohorts of patients who were analyzed and reported separately. The first cohort\nincluded patients with presumed or confirmed primary ABA. The second cohort included patients",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 56,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_57",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "included patients with presumed or confirmed primary ABA. The second cohort included patients\nfrom studies where it was impossible to separate those with primary ABA from those with adjacent\nosteomyelitis (see Table 1  for definitions). Patients in these studies who could definitively be\nidentified as having ABA with adjacent osteomyelitis were excluded from these analyses [37].\nOur systematic review showed that for children with presumed or confirmed primary ABA, the\npooled blood culture positivity rate among the 15 included studies [12, 24, 50-59, 66-68] was 20.0%\n(95%CI: 13.7 to 26.2%) and the median rate of blood culture positivity was 21.7% (ranging from\n6.2% to 53.8%) (see Figure 2). The range of blood culture positivity rates varied greatly between",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 57,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_58",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "6.2% to 53.8%) (see Figure 2). The range of blood culture positivity rates varied greatly between\nstudies, mainly due to heterogeneity of included patients (presumed vs confirmed ABA) and in\ndiagnostic testing methods. For cohorts including both children with primary ABA and ABA with\nadjacent osteomyelitis, the pooled blood culture positivity rate among the 7 studies [28, 60-65] was\n27.0% (95%CI: 21.0 to 33.0%) and the median rate was 21.5% (ranging from 15.5 to 37.0%) (see\nSupplementary Material Figure I ).\nPathogen identification in ABA is optimized when cultures of multiple sites, including blood, synovial\nfluid, and bone (if adjacent osteomyelitis is present) are evaluated. A blood culture adds minimal",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 58,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_59",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "fluid, and bone (if adjacent osteomyelitis is present) are evaluated. A blood culture adds minimal\ncost to care in these patients and can often be collected during first venipuncture and/or placement\nof peripheral intravenous (IV) access. Patients with bacteremia and ABA frequently have positive\nsynovial fluid cultures [62]; however, in case series of ABA there are a few patients with a positive\nblood culture but negative synovial fluid culture, particularly if antibiotics were given before synovial\nfluid collection [53-55, 57, 64, 69, 70]. Obtaining a blood culture does not eliminate the need for\nobtaining a synovial fluid sample as the latter is more likely to be positive than the blood culture.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 59,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_60",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Synovial fluid specimens are usually collected early in hospitalization at the time of diagnostic\nand/or therapeutic joint aspiration or surgical debridement and irrigation. However, a blood culture\nmay be positive earlier than cultures from other sites; susceptibilities may provide information for\nfocusing antibiotic therapy. Utilization of rapid molecular assays for identification of MRSA for\npositive blood cultures or fluorescent in situ hybridization may expedite definitive antibiotic therapy.\nIdentification of a pathogen by blood culture can help confirm the diagnosis of ABA given that other\nconditions, including transient nonbacterial synovitis, reactive arthritis, and rheumatologic\nconditions can manifest similarly. Pathogen identification may reduce the need for multiple",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 60,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_61",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "conditions can manifest similarly. Pathogen identification may reduce the need for multiple\nantibiotics in areas of high prevalence of resistance (MRSA) or patients with risk factors for\npathogens other than typical Gram-positive etiologies (e.g., young children at risk for K. kingae\ninfection or children with hemoglobinopathies who have increased risk for infection with Salmonella\nspp).\nIn otherwise healthy children being evaluated for ABA, false positive blood cultures due to\ncontamination with skin or oral flora, occur, but with rates generally <5% [29, 51, 58, 70]. Coagulase\nnegative staphylococci, diphtheroids, viridans group streptococci and Cutibacterium acnes are most\noften contaminants in the absence of prosthetic joint material. Consultation with a pediatric",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 61,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_62",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "often contaminants in the absence of prosthetic joint material. Consultation with a pediatric\ninfectious disease specialist can assist in determination as to whether other culture results\nrepresent contamination.\nIn circumstances where obtaining blood for culture cannot readily be accomplished and there are\nconcerns for possible associated sepsis or rapid progression of infection, initiation of antimicrobial\ntherapy should not be delayed [71]. (See Question IV).\nRationale for Recommendation\nBlood cultures performed before antibiotic administration in children with suspected ABA will\nidentify the etiology of infection in about 20% of cases and may provide the only positive diagnostic\nresult. A positive blood culture does not obviate the need for an invasive diagnostic procedure with",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 62,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_63",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "additional cultures, as synovial fluid needle aspiration or joint irrigation is often therapeutic. Blood\ncultures have relatively low cost, and the primary undesirable effects are those associated with\nvenipuncture. False positive results due to contamination are often readily discernible and do not\ngenerate undesirable consequences once the organism is speciated. The panel made a strong\nrecommendation for the use of blood cultures as part of the initial evaluation for potential ABA\nbased on benefits that clearly outweigh risks.\nC-reactive Protein (CRP)\nSummary of Evidence\nABA is suspected in children presenting with an acutely painful and/or swollen joint. Blood markers\nof systemic inflammation, such as CRP, can aid in distinguishing ABA (particularly caused by S.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 63,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_64",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "of systemic inflammation, such as CRP, can aid in distinguishing ABA (particularly caused by S.\naureus) from transient nonbacterial synovitis, but not necessarily other inflammatory conditions\nsuch as reactive arthritis, acute rheumatic fever (ARF), or JIA, all of which may also be associated\nwith an elevated CRP. The serum CRP is usually, but not always, elevated at the time of presentation\nof children with ABA [72-77].\nCRP alone, or when used in combination with clinical history and examination (weight bearing\nstatus, fever, duration of symptoms) has insufficient specificity or sensitivity to confirm or rule-out\nthe diagnosis of ABA. However, it is useful to obtain a CRP at the time of clinical presentation",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 64,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_65",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "the diagnosis of ABA. However, it is useful to obtain a CRP at the time of clinical presentation\nbecause, if elevated, it can be used to monitor appropriate response to management.\nOur systematic review of the literature identified three prospective cohort studies and one\nretrospective case-control study assessing the diagnostic test accuracy of CRP in children\npresenting with various signs and symptoms (fever, limp, swelling, pseudo-paralysis, or failure to\nbear weight) suspicious for musculoskeletal infections from 2005 to 2022 [78-81]. Collectively,\nthese studies suggested very limited value for CRP as a confirmatory diagnostic test for ABA in\nchildren. Numeric cut-off levels varied between studies and were often not set a priori, and none",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 65,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_66",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "children. Numeric cut-off levels varied between studies and were often not set a priori, and none\nestablished a definitive CRP value above which the diagnosis of ABA should be suspected or below\nwhich it could be excluded. All four included studies had other significant methodological limitations\n(Table 2 ).\nA recent prospective study evaluated the predictive value of CRP in patients presenting with\nsuspected musculoskeletal infection, “ABA, osteomyelitis, and pyomyositis.” This study identified, a\nposteriori, the optimal cut-off from the cohort of included patients and may have resulted in an\noverestimation of diagnostic test accuracy. This cut-off value of 23.8 mg/L (2.38 md/dL) has not\nsubsequently been validated in a prospective study. The study was also limited by a small sample",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 66,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_67",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "subsequently been validated in a prospective study. The study was also limited by a small sample\nsize and lack of any documented microbiology results [80]. Another prospective cohort\nstudy evaluated two CRP cutoff levels (100 and 500 mg/L [10 and 50 mg/dL]) in children with\ncompatible clinical, culture, and imaging manifestations of bone and joint infections, but was limited\nby small sample size [78]. A third study prospectively evaluated patients presenting to the\nEmergency Department with non-traumatic limp or pseudo-paralysis, but inclusion required\nabnormal ESR or CRP (>10 mm/hr and >100 mg/L respectively) [79]. Thirteen of 64 (20%) of\nchildren in this study had confirmed infections caused by S. aureus; specific testing for K. kingae",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 67,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_68",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "children in this study had confirmed infections caused by S. aureus; specific testing for K. kingae\nwas not performed. No evaluation of the children without elevated markers was reported. An\nadditional study reported on the accuracy of CRP in children with definite ABA. The study compared\nCRP values at three levels, defined as mild (> 4 mg/L), moderate (> 40 mg/L) and severe (> 100\nmg/L), in children with three confirmed diagnoses: ABA, osteomyelitis and ARF [81]. At the mild\nlevel, sensitivity was 100% versus 74% and 41% at the higher cutoffs (Table 2 ).\nIn one other prospective study of 134 culture-positive ABA patients, a predetermined cutoff of 20\nmg/L [73] had a sensitivity of 95.5% in this highly selected population. Specificity and positive",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 68,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_69",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "mg/L [73] had a sensitivity of 95.5% in this highly selected population. Specificity and positive\npredictive value could not be determined as they only included patients with culture positive ABA.\nOur systematic review of the literature identified two published studies from 2005 to 2022\nspecifically evaluating the diagnostic testing accuracy of CRP in differentiating ABA and transient\nnonbacterial synovitis of the hip [74, 76]. These studies evaluated the diagnostic test accuracy of\nCRP at a pre-determined cut-off of >20 mg/L in a total of 359 children with hip joint effusion\nidentified on ultrasound. The pooled sensitivity and specificity were 85.7% and 91.9% respectively,\nbut prevalence of ABA greatly varied between studies due to differences in patient selection: 9.3%",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 69,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_70",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "but prevalence of ABA greatly varied between studies due to differences in patient selection: 9.3%\n[76] of all children with a hip effusion on ultrasound had ABA, while 70.8% [74] of a selected group\nof patients with high suspicion for ABA undergoing hip aspiration had ABA.\nA multivariable prediction model in one of these studies [76] showed that refusal to weight bear and\nCRP > 20 mg/L were independent determinants in differentiating ABA from transient nonbacterial\nsynovitis of the hip, with increased CRP level being the strongest predictive factor (odds ratio 81.9,\np-value < 0.001). Children with neither predictor had <1% probability of ABA, indicating excellent\nnegative predictive value of their model. In a cohort of 32 children presenting with painful hip",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 70,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_71",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "negative predictive value of their model. In a cohort of 32 children presenting with painful hip\neffusion referred for ultrasound-guided joint aspiration and a prevalence of confirmed or presumed\nABA of 21.9% [82], a pre-determined CRP cut-off of >10 mg/L was predictive of ABA (OR 7.9, p-\nvalue=0.03).\nIn addition to these studies, a recent meta-analysis assessing the diagnostic test accuracy of CRP\nfor bone and joint infections in children and adolescents suggested that at a threshold of 20 mg/L,\nthe estimated pooled sensitivity of C-reactive protein was 86% (68%-96%) and the pooled\nspecificity was 90% (83%-94%) [83]. Nevertheless, this meta-analysis only included 4 studies\nwhich were limited by heterogeneity of included population (and thus the pre-test probability of",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 71,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_72",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "which were limited by heterogeneity of included population (and thus the pre-test probability of\nhaving ABA), methodological limitations and/or small sample size (e.g., only 2 of the 4 studies\nincluded at least 10 ABA cases).\nIn one study of ABA, CRP values appear to be higher when patients had bacteremia [50, 84].\nAnother study of ABA found that a markedly elevated CRP was associated with the need for more\nthan one surgical procedure (OR = 1.1; 95 % CI = 1.03–1.18; p = 0.005); for every 10 mg/L of increase\nin CRP, the odds of undergoing a second surgery increased by 9.6% [52]. The authors concluded\nthat a CRP of 150 mg/L was the level above which a second surgery would likely be needed.\nThe relationship between CRP level and adjacent osteomyelitis in ABA has been examined in",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 72,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_73",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "The relationship between CRP level and adjacent osteomyelitis in ABA has been examined in\nmultiple studies [24, 51, 67, 73, 85-87]. Generally, CRP was higher in cases of ABA with adjacent\nosteomyelitis compared with either site of infection on its own, but substantial overlap in ranges\nlimits the utility of CRP alone in this determination. CRP has been used as one factor in an algorithm\ndeveloped to guide performance of MRI to detect osteomyelitis associated with ABA, but the utility\nof this approach also remains uncertain (See Question II) [86, 88-90].\nInitial CRP results may vary by causative pathogen. CRP values appear to be higher on average for\nosteoarticular infections caused by S. aureus, although none of these studies report CRP values for",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 73,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_74",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "osteoarticular infections caused by S. aureus, although none of these studies report CRP values for\npatients with ABA separately [23, 91], and many studies did not perform molecular diagnostic\nstudies on joint fluid to assess for the presence of K. kingae. Some, but not all, studies have\ndescribed higher mean CRP concentrations for cases due to MRSA than methicillin-susceptible S.\naureus (MSSA), either for all osteoarticular infections (site of infection not further defined in data\npresented) [23, 92, 93] or for ABA with or without concomitant osteomyelitis [62].\nSeveral studies provided comparisons between suspected ABA with no identified pathogen [24, 53]\nor suspected ABA/osteomyelitis with no identified pathogen [51] versus those with an identified",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 74,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_75",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "or suspected ABA/osteomyelitis with no identified pathogen [51] versus those with an identified\netiology (by culture, PCR, or both). These reported lower CRP concentrations in cases without an\nidentified etiology, but most reporting institutions were not pursuing identification of K. kingae as a\npathogen with routine performance of molecular studies on synovial fluid at the time. One study\nfound no difference in CRP concentrations between cases with and without identified etiology [50].\nThus, CRP concentrations cannot be used to reliably distinguish ABA from causes of arthritis with\nno identified bacterial pathogen.\nIdentification of K. kingae as an important and common etiology of osteoarticular infections in young",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 75,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_76",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "children has increased as more centers are performing PCR on bone and synovial fluid specimens.\nTwo studies [30, 94] reported on a combined total of 54 children with ABA or osteomyelitis due to K.\nkingae; these patients are reported as having mild or no elevation in CRP but provide no comparison\nto other etiologies. Other studies provided comparisons of CRP levels in children with ABA due to K.\nkingae versus those with all other pathogens combined [25, 29], or versus those with S. aureus\ninfections alone [28, 95]. These studies show lower CRP concentrations at admission for children\nwith K. kingae infection than with other pathogens; however, they do not provide cut-off values that\nwould definitively distinguish etiology using CRP.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 76,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_77",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "would definitively distinguish etiology using CRP.\nLower CRP levels are seen in Lyme arthritis compared with ABA. Lyme disease should be\nconsidered in afebrile, ambulatory children presenting with large joint arthritis (particularly the knee)\nwho have low CRP and/or ESR and appropriate epidemiologic risks for Lyme disease [96-99].\nRationale for Recommendation\nThe primary utility of CRP on admission is as a baseline for serial measurements during the\ntreatment course. The existing literature regarding CRP as a diagnostic test for ABA is limited by\nsmall sample sizes, suboptimal methodology, varied populations of interest (i.e., wide range of\npretest probabilities) and control groups, varied reference standards, use of different numeric cut-",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 77,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_78",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "offs, and verification bias. Results suggest limited accuracy in discriminating ABA caused by any\nbacterial pathogen from other infectious or non-infectious processes. Despite these limitations, in a\nchild with suspected ABA, we suggest performing a CRP on initial evaluation. CRP is offered in most\nhospital settings, can be obtained simultaneously with blood being drawn for culture and other\ntests, is relatively inexpensive, and produces results that usually are quickly available. When taken in\ncontext of the clinical presentation and other testing modalities, CRP may add benefit for\nmultidisciplinary clinical decision making for children with clinically suspected ABA. Although not\nspecifically analyzed in published studies (particularly those prior to widespread routine use of",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 78,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_79",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "specifically analyzed in published studies (particularly those prior to widespread routine use of\nmolecular tests for diagnosis of ABA), children with a low initial CRP are likely to include many with\nK. kingae infections, for whom long-term outcomes are excellent [24, 94]. Normal or minimally\nelevated concentrations of serum CRP do not exclude ABA but should prompt investigation of\nadditional non-infectious etiologies.\nProcalcitonin\nSummary of Evidence\nProcalcitonin (PCT) is an acute phase reactant that increases during infection. It is purported to rise\nmore rapidly and be more specific for bacterial infection compared with other markers of\ninflammation. The diagnostic accuracy of procalcitonin for ABA has been evaluated in three",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 79,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_80",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "inflammation. The diagnostic accuracy of procalcitonin for ABA has been evaluated in three\nprospective, cross-sectional studies [78, 80, 100] in which children with ABA or osteomyelitis were\nincluded. These studies used varying combinations of clinical, microbiological, and radiographic\ncriteria to classify patients as having ABA or osteomyelitis. Clinicians were blinded to PCT results in\ntwo of the included studies [78, 100]. The studies had different disease prevalence as a result of\ndifferences in inclusion criteria. One included only patients with fever along with musculoskeletal\ncomplaints (ABA prevalence 52.2%) [78], whereas two included both febrile and afebrile patients\n(ABA prevalence 14.2% [100] and 21.1% [80], respectively). A PCT cut-off value ≥ 0.5 ng/mL was",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 80,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_81",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "(ABA prevalence 14.2% [100] and 21.1% [80], respectively). A PCT cut-off value ≥ 0.5 ng/mL was\nconsidered a priori as positive in two of these studies [78, 100], while the other derived the optimal\ncut-off value from their studied cohort [80].\nAt a PCT cut-off value of 0.5 ng/mL, the two included studies reported a high specificity (96.9%\n[100] and 100.0% [78]) of PCT when used to discriminate confirmed and presumed osteoarticular\ninfections vs. non-infected patients, while reporting a very low sensitivity (12.5% [100] and 43.5%,\n[78]. In the third study, the optimal cut-off was determined to be 0.1 ng/mL, and the authors reported\nthat patients with a PCT value over 0.1 ng/mL were 2.5 times more likely to have acute",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 81,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_82",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "that patients with a PCT value over 0.1 ng/mL were 2.5 times more likely to have acute\nmusculoskeletal infections than those with a PCT value below this cut-off [80]. Nevertheless, this\nsame study showed that CRP performed better than PCT [80].\nIn addition to these studies, a recent meta-analysis assessing the diagnostic test accuracy of serum\nPCT for bone and joint infections in children and adolescents also confirmed the paucity of\npublished data, precluding any formal conclusion [83]. Another meta-analysis [101] of 10 studies of\nPCT in osteoarticular infection not restricted to ABA, concluded superior positive and negative\nlikelihood ratios and improved area under a receiver operating characteristic curve (AUC) for PCT",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 82,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_83",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "likelihood ratios and improved area under a receiver operating characteristic curve (AUC) for PCT\ncompared with CRP; however, the results of this meta-analysis were primarily based on adult\npopulations, thus not considered generalizable to the pediatric population.\nRationale for Recommendation\nPCT has utility in risk stratification among bacterial versus nonbacterial etiologies of some clinical\nscenarios. However, currently available data regarding accuracy of PCT in the diagnosis of children\nwith ABA have limitations of relatively small sample sizes of children with ABA or osteomyelitis.\nValidity is uncertain and the sensitivity appears suboptimal. Also, no prospective evaluation of PCT\nto distinguish successful from unsuccessful antimicrobial/surgical therapy of ABA has not been",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 83,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_84",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "to distinguish successful from unsuccessful antimicrobial/surgical therapy of ABA has not been\nconducted. In addition, PCT is not routinely available in many hospitals and is more expensive than\nCRP.\nComplete Blood Count (CBC)\nBackground\nA complete blood cell count (CBC) with differential generally should be performed on initial\nevaluation of children with suspected ABA (see Table 1 for definitions) to assess the severity of\ninfectious processes as well as to provide useful information regarding alternative diagnoses (e.g.,\nleukemia). The peripheral white blood cell (WBC) count is often but not always elevated in children\nwith ABA [59, 72, 74, 80, 102-104].\nThe WBC is higher on average with adjacent osteomyelitis infection than without [86, 88] and may",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 84,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_85",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "The WBC is higher on average with adjacent osteomyelitis infection than without [86, 88] and may\nbe higher when ABA is caused by S. aureus or streptococcal species than K. kingae [95, 105];\nhowever, substantial overlap precludes the use of a specific diagnostic cut-off value. WBC does not\ndiffer on average, between confirmed and presumed ABA cases (see Table 1 for definitions) [24,\n106]. WBC on admission also is not useful in distinguishing ABA from Lyme arthritis [96].\nThe WBC is often higher in children with ABA than transient nonbacterial synovitis, a clinically\ndefined syndrome traditionally often referred to as toxic synovitis (see Table 1 for definitions), but\nthe substantial overlap precludes diagnostic value in distinguishing these entities [74-77, 107, 108].",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 85,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_86",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "There is also overlap in WBC values between ABA and acute rheumatic fever (ARF) [109].\nDiscriminatory value of the peripheral blood WBC is, thus, limited for the differential diagnosis of\nsuspected ABA, but the information provided by a CBC can provide important adjunctive information\nfor decision-making for children with these clinical presentations.\nErythrocyte Sedimentation Rate\nBackground\nThe Erythrocyte Sedimentation Rate (ESR) is usually, but not always, elevated in children with ABA\nat the time of presentation. [59, 72, 74, 102, 103]. Like CRP, the ESR is usually higher in ABA than in\ntransient nonbacterial synovitis [74, 75, 77, 108] or ARF [109]. ESR is also typically higher in children",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 86,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_87",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "who have ABA with an adjacent musculoskeletal infection than without [88], lower in Lyme arthritis\nthan ABA caused by pyogenic bacteria [96], and lower in ABA caused by K. kingae compared with\nother bacterial pathogens (S. aureus, beta-hemolytic streptococci, and pneumococci) [105].\nHowever, the overlap of ESR ranges in each of these situations precludes discriminatory utility. The\nESR often does not normalize until the fourth week after initiation of therapy for ABA, well after\nantimicrobial therapy has usually been discontinued (see Question X).\nTherefore, the Guideline Panel does not see value in the routine inclusion of ESR testing in children\nbeing evaluated for suspected ABA as a diagnostic test to differentiate bacterial from nonbacterial",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 87,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_88",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "being evaluated for suspected ABA as a diagnostic test to differentiate bacterial from nonbacterial\ncauses of joint inflammation. In addition, the ESR does not substantially assist in the assessment of\nthe pathogen. It has also not been found helpful for the assessment of adjacent musculoskeletal\ninfection to determine the need for a more extended duration of antimicrobial therapy.\nLyme Serology\nBackground\nChildren living in Lyme disease-endemic areas in North America and Europe may develop arthritis\nas the result of Borrelia burgdorferi infection which may be difficult to distinguish, clinically, from\nABA. Synovial fluid WBC counts in Lyme arthritis overlap with those in ABA [110]. Clinicians need to",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 88,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_89",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "make initial management decisions based on clinical factors without waiting for the results of\nbacteriologic studies and Lyme disease serologies to avoid joint irrigation or arthrotomy that are\nunnecessary for Lyme arthritis. Lyme arthritis typically involves the large joints, particularly the knee,\nwhich is affected in 90% of cases [96, 97]. The hip, elbow, and shoulder may also be involved,\nusually one joint at a time. The hallmark of Lyme arthritis is a large joint effusion. However, patients\nusually do not experience the severe pain and systemic toxicity more often seen in ABA caused by\nmany other bacterial etiologies. Children with Lyme arthritis are more likely to be weight bearing at\npresentation, lack fever, and have lower inflammatory markers. A peripheral WBC <10,000",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 89,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_90",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "presentation, lack fever, and have lower inflammatory markers. A peripheral WBC <10,000\ncells/microliter and ESR <40 mm/hr in a weight bearing child with arthritis of the knee indicates a\nvery low risk for ABA [96-99]. We endorse the recently updated IDSA Lyme Disease guideline in its\nstrong recommendations regarding the diagnostic testing in suspected Lyme arthritis; namely, in\nchildren with known prior exposure and in those living in areas with high background\nseroprevalence, we support the recommendation to use serum antibody testing (ELISA with\nconfirmatory Western blot and interpretation of bands) over PCR or culture of blood or synovial\nfluid. To improve diagnostic specificity for the seropositive child in whom a definitive diagnosis is",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 90,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_91",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "required, PCR of synovial fluid or synovial tissue is preferred over culture of B. burgdorferi [111].\nResearch Needs\nFuture prospective studies to determine whether a particular serum CRP threshold is reasonably\npredictive of the diagnosis of ABA would be helpful. Use of an appropriate reference standard such\nas a positive culture or molecular test from joint fluid or blood will be essential. Similar prospective\nevaluation of CRP utility in ABA caused by various organisms (e.g., S. aureus, K. kingae, S.\npyogenes, S. pneumoniae) would be important.\nThe roles of PCT or other inflammatory markers or new, more accurate and precise biosignatures\nalso may merit further evaluation of clinical utility for diagnostic purposes and for serial assessment",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 91,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_92",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "in support of management decisions regarding the course of therapy. Studies evaluating the utility\nof emerging molecular diagnostic technologies, including nucleic acid amplification techniques and\nmetagenomic next generation sequencing tests on blood and tissue specimens will be important, as\nthese may increase the portion of ABA cases for which the microbial etiology is identified [112].\nII. What imaging studies should be performed in children with suspected ABA?\nRecommendations:\n1. In children with suspected ABA, we recommend obtaining plain radiography of the affected joint\nand adjacent bones rather than not performing plain radiographs (strong recommendation,\nmoderate certainty of evidence). Comment: Despite the low sensitivity of plain radiography for",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 92,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_93",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "moderate certainty of evidence). Comment: Despite the low sensitivity of plain radiography for\ndetecting presence of joint effusion or adjacent osteomyelitis on initial presentation, other\nimportant etiologies of acute musculoskeletal pain may be identified.\n2. In children with suspected ABA in whom further imaging studies are required to detect the\npresence of joint effusion, particularly of the hip or the shoulder, we recommend performing\nultrasonography of the affected joint before performing more complex and less widely available\nimaging tests (strong recommendation, moderate certainty of evidence). Comment:\nUltrasonography documenting the absence of joint effusion suggests that ABA is not present.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 93,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_94",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Ultrasonography documenting the absence of joint effusion suggests that ABA is not present.\n3. In children with suspected ABA in whom further imaging studies are required to assess the\nextent of inflammation and infection, including adjacent osteomyelitis and pyomyositis, we\nsuggest performing a magnetic resonance imaging (MRI) study rather than other imaging\nmodalities (e.g., computerized tomography (CT) or bone scintigraphy) (conditional\nrecommendation, very low certainty of evidence). Comment: Children with ABA at high risk of\nadjacent osteomyelitis include those with more than 3 or 4 days of symptoms prior to\npresentation, S. aureus infection, and marked elevation of CRP, but these risk factors require\nfurther validation.\nBackground",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 94,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_95",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "further validation.\nBackground\nIn a child presenting with musculoskeletal pain and joint swelling, synovial thickening, and effusion\nin joints visible or palpable on physical examination, such as the knee, ankle, or elbow, imaging is\nnot always required prior to aspirating the affected joint by an experienced provider. When joint\nswelling is not clinically apparent, as with the hip or shoulder, or when it is unclear if swelling is due\nto effusion or other intra-articular abnormalities such as synovitis, imaging can be performed to aid\nin determining presence of effusion, osteomyelitis, foreign bodies, or other nonABA disorders that\ncause joint inflammation. Advanced imaging with MRI may provide anatomic detail needed to define",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 95,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_96",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "cause joint inflammation. Advanced imaging with MRI may provide anatomic detail needed to define\nthe extent of infection in and around the infected joint including identification of adjacent\nosteomyelitis and soft tissue abscesses.\nPlain Radiographs\nSummary of Evidence\nPlain radiographs may be helpful in providing evidence consistent with infection or other etiologies\nof acute musculoskeletal pain. Early in ABA, there may be soft tissue swelling, blurring of fat planes,\nand joint widening with effusion. These radiographic findings progress to joint space narrowing from\ncartilage destruction and subchondral bone loss in later stages of infection. Adjacent osteomyelitis\nmay be visible on plain radiographs if bone disease has been present for more than 10- 20 days.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 96,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_97",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "may be visible on plain radiographs if bone disease has been present for more than 10- 20 days.\nNormal plain radiographs do not rule out ABA or acute osteomyelitis. Plain radiographs are most\nuseful to identify alternative etiologies of acute musculoskeletal pain including fractures, tumors,\nslipped capital femoral epiphysis, or Legg-Calve-Perthes disease.\nOur systematic review of the literature identified a total of 9 studies published 2005 through 2022,\nincluding 736 patients with ABA, and reporting on sensitivity of plain radiography for the diagnosis\nof ABA with or without adjacent osteomyelitis (see Supplementary Material Figures IIa ) [12, 25,\n51, 54, 57, 63-65, 113]. The overall sensitivity of plain radiography for the presence of osteoarticular",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 97,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_98",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "infections was 25.1% (95%CI: 15.7 to 34.6%), but abnormalities reported on plain radiography varied\namong studies (from swelling of soft tissue to joint effusion, or signs of osteomyelitis). Other\nsources of heterogeneity between studies such as presence of verification bias (i.e., not all tests\nwere performed in all patients) and variation in the reference standard (final diagnosis based on\nvarious sets of criteria) impeded further meaningful interpretation of the pooled results.\nRationale for Recommendation\nAlthough the sensitivity of plain radiographs for diagnosis of ABA is low, their value for confirming\npresence of effusion and providing evidence of alternative diagnoses outweighs the concern around",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 98,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_99",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "presence of effusion and providing evidence of alternative diagnoses outweighs the concern around\nthe high false negative rate for ABA with or without adjacent osteomyelitis. Plain radiographs are\nreadily available, have low radiation dosage and relatively low costs, and do not require sedation.\nImportantly, normal findings in plain radiographs at presentation do not exclude the presence of\nABA or osteomyelitis. Abnormalities seen on subsequent plain radiographs in the appropriately\nmanaged child may represent the natural history of the infectious process rather than evidence of\ndeterioration if the child is clinically improving. Because the overall benefits exceed risks, the panel\nmakes a strong recommendation that plain radiographs remain a routine part of initial evaluation of",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 99,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_100",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "makes a strong recommendation that plain radiographs remain a routine part of initial evaluation of\nchildren with ABA.\nUltrasound\nSummary of Evidence\nUltrasound is a relatively low cost and noninvasive imaging study that can be used to characterize\nintra-articular and extra-articular abnormalities identified in children presenting with swelling or pain\nin or near a joint. It is especially helpful in determining a further course of action in a child with\nlimitations in weight bearing and movement at the hip joint where direct visualization of the joint is\nimpossible. Findings on ultrasound compatible with ABA include joint effusion and capsular\nthickening. Transient nonbacterial synovitis, the most common cause of an acute painful hip in",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 100,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_101",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "thickening. Transient nonbacterial synovitis, the most common cause of an acute painful hip in\nchildren, is defined by the presence of only mild inflammation in synovial fluid and negative culture\nplus negative results of any molecular pathogen tests that are performed. This condition is most\noften self-limited. Advanced imaging may be required to distinguish transient nonbacterial synovitis\nfrom ABA to avoid unnecessary, invasive interventions in children with this benign condition, as\nthere is significant overlap in the clinical presentation of these two conditions. It is possible that an\nundefined proportion of children previously diagnosed with transient nonbacterial synovitis and\nwhose synovial fluid did not undergo molecular testing had K. kingae infection with resultant mild",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 101,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_102",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "whose synovial fluid did not undergo molecular testing had K. kingae infection with resultant mild\ninflammation, negative cultures, and spontaneous resolution of disease [24]. In addition to the\npresence of effusion and synovial thickening, the echogenicity of the joint fluid may be helpful in\ndistinguishing ABA from other etiologies of inflammation causing effusion. Ultrasound may also\nvisualize extra-articular abnormalities, depending on the extent of the image, such as subperiosteal\nor soft tissue abscess, indicative of osteomyelitis or soft tissue infection.\nOur systematic review of the literature identified a total of 7 studies published 2005 through 2022,\nincluding 473 patients with ABA reporting on sensitivity of ultrasonography for the diagnosis of ABA",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 102,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_103",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "(see Supplementary Material Figures IIa ) [12, 25, 51, 57, 64, 69, 113]. In these studies, although\nultrasonography was performed for suspected ABA of the hip [64, 69] they may have included\nexaminations of other joints (knee, shoulder, ankle, elbow) [57], or the joints being assessed were\nnot specified [12, 25, 51, 113]. The overall sensitivity of ultrasonography for the presence of findings\ncompatible with ABA (joint effusion, synovial thickening) using a variety of reference standards was\n81.0% (95%CI: 72.8 to 89.2%) when all cases of ABA were considered (including those with\nadjacent osteomyelitis) but increased to 90.8% (95%CI: 83.2 to 98.5%) in patients with primary ABA\n[12, 25, 51, 57, 64, 69, 113]. In fact, the sensitivity of ultrasonography to detect increased synovial",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 103,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_104",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "fluid in the presence of adjacent osteomyelitis ranged from 24.6 to 65.2%, reflecting that most joint\neffusions adjacent to osteomyelitis are likely to represent an inflammatory reaction rather than true\ninfection [12, 25]. Heterogeneity in reference standards used to determine the presence of ABA in\nthese studies (varying combinations of criteria including clinical presentation, synovial fluid cell\ncounts, cultures, molecular diagnostic testing, and imaging) might limit the interpretation of the\npooled results.\nOur systematic review of the literature identified 2 studies reporting on the diagnostic testing\naccuracy of ultrasound to distinguish transient nonbacterial synovitis from ABA in children",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 104,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_105",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "accuracy of ultrasound to distinguish transient nonbacterial synovitis from ABA in children\npresenting with acute, atraumatic limp or hip pain [76, 114]. In the largest study, [76] the presence of\nhip effusion (without additional criteria) was considered indicative of possible ABA, but other\nnonstandardized clinical features were used to determine need for arthrotomy by treating clinicians.\nAmong 680 children, 369 had no effusion present, none required subsequent treatment for ABA,\nand all made a complete spontaneous recovery with no sequelae at three months’ follow-up (i.e.,\nNPV of 100%). Among the 311 with effusion, only 42 (13.5%) underwent arthrotomy and only 29\n(9.3%) were confirmed to have ABA (i.e., PPV 9.3%) with the remaining patients having a benign",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 105,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_106",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "(9.3%) were confirmed to have ABA (i.e., PPV 9.3%) with the remaining patients having a benign\ncourse of illness. An additional study evaluated the diagnostic testing accuracy of ultrasound to\ndifferentiate hip ABA and transient nonbacterial synovitis in a total of 127 patients presenting with an\nacutely painful hip [114]. In this study, predominant capsular thickening relative to effusion was\nconsidered an indicator of ABA. The pre-test probability for ABA was 46.5% and the sensitivity,\nspecificity, positive and negative predictive values for ultrasound in diagnosing hip ABA were\n86.4%, 89.7%, 87.9% and 88.4%, respectively.\nRationale for Recommendation\nUltrasonography is readily available at many institutions, is relatively low cost, and does not require",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 106,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_107",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "sedation. The expertise of sonographers and radiologists at institutions that routinely care for few\ncases of pediatric ABA may not equal that of individuals who practice at facilities where ABA in\nchildren is more commonly seen. The sensitivity of ultrasound for joint effusion is high\n(approximately 90%), exceeding the accuracy of the clinical examination, laboratory, and plain\nradiograph findings, particularly for the hip [114]; however, the absence of a joint effusion does not\ncompletely rule out ABA. Many of the false negative ultrasound examinations were performed in the\nfirst 24 hours of illness; thus, children with a negative ultrasound result for effusion should have a\nrepeat ultrasound examination or MRI if clinical suspicion for ABA persists. Delay in appropriate",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 107,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_108",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "repeat ultrasound examination or MRI if clinical suspicion for ABA persists. Delay in appropriate\ntherapy in children with falsely negative ultrasounds results in unfavorable outcomes for affected\njoints [114]. Because the overall benefits exceed risks, the panel makes a strong recommendation\nthat ultrasonography of the affected joint be performed before performing more complex and less\nwidely available imaging tests.\nAdvanced Imaging: MRI, Scintigraphy and CT\nSummary of Evidence\nWhen an ultrasound is negative, advanced imaging modalities such as MRI or CT can be used to aid\nin determining the need for joint aspiration or arthrotomy. Bone scintigraphy for the diagnosis of\nbone and joint infections is no longer routinely available in many pediatric centers and has been",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 108,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_109",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "bone and joint infections is no longer routinely available in many pediatric centers and has been\nreplaced by more anatomically detailed techniques that do not require radionuclide exposure. MRI is\nhighly sensitive and is the preferred study to differentiate between bone, joint, and soft tissue\ninvolvement. Findings on MRI that have been reported in association with ABA include joint effusion,\nsynovial thickening, and enhancement; associated enhancement/edema of soft tissues and bone\nmarrow may also be present. CT may demonstrate joint effusion and synovial thickening as well as\nsoft tissue abnormalities but requires significant ionizing radiation exposure. MRI is generally the\nmodality of choice for the diagnosis of osteomyelitis [37], but risks (and availability of) sedation may",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 109,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_110",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "influence this choice when sedation is required to accomplish the study.\nOur systematic review of the literature identified a total of 5 studies [12, 25, 51, 113, 115] published\n2005 through 2022 reporting on the diagnostic test accuracy of MRI for the diagnosis of ABA. Most\nstudies were retrospective and not all study subjects had all imaging performed. Direct comparisons\nbetween the different advanced imaging modalities were not available. The reference standards for\nthe final diagnoses in these subjects were various combinations of clinical examination findings,\nlaboratory results (inflammatory markers, synovial fluid cell count, cultures), response to antibiotics\n(or to no treatment), and the imaging studies themselves. While most studies report a sensitivity of",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 110,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_111",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "MRI for the diagnosis of ABA in the range of 90-100% [25, 51, 113, 115], the proportion of patients\nwith ABA imaged with MRI varied greatly between studies (range 9% to 53%) except one study\nwhere only subjects with MRI were included [115]. One study reported a substantially lower\nsensitivity of 56% in children with primary ABA [12]. Since most patients in these studies did not\nundergo MRI for ABA, the cases that did may reflect a selection bias toward the most difficult to\ndiagnose patients.\nOnly one retrospective study examined variations in MRI techniques to diagnose musculoskeletal\ninfections in children. This study examined the accuracy of fluid sensitive MRI sequences in 88\nconsecutive children suspected of musculoskeletal infections of which 13 had ABA and",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 111,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_112",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "consecutive children suspected of musculoskeletal infections of which 13 had ABA and\ndemonstrated these abbreviated MRI studies could accurately diagnose ABA (13/13 abnormal) [115].\nTwo studies evaluated the accuracy of MRI to differentiate hip ABA from transient nonbacterial\nsynovitis in a total of 132 patients [116, 117]. These studies had an overall pre-test probability for ABA\nof 28.0%. These studies did not include all the same diagnostic criteria; however, both studies did\nassess differences in the grade (magnitude) of joint effusion, presence of synovial thickening and\nenhancement, alterations in signal intensity in soft tissue and bone marrow, changes in femoral head\nperfusion, and contralateral joint changes (effusion, synovial thickening). The pooled analysis of the",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 112,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_113",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "most predictive criteria from each study showed that MRI has a sensitivity ranging from 83.3 to\n84.2% and a specificity ranging from 93.5 to 100% to differentiate ABA from transient nonbacterial\nsynovitis. Contralateral effusion was found to be a significant predictor of transient nonbacterial\nsynovitis, and alterations in signal intensity of soft tissue compared to contralateral hip was a\nsignificant predictor of ABA in two studies [116, 117].\nA single study evaluated the accuracy of MRI to differentiate ABA from inflammatory arthritis (e.g.,\npost-infectious arthritis such as ARF, transient nonbacterial synovitis, and JIA) in a cohort of 59\nchildren presenting with recent-onset arthritis of various joints [118]. The multivariate analysis",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 113,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_114",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "children presenting with recent-onset arthritis of various joints [118]. The multivariate analysis\nidentified the presence of bone marrow edema and absence of low signal intensity of the synovial\ntissue as being independently associated with the presence of ABA.\nAlthough bone scintigraphy is no longer routinely recommended, the sensitivity of this diagnostic\ntest for the diagnosis of primary ABA was estimated at 81.9% (95% CI: 76.2 to 86.8%) in a total of\n212 children in 5 studies (see Supplementary Material Figures IIa ) [12, 25, 59, 64, 65] but ranged\nwidely from 52% to 91%. The wide variation observed in diagnostic test accuracy of this imaging\nmodality may have resulted from differences in population selection (suspected vs confirmed ABA,",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 114,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_115",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "modality may have resulted from differences in population selection (suspected vs confirmed ABA,\nABA caused by various bacteria vs restricted to S. aureus only), in the timing of each imaging study,\nin the reference standard (MRI only vs extended reference standard including multiple tests), and\nfrom potential verification bias (not all patients received the same tests in all studies).\nData regarding the accuracy of CT for the diagnosis of ABA in children are too limited in terms of\nsample size and number of studies to be meaningfully estimable.\nAjacent Musculoskeletal Infections in Children with ABA\nOur systematic review identified a total of 14 studies published 2005 through 2022 including 1,429",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 115,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_116",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Our systematic review identified a total of 14 studies published 2005 through 2022 including 1,429\nchildren with ABA (ranging from 20 to 310 children) that reported on the prevalence of adjacent\nosteomyelitis (see Figure 3) [12, 25, 51, 57, 60, 62-65, 90, 113, 119-121]. Overall, 32.2% (95%CI: 22.4\nto 42.0%) of children with ABA had adjacent osteomyelitis, ranging from 7.7% to 68.2% (highest rate\nbeing reported in a study evaluating ABA of the shoulder). Four studies reported on the risk factors\nor clinical features associated with adjacent osteomyelitis [60, 62, 113, 119]. The following were\nsignificantly associated with adjacent osteomyelitis on univariate analyses: newborn (up to 4\nmonths) or adolescent age group (13-20 years), longer duration of symptoms and/or fever before",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 116,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_117",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "months) or adolescent age group (13-20 years), longer duration of symptoms and/or fever before\nadmission, higher temperature at presentation, higher CRP at presentation, infection of the shoulder,\npresence of bacteremia, positive Gram stain of joint fluid, and S. aureus as causative pathogen.\nMultivariate analysis was performed in two studies. A recent study of 71 children with ABA who\nunderwent MRI [60] identified positive joint fluid bacterial culture (p-value=0.02) and pain for more\nthan 4 days before admission (p-value=0.004) as risk factors for adjacent osteomyelitis. Another\nstudy reported S. aureus as the causative pathogen (p-value P<0.0001) and symptom duration of\nmore than 3 days at presentation (p-value=0.005) as risk factors for adjacent osteomyelitis [62].",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 117,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_118",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "more than 3 days at presentation (p-value=0.005) as risk factors for adjacent osteomyelitis [62].\nOur systematic review of studies published 2005 through 2022 identified two studies from a single\ncenter that described derivation [88] and then validation [89] of an algorithm to predict adjacent\nmusculoskeletal infections (including adjacent osteomyelitis, subperiosteal abscess or intramuscular\nabscess) in children with ABA. The derivation study reviewed 144 children with ABA and identified\nadjacent infections in 87 (61%) [88]. Independent predictive factors of presence of adjacent\ninfections on admission were older age (above 3.6 years), higher CRP (>13.8 mg/L), longer duration\nof symptoms (more than 3 days), lower platelets (<314 X10(3) cells/µL), and higher ANC (> 8.6 X",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 118,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_119",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "of symptoms (more than 3 days), lower platelets (<314 X10(3) cells/µL), and higher ANC (> 8.6 X\n10(3) cells/µL) [88]. In the subsequent validation study, among 109 children surgically treated for\nsuspected ABA, the positive predictive value of the algorithm was 91% (95% CI: 0.78-0.97), albeit\nusing a slightly lower CRP cut-off of 8.9 mg/L [89].\nApplication of this algorithm to 120 children from a different center found a positive predictive value\nof only 55.9%, with a receiver operating curve showing poor discrimination based on an AUC of\nonly 0.54 [86]. In a separate study, among 51 children with ABA of the hip managed according to\nthis algorithm, both sensitivity and specificity were lower compared to subjects in the original",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 119,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_120",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "this algorithm, both sensitivity and specificity were lower compared to subjects in the original\nstudies [90]. MRI altered management in 5 (9%) but half of the MRIs performed were deemed\nunnecessary.\nTwo other recent studies identified the following associations of adjacent osteomyelitis with ABA:\npresence of bacteremia, persistent fever after initiation of therapy, high CRP, and S. aureus as\netiology [67, 87]. One study also found thrombocytopenia and the need for intensive care as\nassociations with adjacent osteomyelitis, with K. kingae etiology occurring much more commonly in\nchildren with primary ABA without adjacent osteomyelitis [87]. The other study noted return to\nnormal range of motion of the affected joint by the time of discharge in 95% of those with ABA alone",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 120,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_121",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "compared with 65% in those with adjacent osteomyelitis [67].\nOur systematic review of the literature identified one study assessing the impact of the\nimplementation of routine preoperative MRI in patients with ABA to identify adjacent infection\n(osteomyelitis, pyomyositis) on need for repeat surgery (planned or unplanned) and length of stay\n(LOS) in 83 children with osteoarticular infections (see Supplementary Material Table IId ) [122].\nThis retrospective pre/post-implementation study shows that routine MRI in patients with ABA prior\nto arthrotomy reduced the need for repeat surgery (RR: 0.57, 95%CI: 0.33 to 0.96), but had no\nsignificant impact on reducing unplanned repeat surgery (RR: 0.71, 95%CI: 0.45 to 1.11) or LOS (3.2",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 121,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_122",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "significant impact on reducing unplanned repeat surgery (RR: 0.71, 95%CI: 0.45 to 1.11) or LOS (3.2\ndays shorter, p-value=0.2). These estimates were judged uncertain due to very serious risk of bias\n(e.g., type of study design, misclassification bias of the intervention of interest, absence of\nstratification for the type of osteoarticular infections and unadjusted analysis) and imprecision (i.e.,\nfew events and small sample size).\nRationale for Recommendation\nThe presumptive diagnosis of ABA can usually be made by a combination of clinical examination,\nlaboratory tests and ultrasound without advanced imaging by MRI. Obtaining an MRI routinely in all\nchildren presenting with suspected ABA does not appear necessary and may incur risk of",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 122,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_123",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "children presenting with suspected ABA does not appear necessary and may incur risk of\nunnecessary sedation, especially in younger children. However, if examination by plain radiographs\nand ultrasound have not provided sufficient information to determine need for joint aspiration or\narthrotomy, then the advanced imaging modality of choice is MRI; it may be helpful in confirming the\ndiagnosis, determining the extent of infection (involvement of soft tissue and bone), identifying\nabscesses requiring surgical intervention, and distinguishing transient nonbacterial synovitis or\nother inflammatory arthritis from ABA.\nMultiple factors that consistently increase the likelihood of adjacent osteomyelitis in children with",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 123,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_124",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "ABA have now been identified in a number of studies. These include, but may not be limited to,\nseverity of illness, presence of bacteremia, marked elevation of CRP, slow clinical response\n(persistent fever and local signs; need for repeat surgical procedures), and identification of S.\naureus as the pathogen. In such clinical scenarios, obtaining an MRI is appropriate when\nmanagement decisions and clinical course may be impacted. An option is to obtain follow-up plain\nfilms at 2 weeks into therapy when the likelihood of detecting changes indicative of adjacent\nosteomyelitis would be increased. Exclusion of adjacent osteomyelitis is important for determining\nthe duration of needed antimicrobial therapy (See Questions XI, XII and XIII).\nResearch Needs",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 124,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_125",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "the duration of needed antimicrobial therapy (See Questions XI, XII and XIII).\nResearch Needs\nAdditional prospective, controlled studies that assess the comparative utility of ultrasonography and\nnewer, limited sequence/rapid MRI techniques for diagnosis and prediction of complications of ABA\nby pathogen (particularly MRSA and MSSA) are needed. Additional prospective studies that evaluate\nthe utility of MRI at presentation or early in the clinical course of children with ABA, stratified by\nclinical and laboratory findings on admission (and within the subsequent 48 to 72 hours), as well as\nby infected joint site and specific pathogen, would be helpful.\nIII. For children with suspected ABA, when should diagnostic invasive procedures be performed",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 125,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_126",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "III. For children with suspected ABA, when should diagnostic invasive procedures be performed\nto collect synovial fluid from affected joint(s) and which diagnostic tests should be performed on\nthe collected joint fluid?\nRecommendations:\n1. In children with suspected ABA, we suggest collecting synovial fluid from the affected joint by\narthrocentesis prior to starting empiric antimicrobial therapy (conditional recommendation,\nmoderate certainty of evidence).\n2. On joint fluid obtained by arthrocentesis, we recommend performing white blood cell count and\ndifferential and routine microbiological cultures (aerobic bacterial culture and Gram stain)\n(strong recommendation, moderate certainty of evidence). Comment: Further diagnostic",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 126,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_127",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "(strong recommendation, moderate certainty of evidence). Comment: Further diagnostic\ntesting may be beneficial in certain situations: 1) molecular testing for specimens from which no\npathogen has been identified by Gram stain and aerobic bacterial culture, (particularly in\npreschool-aged children at higher risk of K. kingae infection); and 2) more extensive scope of\nmicrobial testing, beyond aerobic bacterial culture (e.g., anaerobic, fungal, and/or mycobacterial\ncultures and stains; molecular testing, which may include metagenomic next-generation\nsequencing), in children who are immunocompromised or who have a history of penetrating\ninjury. Additional molecular tests may be performed on synovial samples held in the laboratory,",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 127,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_128",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "injury. Additional molecular tests may be performed on synovial samples held in the laboratory,\nor for additional cultures, a repeat arthrocentesis may be required.\nSummary of Evidence\nThe collection of synovial fluid of the affected joint(s) is a critical aspect of management of\nsuspected ABA for diagnostic and therapeutic purposes. The initial invasive procedure to collect\nsynovial fluid can be performed by arthrocentesis, potentially to be immediately followed by surgical\ndrainage (arthroscopy or arthrotomy) as needed.\nThe choice and timing of the initial procedure is influenced by:\nTherapeutic need for drainage\nSeverity of infection (based on vital signs, physical findings including clinical toxicity, and\ninflammatory marker elevation)",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 128,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_129",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "inflammatory marker elevation)\nLocation, size, and ease of accessibility of the affected joint\nThe requirement for anesthesia or sedation to perform supplemental imaging and/or\narthrocentesis with the possibility of subsequent arthrotomy\nAvailability of local resources to support necessary interventions\nHistorically, there has been a sense of urgency regarding aspirating a joint suspected of being\ninfected by bacteria. However, recent experience has demonstrated a very low complication rate\n(<1%) for children with primary ABA. In contrast, the complication rate for children with ABA with\nadjacent osteomyelitis has been reported to be 38% [87]. In this study, children with adjacent\nosteomyelitis were significantly older (7.6 vs 2.7 years), had higher inflammatory markers (initial CRP",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 129,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_130",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "16.2 vs 5.2 mg/dL) and had higher rates of bacteremia (71.7% vs 9.7%). To determine if\nosteomyelitis is present, which would influence further evaluation and management, it is important\nto systematically gather all relevant data (history, physical examination, laboratory tests, and\nimaging) prior to proceeding with arthrocentesis and surgery.\nThe most common initial step in directly evaluating a joint space for the presence of infection is to\nobtain a synovial fluid sample by arthrocentesis, if practical. An exception is when there is suspicion\nof infection of a hip or shoulder joint, where more invasive procedures often are the best initial\napproach, depending on the clinical circumstances [see below]. Arthrocentesis is quick and",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 130,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_131",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "approach, depending on the clinical circumstances [see below]. Arthrocentesis is quick and\nminimally invasive and may be done with the child under sedation, general anesthesia, or awake,\ndepending on the age and the ability of the child to cooperate with the procedure. Arthrocentesis\nmay be performed by orthopedic surgeons, rheumatologists, interventional radiologists, or other\ntrained providers. When the initial procedure is performed by a non-orthopedist and the fluid\nappears purulent (or initial testing suggests bacterial infection), orthopedic consultation for possible\nadditional procedures such as arthroscopy or arthrotomy should be considered. However, aspiration\nof the infected joint via arthrocentesis may not only serve to verify the diagnosis of ABA but may",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 131,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_132",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "of the infected joint via arthrocentesis may not only serve to verify the diagnosis of ABA but may\nalso decrease the urgency for initial surgical intervention [123]. Some children demonstrate rapid\nclinical and laboratory improvement following initial aspiration with or without lavage to the extent\nthat subsequent surgical intervention may not be necessary [55, 102, 124]. A recent study of\nchildren in Spain with ABA of the knee found that age < 3 years and CRP < 20 mg/L were predictive\nof successful outcome with aspiration alone [125]. Success with percutaneous aspiration, irrigation\nand tube drainage has been described [126]. Repeated aspiration of infected hips rather than\narthrotomy has also been used with success [127].",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 132,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_133",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "arthrotomy has also been used with success [127].\nThe clinician performing arthrocentesis needs to consider the possibility of osteomyelitis in bone(s)\nadjacent to the involved joint [89, 128]. A more complicated clinical course and worse outcomes are\nassociated when ABA is associated with adjacent osteomyelitis [87, 129, 130]. A retrospective study\nof children with ABA of the hip showed that aspiration of the femoral neck demonstrated adjacent\nosteomyelitis in some cases when MRI did not show evidence of bone involvement [120]. For\nchildren with ABA with adjacent osteomyelitis, procedures to provide drainage of the joint may need\nto be accompanied by additional procedures to debride the adjacent bone and soft tissue.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 133,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_134",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "to be accompanied by additional procedures to debride the adjacent bone and soft tissue.\nSpecimens from affected tissues should be submitted for culture and histopathology.\nDrainage and irrigation of the infected joint via arthroscopy or arthrotomy is commonly performed in\nNorth America when ABA is the presumed or confirmed diagnosis. The goals of drainage are to\ndecompress the joint and remove inflammatory debris. Arthrotomy or arthroscopy may be\nperformed initially in lieu of or may be indicated after arthrocentesis. The decision to proceed to one\nof these procedures immediately after arthrocentesis may be based on the gross appearance of the\njoint fluid, or joint fluid WBC count and differential, in the context of the clinical presentation and the",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 134,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_135",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "specific joint that is infected. If an open or arthroscopic procedure is deemed unnecessary, the child\nshould be observed closely for the need for further drainage of the infected joint. However, if\nadditional procedures are deemed important but cannot be performed due to lack of resources,\ntransfer to a facility with appropriate resources should be considered [See Question VI]. No North\nAmerican studies have prospectively compared differences in outcomes between repeated needle\naspirations and formal arthrotomy with irrigation for various joints (e.g., hip or shoulder) affected by\ncommon ABA pathogens. One study in Malawi randomized 61 children to aspiration versus\narthrotomy for ABA of the shoulder and found no difference in outcomes. Nontyphoidal Salmonella",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 135,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_136",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "arthrotomy for ABA of the shoulder and found no difference in outcomes. Nontyphoidal Salmonella\nspecies accounted for 80% of the positive joint fluid cultures in this study, so these findings may not\nbe generalizable to other populations [131].\nArthroscopic drainage is safe and effective in a wide variety of joints including the hip, knee, ankle,\nshoulder, elbow, and wrist when performed by qualified surgeons [132-137]. Minimal invasiveness,\nshorter hospitalization, and improved visualization of the joint space for prognostic evaluation of the\narticular surface are all reported as potential advantages of arthroscopy over open drainage. A\nrecent Australian study comparing arthroscopic and open treatment of children with ABA of the",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 136,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_137",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "recent Australian study comparing arthroscopic and open treatment of children with ABA of the\nknee demonstrated that arthroscopy was associated with fewer repeat irrigations and shorter time\nto achieving range of motion and weight bearing [138].\nHistorically, arthrotomy has been recommended for ABA of the hips and shoulders, due to the risk of\navascular necrosis from increased intracapsular pressure. A South African study of children with\nABA of the hip reported uncomplicated recovery when treatment with antibiotics and arthrotomy\noccurred within 5 days of the onset of symptoms (although many children from this small study did\nnot present for medical attention early in their infection), but significant and permanent hip damage",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 137,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_138",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "when arthrotomy was delayed [139]. In recent years, arthroscopic drainage of the hip and shoulder\njoint has resulted in good outcomes[133, 134, 140] and offers several advantages over open\ndrainage as noted above.\nRegardless of the initial means of obtaining joint fluid, an adequate volume of fluid should be\nsubmitted to the laboratory rather than simply submitting a culture swab. Synovial fluid WBC count\nand Gram stain should be performed and provide results that are rapidly available. The WBC count\nis an important tool for helping to distinguish infection from other pathologic processes [141] but it is\nonly a rough guide that should be interpreted in the context of clinical and other laboratory data. In",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 138,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_139",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "ABA, the joint fluid WBC count is usually greater than 50,000/µl and often exceeds 100,000/µl, with\na neutrophil predominance [142], while in transient nonbacterial synovitis the WBC count is\ncommonly 5000 to 15,000/µl, often with mononuclear predominance. In JIA it is typically < 50,000/\nµl.\nThe cellular profile of Lyme arthritis may mimic that of ABA with polymorphonuclear cell\npredominance [96, 143] with over half of pediatric cases exceeding 50,000 WBC/µl [97, 110]. In one\nstudy in a Lyme endemic area, children with intermediate (25,000 to 75,000 cells/mm3 ) WBC\ncounts in hip joint fluid were most likely to have ABA, followed by Lyme arthritis and then transient\nnonbacterial synovitis [144]. Two small recent studies suggest potential moderate utility of urine",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 139,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_140",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "nonbacterial synovitis [144]. Two small recent studies suggest potential moderate utility of urine\ndipstick leukocyte esterase test results on synovial fluid as a rapid means of differentiating infection\nfrom other causes of arthritis [145, 146], but further validation is required.\nIn some cases of culture positive ABA, the Gram stain may be negative [147], likely due to a low\nconcentration of organisms. However, when positive, the Gram stain can provide timely information\nto guide the initial selection of antimicrobials [148, 149]. In general, narrowing antimicrobial therapy\nbased solely on the Gram stain is not advised; however, identification of unanticipated pathogens\nmay provide an opportunity for rapid initiation of additional pathogendirected therapy.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 140,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_141",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "may provide an opportunity for rapid initiation of additional pathogendirected therapy.\nCultures for aerobic bacteria are routinely performed, and in addition, laboratories should use\nchocolate (lysed sheep’s blood) agar to enhance recovery of N. gonorrhoeae and Haemophilus\ninfluenzae type b. For young children it is now common practice to inoculate a sample of joint fluid\ndirectly into an aerobic blood culture bottle in an effort to enhance recovery of fastidious microbes\nsuch as K. kingae [150, 151]. Recent studies have shown that this approach enhances the recovery\nof other pathogens as well [106, 152]. Anaerobic, fungal, and mycobacterial cultures should not be\nperformed routinely in otherwise healthy children with primary ABA because of negligible yield, but",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 141,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_142",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "performed routinely in otherwise healthy children with primary ABA because of negligible yield, but\nshould be performed for children who are immunocompromised, have penetrating injury to the joint,\nor have failed primary treatment [70]. Other studies on joint fluid (e.g., pH, protein, LDH, lactate) are\nno longer recommended for routine use in children with suspected ABA.\nIdentification of the microbial etiology for ABA enables appropriate antibiotic therapy to be provided\nand helps guide other management decisions. Our systematic review of the literature included a\ntotal of 19 studies reporting on the added diagnostic yield of culture of synovial fluid to results of\nblood cultures alone for pathogen identification in pediatric ABA 2005 through 2022 [12, 24, 50, 52-",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 142,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_143",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "59, 61-68]. These studies collectively included 2,090 patients with presumed or confirmed ABA\n(ranging from 18 to 268 patients per study). In our analysis, we addressed two cohorts who were\nanalyzed and reported separately: the first cohort with presumed or confirmed primary ABA [12, 24,\n50, 52-59, 66-68] and the second cohort from studies where it was impossible to separate those\nwith primary ABA from those with adjacent osteomyelitis [61-65]. Patients in these studies who\ncould definitively be identified as having ABA with adjacent osteomyelitis were excluded from these\nanalyses [37] (see Table 1  for definitions). Both analyzed subgroups showed a similar increase in\nthe yield of pathogen identification when synovial fluid was cultured in addition to cultures of blood:",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 143,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_144",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "risk difference (RD) (increase in yield) was 26.8% (95% CI: 20.1 to 33.5%) among 14 studies that\nincluded 1,545 patients with primary ABA and was 28.3% (95% CI: 19.0 to 37.7%) among 5 studies\nwith 545 patients with either primary ABA or ABA with adjacent osteomyelitis (see Supplementary\nMaterial Figures IIIa ).\nOur systematic review of the literature also included a total of 34 studies reporting on the positivity\nrate of synovial fluid culture in pediatric ABA 2005 through 2022 [12, 25, 28, 50-66, 68, 69, 76, 90,\n112, 121, 147, 153-159]. These studies collectively included 2,936 patients with pediatric ABA\n(ranging from 14 to 302 patients per study). Cohorts of patients were similarly stratified according to",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 144,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_145",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "the final diagnosis. The yield of routine aerobic bacterial culture averaged 40.1% (95% CI: 33.5 to\n46.7%) in 25 studies [12, 50-59, 66, 68, 69, 76, 112, 121, 147, 153-159] including 2,001 patients with\nprimary ABA, and 41.7% (95% CI: 32.8 to 50.7%) in 9 studies [25, 28, 60-65, 90] of 935 patients\nwith either ABA or ABA with adjacent osteomyelitis) (see Supplementary Material Figures IIIb ).\nThese analyses may underestimate the value of synovial fluid cultures (or subsequent molecular\ntesting) since many studies included suspected cases of ABA which 1) had cultures rendered\nnegative due to prior administration of antibiotics, 2) did not perform molecular testing, or 3) had\nconfirmation of an alternate diagnosis (e.g., inflammatory, or reactive arthritis) later in the course of\ndisease.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 145,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_146",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "disease.\nPCR-based testing using either single or multiple pathogen-targeted PCR (e.g., to specifically detect\nK. kingae), and 16S ribosomal ribonucleic acid (16S rRNA) gene amplification and sequencing were\nincreasingly used in the past decade, especially in cases with no identified pathogen. Our\nsystematic review of the literature included a total of 11 studies [28, 53, 54, 61, 66, 68, 112, 153, 155,\n157, 159] reporting on the added value of PCR-based testing on synovial fluid in addition to culture in\npediatric ABA 2005 through 2022. All studies included 16s rRNA or DNA amplification and\nsequencing. These studies collectively included 762 patients with pediatric ABA (ranging from 14 to\n268 patients per study). Patient data were analyzed in two strata: one cohort with primary ABA and",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 146,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_147",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "268 patients per study). Patient data were analyzed in two strata: one cohort with primary ABA and\nthe other with ABA with adjacent osteomyelitis. Both subgroups showed a significant increase in the\nyield of pathogen identification when PCR-based testing on synovial fluid was performed in addition\nto culture: a risk difference of 18.7% (95% CI: 12.1 to 25.3%) in 9 studies including 672 patients with\nprimary ABA [53, 54, 66, 68, 112, 153, 155, 157, 159] and a risk difference of 17.5% (95% CI: 5.8 to\n29.1%) in 2 studies including 176 patients included in cohorts not differentiating cases of primary\nABA and ABA with adjacent osteomyelitis [28, 61] (see Supplementary Material Figures IIIc ).\nWhen synovial fluid is initially obtained, it is reasonable to hold fluid for PCR and other molecular",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 147,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_148",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "testing that may be ordered later in situations where Gram stain and culture do not demonstrate a\npathogen; this technology is particularly important for demonstration of K. kingae, which often fails\nto grow with conventional cultures [27, 29, 61] or when antimicrobial therapy has been given prior to\nobtaining the synovial fluid [153].\nPCR technology has also been developed for detection of resistance markers for S. aureus (e.g.,\nmecA and erm genes). Application of these molecular tests for pediatric musculoskeletal infections\nhas been described [160, 161]. In these studies, there was excellent concordance for detection of\nmethicillin and clindamycin resistance, compared with conventional microbiological methods.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 148,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_149",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "methicillin and clindamycin resistance, compared with conventional microbiological methods.\nTarget-enriched multiplex polymerase chain reaction (TEM-PCR) technology can detect multiple\nbone and joint pathogens as well as resistance genes (e.g., mecA, ermA, ermC) and the virulence\nmarker Panton-Valentine leukocidin [161]. Even in culture positive musculoskeletal infections, rapid\nidentification of resistance by PCR can support more focused antimicrobial use. One study\npredicted that a musculoskeletal diagnostic panel would have decreased the time to pathogen\nidentification (by 7 hours), time to definitive antimicrobial therapy (by 22 hours) and hospital LOS (by\n26 hours) [162].\nNewer molecular techniques include metagenomic next-generation sequencing (mNGS), in which",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 149,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_150",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Newer molecular techniques include metagenomic next-generation sequencing (mNGS), in which\nnon-human nucleic acid sequences from microbial pathogens can be detected in plasma or in\nosteoarticular tissues and synovial fluid and matched with published whole genome sequences of\npathogens in order to detect matching sequences. This technique provides the potential to identify\nvirtually all infecting bacterial pathogens causing osteoarticular infections, in contrast to most PCR\ntechniques that can only identify one specific pathogen per PCR primer. This technique was\nrecently studied prospectively in pediatric osteoarticular infections in otherwise healthy children,\nwith 21 children enrolled with clinically diagnosed ABA [112]. Only 25% of synovial fluid bacterial",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 150,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_151",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "with 21 children enrolled with clinically diagnosed ABA [112]. Only 25% of synovial fluid bacterial\ncultures were positive, but mNGS identified a pathogen in 50%, similar to diagnosis rates in children\nanalyzed by culture plus PCR for K. kingae and B. burgdorferi. Both molecular techniques (PCR and\nmNGS) were able to diagnose K. kingae infections in children whose cultures were negative.\nRationale for Recommendation\nThis recommendation places a high value on confirming the microbiological diagnosis to allow\noptimization of the spectrum and duration of antimicrobial therapy. Indirect evidence shows that\nidentifying the causal pathogens is likely to lead to improved patient-important outcomes by",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 151,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_152",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "identifying the causal pathogens is likely to lead to improved patient-important outcomes by\nallowing for focused therapy with the narrowest spectrum antibiotics with the least toxicity, given for\nthe shortest microbiologically and clinically effective duration.\nObtaining specimens for culture and molecular tests from joint aspiration or other procedures\nimproves the likelihood of identification of and antimicrobial susceptibility data for the pathogen.\nThere is a wide range of pathogens that cause ABA. Knowledge of the pathogen and its\nsusceptibility pattern often simplifies treatment decisions by allowing antimicrobial therapy to be\nfocused on a specific organism that also allows for the transition to a pathogen-specific oral agent",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 152,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_153",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "for completion of the course of antimicrobial therapy. Despite the potential harms and costs\nassociated with these invasive procedures, the benefits of pathogen-related information are felt to\noutweigh undesirable effects of the procedures. The choice of the procedure(s) to obtain synovial\nfluid is based on patient- and institution-specific considerations, resources, and experience.\nResearch Needs\nProspective studies are needed on invasively collected joint tissue and synovial fluid that assess 1)\nthe sensitivity and specificity of advanced molecular testing, including next generation sequencing\nfor bacterial genomes to identify microbial etiology and 2) ability of such testing to provide\nsusceptibility data. Studies of inflammatory markers or biomarkers in serum and synovial fluid as",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 153,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_154",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "susceptibility data. Studies of inflammatory markers or biomarkers in serum and synovial fluid as\nmeans of distinguishing between infectious from non-infectious etiologies of arthritis would be\nhelpful.\nIV. At the time of presentation, can parenteral antimicrobial agent administration be delayed until\njoint specimens have been obtained?\nRecommendations:\n1. In children with presumed ABA who are ill-appearing or have rapidly progressive infection, we\nrecommend immediately starting empiric antimicrobial therapy (after blood cultures are\nobtained if possible) rather than withholding antibiotics until invasive diagnostic procedures are\nperformed (strong recommendation, moderate certainty of evidence). Comment: Invasive",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 154,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_155",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "performed (strong recommendation, moderate certainty of evidence). Comment: Invasive\ndiagnostic procedures should occur as soon as feasible, even if antibiotics have already been\nadministered.\n2. In children with presumed ABA who do not appear clinically ill, we suggest withholding\nantimicrobial therapy, while under careful observation, until an initial joint aspirate is collected\nfor diagnostic purposes (conditional recommendation, very low certainty of evidence).\nComment: The decision to initiate antimicrobials prior to invasive diagnostic procedures\ndepends on the severity of the clinical presentation, local accessibility to experts and resources\nor, if appropriate, the time required for transport to a higher level of care for additional",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 155,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_156",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "or, if appropriate, the time required for transport to a higher level of care for additional\ndiagnostic or debridement procedures. The ability to diagnose pathogens by molecular\ndiagnostic techniques suggests that critical information on pathogen identity is now less\ndependent on obtaining bacterial cultures prior to starting antimicrobial therapy.\nSummary of Evidence\nIn an attempt to maximize the identification and susceptibility testing of bacterial pathogens by\nculture, the standard of care for all bacterial infections has been to obtain cultures prior to\nadministration of antimicrobial therapy. However, the clinical status of the child also has an\nimportant impact on the timing of the first dose of empiric antimicrobial therapy. For children with",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 156,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_157",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "ABA accompanied by sepsis, extrapolation of data on outcomes from sepsis (without arthritis) in\nchildren based on timing of the start of appropriate antimicrobial agents is reasonable, as data\nspecific to sepsis with ABA have not been published. For the ill-appearing child with clinical sepsis\nand rapidly progressive disease, early antibiotic therapy is associated with improved outcomes. In a\nretrospective, multicenter study of 130 children with sepsis (21%) or septic shock (79%),\nantimicrobials given >3 hours after presentation were associated with a 4.92-fold increased risk of\nmortality (95% CI: 1.3 to 18.6) [163]. In a study of 1,179 children with sepsis at 54 hospitals,\ncompletion of a sepsis bundle, including empiric therapy with broad spectrum antimicrobials within 1",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 157,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_158",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "hour of presentation, was associated with a lower risk of in-hospital mortality (Odds ratio [OR]: 0.59;\n95% CI: 0.38 to 0.93, p-value = 0.02) [164].\nPublished data from adults with sepsis demonstrates the advantages of immediate therapy (rather\nthan delayed therapy) [71]. For adults with septic shock, a large, retrospective cohort study\ndemonstrated that appropriate therapy within one hour from documentation of hypotension yielded\na survival rate of 80%, but each hour of delay during the first 6 hours of shock was associated with\na 7.6% decrease in survival [165]. Results from a large retrospective review of 18,000 adults with\nsepsis from 165 ICUs in Europe, the US, and South America confirmed increasing mortality rate with",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 158,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_159",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "sepsis from 165 ICUs in Europe, the US, and South America confirmed increasing mortality rate with\neach additional hour of time to first administration of antimicrobials during the first 6 hours following\ndiagnosis of sepsis [166]. Improved metrics in other patient-important outcomes such as intensive\ncare unit (ICU) LOS and overall hospital LOS, have also been identified with earlier antimicrobial\ntherapy [167]. These data indirectly support the recommendation for early administration of\nantimicrobials to children with sepsis and suspected ABA if resources for invasive sampling of fluid\nfrom the infected joint are not immediately available at the time of presentation for medical care.\nFor children with more indolent infection, the question of whether there is a benefit to withholding",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 159,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_160",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "antimicrobials until joint fluid can be obtained by those qualified to perform such procedures is\nimportant, particularly when considering the benefits of pathogen identification and susceptibility\ntesting by culture. For children who require transfer to a higher level of care, a delay of several hours\nprior to sampling the infected joint may occur.\nIn our systematic review of the literature, we were unable to find prospectively collected data to\naddress the risks and benefits of delays in the start of empiric antimicrobial therapy for children with\npresumed ABA. We did identify six retrospective observational studies that assessed the impact of\nempiric antibiotic administration prior to joint fluid collection in children with suspected ABA (see",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 160,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_161",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Table 3  and Supplementary Material Figures IV ) [54, 62, 66, 112, 154, 155]. All six studies had\nsmall sample sizes and reported only unadjusted analyses. These studies often did not provide\ncritical information such as specifics of antibiotics that were administered, or their appropriateness,\nor duration of antibiotic pre-treatment.\nAll six studies reported the yield of positive culture with or without antibiotic pre-treatment, but only\none reported the patient-important outcomes of complications, requirement for repeated joint\ndebridement and time from symptom onset to initial joint debridement [154]. The pooled analysis of\nthe six studies suggests a comparable yield of synovial fluid cultures with or without antibiotic pre-",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 161,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_162",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "treatment (RD: 1.2% increased yield (95%CI: -12.0 to 14.5%)).\nThe analysis of these patient-important outcomes, mainly derived from retrospective data review,\nshowed that delaying antibiotics until after joint fluid collection may or may not have reduced the\nincidence of complications (RD: -12.0%, 95%CI: -33.0 to 9.0%) and the requirement for repeated\nirrigation and debridement (“washouts”) (RD: -4.0%, 95%CI: -25.3 to 17.3%). However, the certainty\nin the evidence was judged to be very low due to 1) very serious risk of bias (retrospective study\ndesign, missing critical information regarding appropriateness, and timing and clinical response to\nthe empiric pretreatment antibiotics, all of which could have influenced the measured outcomes), 2)",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 162,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_163",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "the empiric pretreatment antibiotics, all of which could have influenced the measured outcomes), 2)\nuse of unadjusted analyses (clinical outcomes were not stratified or adjusted for critical variables\nsuch as age and pathogen) and 3) imprecision based on small number of events, small sample size\nand estimates not reaching statistical significance.\nThe yield of bacterial cultures of joint fluid may be suboptimal for the identification of a pathogen\nwithout the addition of molecular diagnostic tests. For example, of the 5 studies included in our\nanalysis, K. kingae was identified in less than 1% of cases (3 reported cases out of 312 children\nevaluated for a pathogen). However, the frequency of isolation, by study site, varied from no",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 163,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_164",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "evaluated for a pathogen). However, the frequency of isolation, by study site, varied from no\nreported K. kingae, to 12% of isolates identified as K. kingae from an institution in Seattle that used\nPCR in addition to culture for microbiologic diagnosis [54]. These data suggest that pretreatment of\nchildren with antibiotics is not likely to impact a pathogen diagnosis by molecular techniques,\ncompared with standard microbiological techniques, although the impact of prior antimicrobial\ntherapy on the positivity rates of molecular-based pathogen tests has not been prospectively\nevaluated. However, it is biologically plausible that the timeframe in which a pathogen’s nucleic\nacids can be detected by PCR or next generation sequencing may be longer following exposure to",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 164,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_165",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "acids can be detected by PCR or next generation sequencing may be longer following exposure to\nantimicrobials compared with standard microbiological culture (see Question III).\nPotential complications of delayed antimicrobial therapy include persisting/increasing inflammation\nin the joint due to lack of effective therapy, which could potentially increase risk for chondrolysis.\nSuch chondrolysis may vary by age of the child, joint involved, and pathogenicity of the organism\ncausing infection, but published data are not available to quantify this risk if it exists. It is also\npossible that early antimicrobial therapy prior to drainage of the infected joint could produce\nincreased inflammation in the joint from the lysis of pathogens in the joint fluid with risk of additional",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 165,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_166",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "cartilage injury, but as noted above, data to quantify this risk have not been published.\nThe risk of complications from joint aspiration by those not experienced or qualified has not been\nprospectively evaluated, but likely depends on the joint involved, the age of the child, and the level\nof training of the person performing this procedure.\nRationale for Recommendation\nThe benefits of early antimicrobial therapy prior to surgical sampling of joint fluid in children with\nsepsis are likely to outweigh any potential harms from not knowing the pathogen or susceptibilities.\nInfants and children with suspected ABA may present to primary care practitioners, urgent care\nclinics or emergency departments in a wide range of settings (rural, suburban, or urban), and so",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 166,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_167",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "clinics or emergency departments in a wide range of settings (rural, suburban, or urban), and so\nmay present at institutions without pediatric orthopedic expertise. Retrospective review of low-\nquality data did not document a decrease in the culture isolation rate with antimicrobial therapy prior\nto sampling the joint fluid, as noted above. Molecular testing may still be able to detect the pathogen\nwhen joint fluid is obtained after antimicrobial therapy if cultures are negative.\nFor children with no signs of sepsis, withholding antibiotic therapy until after sampling of joint fluid\ntheoretically may allow for increased isolation of pathogens and susceptibility testing, particularly\nfor more fastidious pathogens. In addition, children may possibly benefit from waiting for a person",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 167,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_168",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "for more fastidious pathogens. In addition, children may possibly benefit from waiting for a person\nskilled in the procedures for sampling joint fluid to be available, even if this requires transfer to a\nhigher level of care, when compared with having a person not as skilled in these procedures\nemergently perform the sampling, possibly leading to complications. However, no data have been\npublished to support a specific number of hours of delay that can be considered risk-free prior to\nstarting effective antibiotic therapy.\nResearch Needs\nProspectively collected data are important to answer the question of the impact of effective empiric\nantibiotic therapy on relevant outcomes for children with ABA. In future studies, the covariates that",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 168,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_169",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "may impact outcomes in pediatric ABA (joint involved, the age of the infant or child, and the\npathogen responsible for the infection) should be controlled in order to assess a positive or negative\nimpact (and the magnitude of the impact) of antibiotics administered to a child prior to invasive\nsampling of joint fluid. Molecular diagnostic techniques, including PCR targeting pediatric ABA\npathogens, mNGS, or pathogen-specific molecular antigen tests should be prospectively studied\nsimultaneously with joint fluid cultures, to assess the ability to diagnose specific pathogens,\nparticularly fastidious organisms.\nV. Which empiric antimicrobial agent(s) should be provided for children with suspected ABA?\nRecommendations:",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 169,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_170",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Recommendations:\n1. In children with suspected ABA, we recommend using empiric antimicrobial therapy active\nagainst S. aureus (strong recommendation, moderate certainty of evidence). Comment:\nAntimicrobials with activity against community-acquired MRSA (CA-MRSA) should be\nconsidered based on local susceptibility data and severity of disease. Adding empiric\nantimicrobial coverage for pathogens in addition to coverage for S. aureus may be warranted\nwhen other pathogens are suspected based on relevant aspects of immunization, exposure\nhistory, clinical presentation, or physical examination.\n2. In infants and preschool aged children (6 to 48 months of age) with suspected ABA, we suggest\nselecting empiric therapy to include activity against K. kingae rather than only targeting S.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 170,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_171",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "selecting empiric therapy to include activity against K. kingae rather than only targeting S.\naureus (conditional recommendation, very low certainty of evidence). Comment: With K. kingae\nreported as the most frequent pathogen in this age group in recent studies, additional therapy is\nsuggested if empiric therapy used for S. aureus is not active against K. kingae.\nSummary of Evidence\nAs with all infections, empiric therapy for suspected ABA is designed to provide effective therapy\nagainst the most prevalent pathogens that cause injury to the joint. S. aureus has historically been\nknown to be a common pathogen causing ABA in all age groups [91, 168-177]. Our systematic\nreview of the literature found 32 studies of confirmed primary ABA (published 2005 through 2022)",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 171,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_172",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "review of the literature found 32 studies of confirmed primary ABA (published 2005 through 2022)\nincluding 1,729 children in whom a microbiologic etiology was determined by positive culture or PCR\nof tissue and/or blood (see Supplementary Material Table V ) [12, 23, 25, 50-59, 66-69, 76, 94,\n112, 119, 121, 141, 147, 154, 157, 158, 168, 178-181]. Overall, S. aureus has historically been the most\ncommonly detected organism to cause ABA secondary to hematogenous spread in all age groups.\nThe pooled rate of S. aureus infections was 42.6% (95%CI: 35.1 to 47.2%) for those with ABA in\nabsence of osteomyelitis, but significantly higher in those with associated osteomyelitis (n=211 from\n6 studies, 69.9% (95%CI: 47.9 to 78.2%)) [12, 23, 119, 121, 178, 181]. In fact, our analysis showed that",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 172,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_173",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "S. aureus was more than twice as likely to be the causative organism in patients with ABA and\nadjacent osteomyelitis, compared with those with primary ABA (OR: 2.44, 95%CI 1.81 to 3.27).\nThe proportion of CA-MRSA in ABA varied widely geographically and over time during the past few\ndecades but was documented to be as high as 50-60% of all S. aureus isolates in some reports [70,\n179]. Of importance, since 2018, the incidence of CA-MRSA causing bone and joint infections\nappears to be decreasing in reports from North America, which may impact decisions for empiric\ntherapy if this trend continues [182, 183].\nAlso important in the selection of empiric therapy is knowledge of the proportion of bacterial",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 173,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_174",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Also important in the selection of empiric therapy is knowledge of the proportion of bacterial\npathogens other than S. aureus identified from infected joints in children (either by culture or by\nPCR), ranging in our analysis of the literature from 15.4% to 92.1% (see Supplementary Material\nTable V ). Data for this table were extracted from the published literature – primarily retrospective\nreviews. The isolation of pathogens depended on the frequency of sampling inflamed joints;\nsampling frequency was dependent on how each center approached children with inflammation (of\nvarious degrees) that was present in different involved joints (e.g., hips vs knees). The decision to\nsample and analyze the joint fluid was usually at the discretion of a surgeon. The surgical",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 174,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_175",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "sample and analyze the joint fluid was usually at the discretion of a surgeon. The surgical\ntechniques (aspiration, arthroscopy, open procedure) to sample synovial fluid were not\nstandardized. The techniques used for pathogen identification were largely based on standard\nmicrobiology culture in most publications prior to 2010. The decision to pursue molecular testing on\nsynovial fluid for research or for clinical care has evolved over the past 2 decades; molecular\ntechniques used for diagnosis in the literature have not been standardized between institutions. In\nreports from Europe and North America, K. kingae was demonstrated to be a common pathogen in\npediatric ABA in infants and preschool aged children and was the most commonly identified",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 175,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_176",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "pediatric ABA in infants and preschool aged children and was the most commonly identified\npathogen in some [25, 28, 29, 53, 58, 94]. It is likely that recently described high rates of K. kingae\ndetection are based on increased use of sensitive molecular techniques that provide enhanced\ndetection (See Question III). Group A Streptococcus is a relatively common pathogen for pediatric\nABA, representing up to 14% of identified pathogens in some studies [70].\nPrior to widespread immunization with conjugate vaccines against pneumococcus and Hib, these\npolysaccharide encapsulated pathogens were frequent causes of ABA in infants but are now\nunusual in highly immunized populations. Similarly, meningococcus can cause joint infection as part",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 176,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_177",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "unusual in highly immunized populations. Similarly, meningococcus can cause joint infection as part\nof invasive infection, although much less commonly than pneumococcus or Hib. Detection of\npathogens against which vaccines are not effective may also be age-dependent (e.g., Group B\nstreptococcus and E. coli in very young infants). History of exposures to the environment and\npotentially contaminated foods should be obtained, as infection by certain pathogens such as\nSalmonella spp and Brucella spp may occur under these circumstances; empiric therapy that\nprovides additional activity against these pathogens may be appropriate. For adolescents, sexual\nexposure is a risk factor for N. gonorrhoeae septic arthritis/tenosynovitis. Overall, in our review of",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 177,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_178",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "the recent literature, no pathogen other than S. aureus, K. kingae, and group A Streptococcus,\noccurred in greater than 5% of cases of ABA in any study (see Supplementary Material Table V ).\nIn general, the acute nature of ABA is distinct from that caused by mycobacteria (including M.\ntuberculosis) or fungi, that are not addressed in these Guidelines. Similarly, penetrating trauma to\nthe joint or surrounding structures is associated with additional or unusual pathogens that require\nconsideration in the selection of empiric therapy but will not be discussed in these Guidelines.\nDecisions on empiric therapy are best informed by review of the most recent data on ABA\npathogens identified in a clinician’s region, particularly with respect to susceptibility of S. aureus",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 178,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_179",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "isolates. Therapy for S. aureus was developed in the 1940’s, initially with the discovery and use of\npenicillin and subsequently with creation of anti-staphylococcal penicillins and cephalosporins\nactive against penicillin-resistant strains of S. aureus. It is understandable that clinicians used these\nantibiotics several decades ago to treat proven and suspected S. aureus infections in children\nwithout the conduct of randomized, placebo-controlled trials. Initially, efficacy was often assessed\nby comparing the outcomes of those treated with these antibiotics to the outcomes of historical\ncontrols from the pre-antibiotic era. Since the emergence of CA-MRSA infections, no prospective\ncontrolled studies in pediatric ABA have evaluated the efficacy and safety of empiric regimens that",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 179,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_180",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "controlled studies in pediatric ABA have evaluated the efficacy and safety of empiric regimens that\ncompare anti-MRSA regimens with those that only provide activity against MSSA. While currently\nisolated S. aureus strains are almost uniformly penicillin-resistant, many remain susceptible to\nantistaphylococcal penicillins (ASP) such as methicillin (no longer commercially available in the\nUSA), oxacillin, and nafcillin, as well as to first generation cephalosporins such as cefazolin and\ncephalexin. Cefazolin and nafcillin/oxacillin are considered therapeutically equivalent in pediatric\nABA as well as in osteomyelitis, based on retrospective, non-comparative studies in children;\nhowever, no comparative data are available for an ASP and cefazolin.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 180,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_181",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "however, no comparative data are available for an ASP and cefazolin.\nIn regions with low rates of CA-MRSA arthritis (less than ~10%), some experts begin therapy with\noxacillin/nafcillin or cefazolin for children with mild to moderate illness, watching closely for a\nresponse to treatment. In regions where resistance to methicillin is estimated to be 10-20% or\ngreater, consideration should be given for empiric therapy to include agents for which in vitro and\nprospective clinical data exist for antimicrobials with activity against invasive CA-MRSA infection.\nFor these agents, adequate joint drug exposure is expected, even if specific studies of synovial fluid\nconcentrations have not been performed. Effective empiric therapy for CA-MRSA ABA is expected",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 181,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_182",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "concentrations have not been performed. Effective empiric therapy for CA-MRSA ABA is expected\nwith clindamycin (unless local clindamycin resistance rates are high), vancomycin, daptomycin,\nceftaroline, and linezolid. Clindamycin resistance occurs in both MRSA and MSSA, and should be a\nfactor in selecting empiric therapy, given substantial resistance documented in some regions (5% to\n40% of all S. aureus isolates). For reasons of drug safety, when the infecting strain is suspected to\nbe susceptible to both clindamycin and vancomycin, empiric use of clindamycin (which is available\nin both intravenous and oral formulations) is preferred over vancomycin.\nFor children suspected to have S. aureus ABA for whom ASPs, vancomycin, or clindamycin cannot",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 182,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_183",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "For children suspected to have S. aureus ABA for whom ASPs, vancomycin, or clindamycin cannot\nbe used due to concerns for suspected antibiotic resistance or poor tolerability, alternative therapy\nis available. Parenteral daptomycin, parenteral ceftaroline, and parenteral/oral linezolid have been\nstudied in prospective pediatric trials for complicated staphylococcal skin infections, including\nMRSA, and provide additional options for treatment based on in vitro susceptibility testing.\nDaptomycin has also been prospectively studied in pediatric osteomyelitis [184]. Further,\nalternatives to vancomycin should be considered for MRSA infections caused by relatively\nvancomycin-non-susceptible strains (MIC ≥ 2 µg/mL), given the higher vancomycin doses that may",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 183,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_184",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "vancomycin-non-susceptible strains (MIC ≥ 2 µg/mL), given the higher vancomycin doses that may\nbe required to achieve pharmacodynamically targeted serum exposures [185].\nTrimethoprim/sulfamethoxazole (TMP/SMX) demonstrates in vitro activity against most strains of S.\naureus, including CA-MRSA, and has been shown to be effective in the treatment of uncomplicated\nskin infections caused by CA-MRSA, however no controlled, comparative data exist on the use of\nTMP/SMX for ABA caused by CA-MRSA, although some experts recommend use [186]. No\ncontrolled, comparative data exist to suggest superior efficacy or effectiveness of any one of the\nabove agents versus the others in treating invasive MRSA infections in children, assuming that the\nisolate is susceptible.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 184,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_185",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "isolate is susceptible.\nWhile the use of combination antimicrobial therapy for potential synergistic effects is a common\npractice in the treatment of severe infection caused by CA-MRSA, no controlled data are available\non which to base recommendations for such combination therapy to improve outcomes. However,\nuse of multiple agents in combination to increase the antibacterial spectrum of empiric therapy is\nappropriate for severe infections, particularly when coverage of Gram-negative pathogens is\nneeded in addition to S. aureus.\nS. pneumoniae remains an occasional cause of ABA, particularly in children who have not received\npneumococcal conjugate vaccine (PCV) [187]. Antibiotics with activity against S. aureus are usually",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 185,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_186",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "pneumococcal conjugate vaccine (PCV) [187]. Antibiotics with activity against S. aureus are usually\nactive against pneumococci, although some beta-lactam antibiotics may not be effective against\nstrains of pneumococcus with reduced susceptibility to parenteral penicillin (MIC > 2 mcg/ml).\nClindamycin resistance in pneumococcus occurs in up to 10% of strains in some populations of\nchildren [188].\nS. pyogenes is usually susceptible to agents active against CA-MRSA or MSSA, although resistance\nto clindamycin has been reported [189].\nFor K. kingae and other Gram-negative pathogens, many agents active against CA-MRSA do not\nprovide adequate antimicrobial activity, including ASPs, vancomycin, clindamycin, daptomycin and",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 186,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_187",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "provide adequate antimicrobial activity, including ASPs, vancomycin, clindamycin, daptomycin and\nlinezolid, supporting a need for additional empiric antimicrobial coverage with ampicillin or a\ncephalosporin if these antibiotics are used [190]. Current global epidemiologic studies for K. kingae\ndocument beta-lactamase positivity (ampicillin-resistant) rates of approximately 25%, although\nmost beta-lactamase positive strains are colonizing rather than invasive strains [32, 191-193].\nNo controlled data exist on the incidence of complications or outcomes in children with untreated K.\nkingae infections (including endocarditis). However, retrospective data reported for children with\nculture-negative ABA (believed by the authors to include children with unrecognized K. kingae",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 187,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_188",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "culture-negative ABA (believed by the authors to include children with unrecognized K. kingae\ninfection) suggested that active antibiotic therapy may not always be required. Of 89 children with\nculture negative arthritis without osteomyelitis, 55 were less than 5 years of age; only 13% received\nempiric therapy active against K. kingae. At the time of discharge on oral therapy, only 18% received\nan antimicrobial active against K. kingae. No long-term disability was noted in any child at 6 months\nfrom hospital discharge [24]. Although antimicrobial therapy against K kingae is likely to provide\nsome benefit, no published data document the degree of benefit or the risk of adverse outcomes\ncompared with those who receive no active antibiotic treatment.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 188,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_189",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "compared with those who receive no active antibiotic treatment.\nFor the clinically stable child who is treated empirically with clindamycin, vancomycin, daptomycin\nor linezolid, the addition of a cephalosporin (cefazolin, cefuroxime, or cefotaxime/ceftriaxone) or\nampicillin may be considered if K. kingae is suspected based on lack of clinical response or\ndetected by positive cultures or molecular tests. Ceftaroline also demonstrates in vitro activity\nagainst Gram-negative pathogens including Hib, E. coli and K. kingae, similar to\ncefotaxime/ceftriaxone, in addition to providing MRSA activity, and may be considered for empiric\ntherapy if more broad-spectrum activity is needed [194].\nParenteral administration of empiric antimicrobial therapy is appropriate and necessary for the vast",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 189,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_190",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "majority of ABA presentations. Occasional circumstances, with careful consideration, may permit\nuse of an oral regimen from the outset. (See Question XI).\nRationale for Recommendation\nThe existing literature on antimicrobial therapy for pediatric ABA for S. aureus, K. kingae, and other\npathogens is limited by the retrospective nature of published data, as well as inconsistent\nmethodology, varied populations reported, non-standardized surgical management and limited\npatient datasets for clinical and laboratory assessment of disease at the time of treatment or at\npost-hospitalization follow up. All these limitations add some uncertainty to conclusions drawn from\nthe published data. No high quality prospectively collected comparative data are available to",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 190,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_191",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "the published data. No high quality prospectively collected comparative data are available to\nestimate disease burden or outcomes caused by the different ABA pathogens, particularly in light of\ntreatment with different antimicrobial agents.\nDespite the lack of high-quality data, the clinical use of several antimicrobial agents with in vitro\nactivity against S. aureus has been effective for treatment of pediatric ABA over the past 4 decades.\nFurther, the benefits of providing active therapy for treatment of S. aureus (rather than not treating)\nto decrease joint destruction, are judged to be far greater than the potential harms of antimicrobial\ntherapy. Based on this body of indirect evidence, the Guideline Panel agreed that the certainty in the",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 191,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_192",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "balance of the magnitude of benefit over any harms of using empiric antimicrobial therapy active\nagainst S. aureus is high, and that all other considerations clearly favor this course of action (such\nas the patient’s values and preferences, the costs, and feasibility), and thus support a strong\nrecommendation.\nFor K. kingae, no prospectively collected comparative data exist on the impact of one antimicrobial\nversus another, or the impact of antimicrobial treatment vs no antimicrobial treatment, assuming all\nchildren have surgical aspiration/debridement and irrigation of infected joints. The available indirect\nevidence, mainly consisting of a relatively limited number of retrospective reports, shows a possible",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 192,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_193",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "but minimal clinical effect of empirically adding coverage for K. kingae. Thus, even if it is biologically\nplausible that effective antibiotic therapy will produce improved outcomes for pediatric ABA, the\nGuideline Panel agreed that the certainty in the balance of benefits versus harms was very low. This\nagreement is based on existing evidence concerning broadening the spectrum of empiric therapy to\ninclude activity against K. kingae for infants, toddlers, and preschool-aged children (6 to 48 months\nof age). Thus, only a conditional recommendation was made.\nAppropriate choice of empiric therapy should be guided by local antibiotic resistance patterns (CA-\nMRSA) and/or hospital antibiogram as well as disease severity and immunization status. Although",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 193,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_194",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "MRSA) and/or hospital antibiogram as well as disease severity and immunization status. Although\nmany antibiotics may show activity in vitro against bacterial pathogens that cause ABA, lack of\npublished data for treatment of children with ABA using one of these alternative options does not\npermit recommendations for their routine use at this time. Similarly, for the child with relatively mild\ndisease, no prospective data exist on the efficacy of oral therapy used at the start of treatment\n(rather than parenteral therapy). Therefore, our committee did not provide a recommendation for\nstarting treatment by the oral route of administration.\nResearch Needs\nNewer parenterally administered antimicrobial agents with activity against S. aureus, including those",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 194,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_195",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "targeting CA-MRSA (such as ceftaroline, daptomycin, linezolid, oritavancin, dalbavancin, telavancin)\nshould be compared with standard-of-care antimicrobial therapy for MRSA infection (vancomycin\nand clindamycin). Orally administered agents with activity against S. aureus, particularly those\nactive against CA-MRSA (clindamycin, linezolid, tedizolid, TMP/SMX), should be compared for\nefficacy and safety as convalescent oral therapy for ABA. Newer agents with increased activity\nagainst S. aureus, particularly those with excellent absorption, tolerability, and high joint antibiotic\nexposure are needed. Evaluation of combination antibiotic therapy for severe disease would provide\nuseful information to determine if more rapid sterilization of the joint space to improve long-term",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 195,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_196",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "useful information to determine if more rapid sterilization of the joint space to improve long-term\noutcomes might be achieved. The role of medical therapy alone vs open surgical\ndrainage/aspiration/arthroscopic drainage with medical therapy should be investigated to assess the\ntime course of sterilization of the joint, clinical response and long-term morbidity following ABA.\nControlled data on the outcomes of preschool children with documented K. kingae ABA are needed,\nas are controlled data on the benefits of active anti-Kingella therapy, particularly in children with\nadequate source control.\nVI. When should advanced imaging be performed and/or invasive procedures be repeated in the\nmanagement of presumed or confirmed bacterial arthritis in children?\nRecommendations:",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 196,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_197",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "management of presumed or confirmed bacterial arthritis in children?\nRecommendations:\n1. In children with presumed or confirmed ABA who demonstrate a poor clinical and laboratory\nresponse within 48-96 hours (continued fever, persistent bacteremia and/or rising CRP) after\ninitial invasive procedures (open or arthroscopic) and initiation of appropriate antimicrobial\ntherapy, we suggest performing MRI if not previously obtained (conditional recommendation,\nvery low certainty of evidence). Comment: MRI is performed to evaluate for adjacent AHO,\npyomyositis, or abscess as potential indications of ineffective source control to provide a basis\nto determine whether additional invasive procedures should be considered.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 197,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_198",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "to determine whether additional invasive procedures should be considered.\n2. In children with presumed or confirmed primary ABA who demonstrate a poor clinical and\nlaboratory response within 48-96 hours (continued fever, persistent bacteremia and/or rising\nCRP) after initial invasive procedures, and evidence to suggest persisting foci of infection\n(ineffective source control), we suggest additional invasive procedures to ensure adequate\nsource control (conditional recommendation, very low certainty of evidence). Comment: When\nABA is associated with adjacent osteomyelitis, management should follow the osteomyelitis\nguideline [37].\nSummary of Evidence\nFor consideration about initial invasive procedure type and timing, please see Question III. Many",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 198,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_199",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "For consideration about initial invasive procedure type and timing, please see Question III. Many\nchildren will re-accumulate fluid in the joint space despite the initial invasive procedure(s) to\nmanage their ABA, even with placement of drains. Fluid re-accumulation is not a cause for undue\nconcern among children who are clinically improving. Ongoing observation with clinical\nreassessment is generally appropriate. With effective antibiotic and surgical therapy, most children\nwith primary ABA will improve quickly. Ongoing findings of systemic illness or persistent bacteremia\nshould prompt an evaluation for localized disease both within and beyond the joint. \nWhile there are no high-quality data to guide the decision for when repeated invasive surgical",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 199,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_200",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "While there are no high-quality data to guide the decision for when repeated invasive surgical\nprocedures (such as arthroscopy or arthrotomy after arthrocentesis) are required, surgeons should\nconsider performing further procedures on the affected joint for children who are failing to improve\nor are worsening clinically [195]. Retrospective studies of children with ABA of the hip have\nidentified higher preoperative temperature, initial misdiagnosis of ABA, longer time from initial\nsymptoms to surgery, presenting CRP >100 mg/L (normal <10), presenting ESR >40 mm/hour,\nadjacent AHO, and intraoperative cultures positive for MRSA as risks for requiring a repeat\nprocedure [196, 197]. These repeat procedures allow for better source control of the infection and",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 200,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_201",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "procedure [196, 197]. These repeat procedures allow for better source control of the infection and\nmay provide new data from joint fluid or biopsies to support an alternative, non-infectious diagnosis.\nSimilarly, bone biopsy or curettage should be considered in those with concern for adjacent\nosteomyelitis.\nThe choice of method for repeat procedures (open, arthroscopic, repeated needle aspiration) is\nlargely guided by the experience of the orthopedic surgeon. However, if an initial (or serial) needle\naspiration is not successful, then a more extensive approach (arthrotomy or arthroscopy) is\ngenerally indicated. Approximately 10% of children randomized to aspiration in a study conducted in\nMalawi required a second aspiration but had clinical outcomes equivalent to their counterparts",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 201,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_202",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Malawi required a second aspiration but had clinical outcomes equivalent to their counterparts\nrandomized to arthrotomy [131]. While no other studies have prospectively compared differences in\noutcomes between repeated needle aspirations and formal arthrotomy with irrigation for various\njoints (e.g., hip or shoulder) affected by common ABA pathogens, several investigators have\nreported excellent ABA outcomes with serial aspirations, which were required in between 4% to\n20% of patients [102, 126, 127, 198]. A small case series suggests that failure rate with repeated\naspirations may be higher among children older than 10 years, compared those of younger children\n[199].\nSerial arthroscopy may likewise be necessary to address joint fluid re-accumulation or ongoing",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 202,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_203",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Serial arthroscopy may likewise be necessary to address joint fluid re-accumulation or ongoing\nsymptoms for those managed with initial arthroscopy. In two small case series, including young\nchildren and those with hip ABA, serial arthroscopy was reported to be required in approximately 10-\n15% of patients [200, 201]. One small series found that no children with arthroscopy-managed ABA\nof the knee required repeat procedures, compared with 39% of children managed by open\narthrotomy, and that the arthroscopy group improved more quickly as determined by joint range of\nmotion and weight-bearing [138]. In general, however, most experts would favor formal arthrotomy\nwith irrigation and drainage for children with ongoing symptoms during ABA of the hip.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 203,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_204",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "with irrigation and drainage for children with ongoing symptoms during ABA of the hip.\nFollowing initial irrigation and drainage of the infected joint, the surgeon may place a drain to allow\ncontinued evacuation of the joint during the early post-operative period while antibiotics are being\nadministered. No well-conducted studies are available to guide the selection of drain type or the\nlength of time the drain should remain in place. Typically, drains are removed at the bedside when\ntheir output volume becomes low, usually within a few days of surgery. Once the drain has been\nremoved, the moderate amount of ongoing joint inflammation may produce joint fluid that outpaces\nits reabsorption, but as inflammation decreases for children improving on antibiotic therapy,",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 204,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_205",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "its reabsorption, but as inflammation decreases for children improving on antibiotic therapy,\nreabsorption eventually reduces joint swelling in most cases.\nRationale for Recommendation\nThis conditional recommendation is based on very low certainty of evidence, and places high value\non considerations of patient values and preferences, feasibility, acceptability, equity, and cost in\nrecommending that children with primary ABA with worsening symptoms after an initial procedure\nhave advanced imaging and a repeat procedure as necessary for source control.\nResearch Needs\nFuture research needs include comprehensive prospective studies to develop methods of stratifying\nseverity of illness at the initial medical encounter for children with ABA, to predict which children are",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 205,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_206",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "more likely to need repeat invasive procedures. Stratification by pathogen and involved joints will\nfacilitate the clinical utility of such studies. Comparing outcomes from the various types of\nprocedures to obtain source control (needle aspiration, arthrotomy, arthroscopy), by joint and by\npathogen would be helpful, as well as determining the need and outcomes for repeated procedures.\nVII. In children with presumed or confirmed ABA who require a surgical procedure, should\nsurgically administered (intra-articular) antimicrobial agents be routinely used in addition to\nsystemic antimicrobial therapy?\nRecommendation:\nIn children with presumed or confirmed ABA who require a surgical procedure, we recommend",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 206,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_207",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "In children with presumed or confirmed ABA who require a surgical procedure, we recommend\nagainst the routine use of intra-articular antimicrobial agents (strong recommendation, very low\ncertainty of evidence). Comment: This recommendation places a high value on avoiding\nunnecessary harms and costs associated with this intervention.\nSummary of Evidence\nHigh cure rates are achieved with systemic antimicrobials and drainage of infected articular fluid in\nchildren, precluding the need for surgical site (i.e., intra-articular) antimicrobial administration. (See\nQuestion XV). One potential desirable effect of intraarticular administration includes high, local\nantibiotic concentrations with decreased systemic exposure and associated toxicity. However, most",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 207,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_208",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "antibiotic concentrations with decreased systemic exposure and associated toxicity. However, most\nantibiotics achieve excellent concentrations in synovial fluid following parenteral or oral\nadministration [202, 203]. Moreover, there is a theoretical concern (without identifiable formal\nevidence) that intra-articular administration of antibiotics could produce chemical irritation and\ninflammation. Since pediatric data regarding the practice of intra-articular antibiotics are lacking,\ninformation must be drawn primarily from adult data of chronic osteomyelitis and prosthetic joint\ninfections.\nA few case series have reported outcomes in adult patients with chronic osteomyelitis managed by\nsingle-stage surgery using biodegradable tobramycin-impregnated calcium sulfate pellets",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 208,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_209",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "single-stage surgery using biodegradable tobramycin-impregnated calcium sulfate pellets\n(OSTEOSET(®)-T) in association with systemic antibiotic therapy [204, 205]. In children, a few\nretrospective chronic osteomyelitis (not ABA) case series have reported preliminary results on a\nlimited number of patients with relatively short periods of follow-up [206, 207]. The patient\npopulations in these studies form a heterogeneous group in terms of age, bone localization site, and\ntype of chronic infection. These uncontrolled studies suggest that single-stage surgery using\nsurgically placed antibiotics at the local site in association with systemic antibiotic therapy yields\nsatisfactory outcomes and could potentially reduce the risk of recurrence of chronic osteomyelitis",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 209,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_210",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "satisfactory outcomes and could potentially reduce the risk of recurrence of chronic osteomyelitis\n[206, 207]. Prospective data on the use of locally placed antibiotics for osteomyelitis or ABA have\nnot been published. A review article describes advances in the local and targeted delivery of\nantibiotics, including antibiotics in biodegradable materials, for the management of osteomyelitis in\ngeneral, but is not specific to the pediatric population or to ABA [208].\nPotential toxicity associated with the use of aminoglycosides or glycopeptides placed\nintraoperatively, the cost and other potential harms related to the need for a second surgical\nprocedure (when non-biodegradable implants are used) including the risk of general anesthesia,",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 210,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_211",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "procedure (when non-biodegradable implants are used) including the risk of general anesthesia,\nbleeding, surgical site infection, etc. need to be considered. In a study of neonatal osteomyelitis,\nlocally applied gentamicin produced serum concentrations close to the minimal therapeutic\nconcentration over a prolonged period [209]. Although there was no clinical evidence of renal failure\nand serum urea and creatinine levels during treatment with gentamicin remained normal, subclinical\ninjury to the renal tubules, based on urine biomarkers, was reported in this study. Notably, there was\nno impairment of auditory function in the participants. Data regarding toxicity in neonates may not\nbe easily extrapolated to older children who have higher renal aminoglycoside clearance that may",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 211,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_212",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "be easily extrapolated to older children who have higher renal aminoglycoside clearance that may\nresult in lower systemic exposure. In a case series, wound complications were encountered in 52%\nof 21 patients following placement of biodegradable calcium sulfate/tobramycin mixture as an\nadjuvant treatment of chronic osteomyelitis of the tibia following exogenous trauma [205].\nCase series of prosthetic joint infections (PJI) are similarly limited to adults. A retrospective analysis\nof 51 adults with culture negative PJI who received vancomycin and imipenem placed directly into\nthe joint space reported favorable cure rates. [210] The results suggest that the use of intra-articular\nantibiotics may allow for single stage revisions, even for culture negative PJI. However, it is",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 212,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_213",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "antibiotics may allow for single stage revisions, even for culture negative PJI. However, it is\nimportant to note that the pathophysiology of PJI is distinct from ABA in children, based in part on\nbiofilm production on the prosthesis and different bacterial pathogens.\nRationale for Recommendation\nThe primary rationale for this recommendation is that, in general, the outcome of ABA in children\nwho are treated appropriately is not documented to be improved with the addition of intraparticularly\nplaced antibiotics. The potential additional risks of therapy and costs preclude a recommendation\nfor routine surgical placement of antibiotics. A strong recommendation against this practice, despite\nvery low certainty evidence, is made due to uncertain benefit with certain harms and costs.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 213,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_214",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "very low certainty evidence, is made due to uncertain benefit with certain harms and costs.\nResearch Needs\nBetter defining and investigating the ABA populations who may benefit from local antibiotic\nplacement would be helpful. Such populations may include those with unusual infectious causes\nwith the potential of inadequate anti-infective drug exposure (e.g., highly resistant gram-negative\npathogens, those with fungal or mycobacterial pathogens, those with PJI, and those with sites of\ninadequate blood flow).\nVIII. What is the role for adjuvant corticosteroids in children with presumed or confirmed ABA?\nRecommendation:\nIn children with presumed or confirmed ABA, we suggest against using adjunctive corticosteroid",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 214,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_215",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "In children with presumed or confirmed ABA, we suggest against using adjunctive corticosteroid\ntherapy (conditional recommendation, very low certainty of evidence). Comment: This\nrecommendation places a high value on avoiding potential serious harms despite providing potential\nminimal beneficial effects.\nSummary of Evidence\nOur systematic review of the literature (2005 through 2022) identified one randomized controlled\ntrial [211] and two non-randomized studies [212, 213] evaluating the efficacy of corticosteroids as an\nadjunct to standard of care antibiotics in children with ABA (see Supplementary Material Table VIIIa\n). Furthermore, three meta-analyses [214-216] combined the estimates of the RCT that we found",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 215,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_216",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "). Furthermore, three meta-analyses [214-216] combined the estimates of the RCT that we found\n[211] with a previously published RCT (which predated our original year of publication criteria) [217].\nPatient-important outcomes judged critical for decision-making included: recurrence of infection or\nfunctional sequelae (at 12 months), recurrence of symptoms (within the first week), time to normal\njoint function, and serious adverse events, while those judged important but not critical for decision-\nmaking included: time to defervescence, time to normalization of CRP, duration of antibiotics, and\nduration of hospitalization.\nThe best available evidence is an RCT with 49 children with ABA randomized to receiving a four-day",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 216,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_217",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "The best available evidence is an RCT with 49 children with ABA randomized to receiving a four-day\ncourse of parenteral dexamethasone (0.15 mg/kg every 6 hours) in addition to antimicrobials (n=24)\nor placebo with antimicrobials (n=25) [211]. Patients’ characteristics appeared comparable in both\ngroups at baseline. Mean age was 33 months, and joints most frequently involved were the hip\n(42.9%) and knee (36.7%). The causative agent was isolated in only 35% of patients, K. kingae\n(n=7) and MSSA (n=3) being the most common. Results may not be generalizable given the small\npercentage of S. aureus infections. Invasive procedures consisted of percutaneous aspiration and\nsurgical drainage of the hip. Sample size calculation was based on an expected reduction of 3 days",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 217,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_218",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "surgical drainage of the hip. Sample size calculation was based on an expected reduction of 3 days\nof parenteral treatment. This yielded a very small sample size requirement which may have been the\ncause of imbalance between treatment groups for important covariates (causative pathogens, joints\naffected, types of invasive procedures). Additional serious methodological concerns included: loss\nto follow-up at one year was substantial with only 29 (59%) of 49 patients assessed by investigators\nat that time point; and missing data for duration of hospitalization despite this being one of the\nprimary endpoints.\nThe two non-randomized studies provided complementary evidence for outcomes either not\nreported or incompletely reported in the above RCT, specifically recurrence of symptoms within one",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 218,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_219",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "reported or incompletely reported in the above RCT, specifically recurrence of symptoms within one\nweek and duration of hospitalization. One evaluated 60 patients, 30 of whom had surgery and\nreceived IV antibiotics for three weeks, along with saline placebo, and 30 who received the same\ncare with the addition of methylprednisolone 0.15mg/kg/day for 4 days [213]. It is uncertain if the\nresults of the study are generalizable, as no culture results were reported from the hospitals\nparticipating in the study, and no long-term follow-up outcome data were reported. In addition,\npatients with concomitant sepsis were excluded.\nThe second observational study retrospectively evaluated 116 children aged 2 months to 18 years",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 219,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_220",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "The second observational study retrospectively evaluated 116 children aged 2 months to 18 years\nwith ABA: ninety received antibiotics alone and 26 also received a four-day course of\ndexamethasone at the discretion of the attending physician, which could contribute to indication\nbias [212]. Microbiological confirmation was available for only 22% of patients, with K. kingae and\nMSSA being most frequently identified. Patients were comparable at baseline aside from higher\nincidence of knee involvement in the dexamethasone group. Nineteen of the 90 patients in the\ncontrol group and 1 of 26 patients in the corticosteroid group received NSAIDs, which potentially\nconfounds the effect of corticosteroids.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 220,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_221",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "confounds the effect of corticosteroids.\nThe meta-analysis [214] which included the two RCTs [211, 217] also concluded that the addition of\ndexamethasone may increase the proportion of patients without pain and with normal joint function\nat 12 months, as well as reduce the number of days of antibiotic treatment, but was not able to draw\nrobust conclusions due to the low certainty in the evidence. Therefore, the evidence suggests a\npossible minimal but not statistically significant reduction in time to normal joint function, time to\ndefervescence, time to normalization of CRP, and duration of IV antibiotics in the group receiving\ncorticosteroids compared to the group not receiving dexamethasone. Duration of hospitalization",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 221,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_222",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "corticosteroids compared to the group not receiving dexamethasone. Duration of hospitalization\nmay be shorter with the addition of dexamethasone, but this effect was judged to be very uncertain\ndue to unadjusted confounders and small sample sizes of the included studies. The microbiology of\nthe reported patients may also not be generalizable, since S. aureus, which is a common cause of\nmore severe infections, comprised a minority of detected pathogens in these reported studies. A\nhigher incidence of symptom recurrence occurred within one week in the group receiving\ndexamethasone, but the evidence was again considered very uncertain due to serious concerns for\nrisk of bias (as mentioned above) and imprecision (very small sample size) (see Supplementary",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 222,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_223",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "risk of bias (as mentioned above) and imprecision (very small sample size) (see Supplementary\nMaterial Table VIIIa ). No recurrence of infection or functional sequelae at 12 months was reported\nin either group.\nSerious adverse events associated with the use of corticosteroids are critical for decisionmaking.\nDespite the absence of reported adverse events in the three studies included in our analysis, a\nsystematic review of the literature evaluating the toxicity of short-course oral corticosteroids in\nchildren included thirty-eight studies [218] reporting a total of 3,200 children in whom 850 adverse\ndrug reactions (ADRs) were reported. The three most frequent ADRs were vomiting (5.4%),\nbehavioral changes (4.7%), and sleep disturbance (4.3%). Infection was a serious, albeit rare ADR:",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 223,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_224",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "behavioral changes (4.7%), and sleep disturbance (4.3%). Infection was a serious, albeit rare ADR:\nfive RCTs reported a pooled prevalence of infection during treatment periods of 0.9%, but of 3\nchildren infected with varicella zoster, one died and two were admitted to the ICU with severe\ncomplications. When measured, 144 of 369 patients showed increased blood pressure; 21 of 75\npatients showed weight gain; and biochemical hypothalamic–pituitary–adrenal axis suppression was\ndetected in 43 of 53 patients.\nAn additional concern of corticosteroid administration is alteration of the temperature curve (i.e.,\n“masking of fever”) and/or generation of temporary improvement in local signs of inflammation,",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 224,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_225",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "“masking of fever”) and/or generation of temporary improvement in local signs of inflammation,\ngiving the impression of clinical improvement while the infection itself continues to progress.\nCorticosteroids are also problematic if there is diagnostic uncertainty as they may ultimately delay a\ndiagnosis such as leukemia. They may also empirically treat autoimmune conditions such as JIA or\nrheumatic fever-associated arthritis. Other known common side effects of steroids include delayed\nwound healing and/or impaired glucose levels.\nRationale for Recommendation\nThe standard of care of antimicrobial therapy without corticosteroids has historically achieved\nexcellent outcomes in children with ABA. Given that the data at this time are limited in scope, include",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 225,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_226",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "low patient numbers, and provided minimal benefits as considered by the Guidelines Panel in the\ncontext of the known harms with use of corticosteroids, there is not a role for routine use of these\nagents as part of the management of ABA in children at this time. The current literature may not be\ngeneralizable to the North American patient populations in which S. aureus (especially MRSA)\nrepresents a frequently identified pathogen.\nResearch Needs\nControlled studies of corticosteroids for specific pathogens and joints may allow for more definitive\nrecommendations in the future regarding possible benefit and harm.\nIX. In children with presumed or confirmed ABA who respond to initial empiric therapy, how",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 226,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_227",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "IX. In children with presumed or confirmed ABA who respond to initial empiric therapy, how\nshould selection of agents be made for definitive parenteral and oral therapy? (See Section XI for\ndiscussion of oral versus parenteral therapy.)\nRecommendations:\n1. In children with confirmed ABA, selection of a definitive antimicrobial regimen should be based\non the principles of selecting an effective agent against the identified pathogen, with the\nnarrowest spectrum, lowest adverse effect profile and most favorable patient tolerability (Good\nPractice Statement).\n2. In children with presumed ABA with no pathogen identified, selection of a definitive\nantimicrobial regimen should be based on the principles of selecting an effective agent based",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 227,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_228",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "antimicrobial regimen should be based on the principles of selecting an effective agent based\non the most likely causative organism(s), with an antimicrobial spectrum comparable to that of\nempiric therapy to which the patient initially responded, with the lowest adverse effect profile\nand most favorable patient tolerability (Good Practice Statement).\nSummary of Evidence\nAntimicrobial Management in Confirmed ABA\nClinicians should treat ABA with an antimicrobial agent directed specifically toward the causative\norganism at a dose, route, frequency of administration, and duration that are sufficient to eradicate\nthe pathogen. The choice of agent should be based on in vitro susceptibility and published clinical",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 228,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_229",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "the pathogen. The choice of agent should be based on in vitro susceptibility and published clinical\ntrial data, though the latter currently are very limited. In general, the narrowest spectrum antibiotic\nshould be prescribed for both intravenous and subsequent oral therapy. Narrow spectrum therapy\nprovides a number of benefits for both inpatients and outpatients, as outlined by policy statements\nfrom professional societies and by the Centers for Disease Control and Prevention (CDC). These\npotential benefits include reduction of antimicrobial resistance in the individual patient, reduced\nantimicrobial pressure for the environment, reduced toxicity, and often reduced cost [219- 221].\nPreferred and alternative antimicrobial agents for specific pathogens (plus recommended durations",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 229,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_230",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Preferred and alternative antimicrobial agents for specific pathogens (plus recommended durations\nof therapy) are listed in Table 4 . Recommended dosages for specific agents are listed in Table 5\n.\nFor children with ABA caused by MSSA, a beta-lactam agent is preferred for initial parenteral\ntreatment (cefazolin, nafcillin or oxacillin) and for definitive oral treatment (cephalexin). “High dose”\ncephalexin (100 mg/kg/day in 4 divided doses) was first studied with measurement of synovial fluid\nconcentrations and recommended for pediatric bacterial joint infections caused by MSSA in the late\n1970s [3, 222, 223]. No prospective, randomized studies were performed at that time, but over the\npast 4 decades, no reports of failures for MSSA ABA treated with cephalexin confirm that this dose",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 230,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_231",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "past 4 decades, no reports of failures for MSSA ABA treated with cephalexin confirm that this dose\nis adequate for convalescent therapy following initial parenteral therapy and surgical management.\nRecent computer modeling of cephalexin dosing in children, using a pharmacodynamic driver of\n40% T>MIC that is assumed for beta-lactam treatment of acute infections in animal models with\nretrospective validation in adults, suggests that higher doses may be required [224], for strains with\nMICs of 2 and 4 mg/L. The MIC90 for MSSA is 4-8 mg/L [225-227] suggesting that oral therapy\nshould be used only after initial parenteral therapy, surgical debridement, and clinical response to\ntreatment. The bacterial inoculum is generally dramatically reduced at the point of oral switch",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 231,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_232",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "treatment. The bacterial inoculum is generally dramatically reduced at the point of oral switch\ntherapy, and both innate and adaptive immune responses should be significant in assisting the host\nto clear the infection. Thus, “convalescent” oral therapy is not likely to require 40% T>MIC to be\nnecessary for microbial eradication. The higher doses (120 mg/kg/day divided every 8 hours)\nrequired to achieve this pharmacodynamic target in 100%, 90% and 80% of children for MSSA with\nMICs of 0.25, 2 and 4 mg/L, respectively [224], do not appear to be required for good patient\noutcomes following oral transition therapy. Using the same high pharmacodynamic target, additional\nmodeling provided support for a proposed cephalexin dosage (administered Q8H) of 45 mg/kg/day",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 232,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_233",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "modeling provided support for a proposed cephalexin dosage (administered Q8H) of 45 mg/kg/day\nfor MSSA with an MIC of 1 mg/L; 75 mg/kg/day for an MIC of 2 mg/L; and 135 mg/kg/day for an MIC\nof 4 mg/L. Those doses are proposed for children weighing 10-15 kg, with slightly lower doses\nproposed for older children with higher body weights [228]. These studies, as the authors note, are\nbased on serum concentrations, not on concentrations in synovial fluid at the site of infection.\nClindamycin is an alternative for susceptible MSSA isolates when beta-lactam agents cannot be\nused. In a prospective, quasi-randomized trial conducted in the treatment of 252 children with\nosteoarticular infections in Finland [229], 130 (52%) had ABA without osteomyelitis. Those born on",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 233,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_234",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "osteoarticular infections in Finland [229], 130 (52%) had ABA without osteomyelitis. Those born on\nodd days received clindamycin, and those born on even days received a cephalosporin for their\ntreatment. Clindamycin was given at 40 mg/kg/day divided into 4 doses and cephalosporins\n(cephradine, cephalexin, or cefadroxil) were given at 150 mg/kg/day divided into 4 doses, with\ntreatment administered by the oral route after 2-4 days. Outcomes did not differ in terms of\nreinfection rates or permanent sequelae. The high doses of each antibiotic were surprisingly well\ntolerated, with loose stools reported in only 1% (95% CI: 0 to 4%) of those treated with clindamycin\nand 7% (95% CI: 4 to 14%) of those treated with cephalosporins [229]. In another retrospective",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 234,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_235",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "and 7% (95% CI: 4 to 14%) of those treated with cephalosporins [229]. In another retrospective\nstudy of oral clindamycin therapy in 215 children, readmission rates were similar among 190 treated\nwith a dosage of 30 mg/kg/day divided every 8 hours compared with 25 who were treated with a\ndosage of 40 mg/kg/day, at 2.6% and 4%, respectively (p-value=0.4) [230].\nClindamycin and ceftaroline, are preferrable to vancomycin for parenteral therapy for susceptible\nMRSA strains, given their better safety profiles in the treatment of MRSA infections in general [186,\n231]. Clindamycin has an advantage of ready conversion from parenteral to oral therapy due to its\ngood bioavailability. Ceftaroline, as a beta-lactam antibiotic with FDA approval for pediatric and",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 235,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_236",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "good bioavailability. Ceftaroline, as a beta-lactam antibiotic with FDA approval for pediatric and\nneonatal age groups for acute bacterial skin and skin structure infections, including those caused by\nMRSA, can reasonably be considered for treatment over clindamycin, given the safety and efficacy\nof beta-lactams in general, particularly when there are any concerns for endovascular infection\n[186]. Both antibiotics have antibacterial coverage beyond MRSA: clindamycin is active against\nanaerobic bacteria, while ceftaroline has Gram-negative coverage similar to ceftriaxone, a third-\ngeneration cephalosporin.\nCeftaroline and vancomycin are the preferred antimicrobial agents for clindamycin-resistant CA-",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 236,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_237",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Ceftaroline and vancomycin are the preferred antimicrobial agents for clindamycin-resistant CA-\nMRSA infections when initial parenteral therapy is required. Other MRSA-active agents such as\ndaptomycin or linezolid may be considered as alternatives for ABA, although few published data\nexist for treatment outcomes, safety, tolerability, or dosing for ABA of these antimicrobial agents.\nInitial guidelines by IDSA for vancomycin dosing in severe CA-MRSA infections recommended target\nserum trough levels > 15 micrograms/ml [185]. The high doses required to achieve this goal were\nassociated with acute kidney injury and were not associated with improved outcomes in children\nwith osteomyelitis when compared with lower doses [220, 232]. ASHP/IDSA/PIDS/SIDP guidelines",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 237,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_238",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "with osteomyelitis when compared with lower doses [220, 232]. ASHP/IDSA/PIDS/SIDP guidelines\non vancomycin dosing in severe CA-MRSA infection recommend achieving an exposure that\nincorporates both vancomycin exposure over the dosing interval (the “area under the time vs\nvancomycin serum concentration curve” *AUC+), and the MIC of the infecting strain of MRSA, to\nachieve an AUC/MIC of 400 [185, 233]. Linking vancomycin exposure (AUC) as a function of the\nmg/kg dose, to the MIC allows the recommended dose to increase as the MIC increases. If the MIC\nis 2 mcg/mL of greater, the required vancomycin dose to achieve an AUC/MIC exposure of 400 will\noften lead to renal toxicity. However, at MICs of 1.0 mg/L or lower, an AUC/MIC > 400 is often",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 238,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_239",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "often lead to renal toxicity. However, at MICs of 1.0 mg/L or lower, an AUC/MIC > 400 is often\nachieved with a trough significantly less than 15 micrograms/mL.\nFor oral therapy of CA-MRSA ABA, as with parenteral therapy, clindamycin is the preferred agent for\nsusceptible MRSA strains. Limited data exist for linezolid [234] and TMP/SMX, as well as for\ndoxycycline or minocycline.\nK. kingae is generally susceptible to penicillins (with the notable exception of antistaphylococcal\npenicillins) and cephalosporins, as well as fluoroquinolones, and TMP/SMX. K. kingae strains are\nresistant to vancomycin and often resistant to clindamycin and linezolid [32, 190].\nFor penicillin-susceptible S. pneumoniae isolates and S. pyogenes, penicillin or ampicillin are the",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 239,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_240",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "For penicillin-susceptible S. pneumoniae isolates and S. pyogenes, penicillin or ampicillin are the\npreferred parenteral beta-lactam agents, with phenoxymethyl penicillin or amoxicillin for oral\ntherapy. For pneumococcal isolates that are reported as penicillin-non-susceptible, high dose\nparenteral penicillin has been used for pneumococcal pneumonia with penicillin MICs as high as 8.0\nmg/L, though data for penicillin treatment of ABA due to pneumococci with high MICs are not\navailable. For oral treatment, in general, pneumococci with a penicillin or ampicillin MIC < 2 mg/L are\nconsidered susceptible for the treatment of ABA, using high dosage penicillin or amoxicillin for the\nmore resistant strains. Cefotaxime/ceftriaxone should be effective if the pneumococcal isolate is",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 240,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_241",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "more resistant strains. Cefotaxime/ceftriaxone should be effective if the pneumococcal isolate is\nreported as susceptible by the laboratory (MIC < 1 mcg/ml for infections other than meningitis) but is\nmuch broader spectrum than penicillin or amoxicillin. Although no prospective data on ABA\ntreatment exist to support recommendations, in vitro testing may reveal additional options for both\nparenteral and oral therapy, including clindamycin, linezolid, ceftaroline, levofloxacin, or daptomycin.\nOf concern, five of 24 pneumococcal isolates (21%) from children with osteoarticular infections\nfrom 2010 through 2015 in a single center study were resistant to clindamycin [187].\nHib is now a rare etiology of ABA in countries where Hib conjugate vaccines are in routine use, but",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 241,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_242",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Hib is now a rare etiology of ABA in countries where Hib conjugate vaccines are in routine use, but\ninvasive disease continues with both unencapsulated strains as well as encapsulated strains of\nHaemophilus influenzae, particularly serogroup a, but also serogroups f and e. Beta-lactamase\npositivity (e.g. ampicillin-resistance) varies, but appears to be similar to serogroup b [235-237].\nParenteral ampicillin may be used for beta-lactamase negative strains. Parenteral second\n(cefuroxime) or third generation cephalosporins (cefotaxime/ceftriaxone/ceftazidime) may be used\nas alternatives or for beta-lactamase producing isolates. For oral convalescent therapy for\nbetalactamase negative strains, amoxicillin should be used. Oral second (cefuroxime) and third",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 242,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_243",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "betalactamase negative strains, amoxicillin should be used. Oral second (cefuroxime) and third\ngeneration cephalosporins (cefdinir, cefpodoxime, ceftibuten) or beta-lactam/beta-lactamase\ninhibitor combinations (e.g., amoxicillin-clavulanate) should provide effective therapy, although they\nhave not been prospectively studied for pediatric ABA [235-237].\nN. meningitidis may cause ABA alone or as part of a systemic invasive infection (e.g., sepsis,\nmeningitis) [238-240]. Reactive arthritis also can be associated with invasive meningococcal\ndisease [239]. Because the great majority of strains in North America have been susceptible to\npenicillins and third generation cephalosporins, both have routinely been used for parenteral therapy",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 243,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_244",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "for suspected or proven meningococcal ABA. However, emerging resistance to penicillin (and other\nagents) in the U.S. reported recently by the CDC has supported a recommendation by some experts\nfor the use of third generation cephalosporins as empiric therapy for suspected meningococcal ABA\nuntil susceptibility results are available [241]. Although oral agents are commonly prescribed for\nconvalescent therapy of meningococcal ABA, there are no prospective data regarding their use,\ncompared with a complete course with parenteral therapy. When ceftriaxone is not used for\ntreatment, an appropriate prophylaxis regimen to eradicate nasopharyngeal carriage should be\nprovided to the patient.\nN. gonorrhoeae is not an uncommon pathogen among adolescents with ABA [242]. Parenteral",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 244,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_245",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "N. gonorrhoeae is not an uncommon pathogen among adolescents with ABA [242]. Parenteral\ntherapy with a third-generation cephalosporin, typically ceftriaxone, should be started. Oral therapy\ngenerally should be considered only after antibiotic susceptibility data are available. Due to\nincreasing resistance to azithromycin, combination therapy of azithromycin with ceftriaxone is no\nlonger routinely recommended [243]. Oral options may include high dose oral cefixime or a\nfluoroquinolone if susceptibility has been documented [244]. Although the routine use of\nfluoroquinolones is not usually recommended for treatment of infections in children < 18 years old\nbecause of concerns for potential toxicity, use in this circumstance is appropriate. When",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 245,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_246",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "because of concerns for potential toxicity, use in this circumstance is appropriate. When\ngonococcal infection is documented, evaluation for other sexually transmitted infections, including\nHIV and syphilis, is warranted [243, 244].\nSalmonella spp are seen most commonly in children with splenic dysfunction usually associated\nwith a hemoglobinopathy, but may also be documented in immunocompetent children, often\nassociated with osteomyelitis [245-247]. Treatment duration among a series of 12 children with\nSalmonella musculoskeletal infections with successful outcomes did not differ from a comparator\ngroup of children with MSSA infections [247]. Limited data exist on treatment duration for ABA\ncaused by Salmonella spp. Courses longer than 10 to 14 days may be required, depending on the",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 246,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_247",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "caused by Salmonella spp. Courses longer than 10 to 14 days may be required, depending on the\nclinical and laboratory response of an individual child, with treatment up to 4 to 6 weeks, particularly\nin those with associated osteomyelitis.\nBrucella spp can cause ABA following exposures to unpasteurized dairy products or other fluids or\ntissues from infected animals. When brucellosis is confirmed by culture or serologic testing in a\nchild with ABA, the treatment regimens recommended for Brucella infections in general apply,\nusually doxycycline with rifampin for children older than 7 years, and TMP/SMX with rifampin for\nchildren ≤ 7 years (see Tables 4 and 5), although the safety of doxycycline in children ≤ 7 years is",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 247,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_248",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "currently being reassessed. Six-to-12-week minimum courses are recommended, often with the\naddition of gentamicin for the first 1-2 weeks of therapy [248].\nLyme arthritis is the most common form of bacterial arthritis in some endemic geographic regions.\nThis should be treated according to the IDSA Guideline for Prevention and Treatment of Lyme\nDisease [111].\nAntimicrobial Management in Presumed ABA With No Pathogen Identified\nIn the absence of a positive culture, there is no “gold standard” for the treatment of pediatric ABA.\nAs noted in Question III, a microbial etiology for a substantial portion of children with clinical\npresentations consistent with ABA will not be identified by culture or PCR tests. Furthermore,",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 248,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_249",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "presentations consistent with ABA will not be identified by culture or PCR tests. Furthermore,\nsituations in which cultures were not obtained in a clinical scenario compatible with ABA are also\nconsidered to be presumed ABA for the purposes of this discussion. Clinical findings and apparent\nresponse to antimicrobial therapy, plus supporting laboratory test results are relied on to make the\ndetermination to continue antimicrobial therapy for presumed ABA in children with negative culture\nand molecular microbiological testing.\nChildren with presumed ABA tend to have less systemic inflammation, shorter duration of fever, a\nshorter hospital LOS than those with confirmed pyogenic pathogens such as S. aureus, though",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 249,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_250",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "shorter hospital LOS than those with confirmed pyogenic pathogens such as S. aureus, though\noverlap in findings is substantial [24, 29, 65, 179]. Of note, children with documented K. kingae\narthritis tend to have clinical and laboratory findings more similar to those children with presumed\nABA with no pathogen identified than those with other confirmed pathogens [29].\nReasons for negative results of cultures (and any molecular test results, if performed) in children\nwith clinical findings typical of ABA include:\nPresence of fastidious, difficult to isolate organisms such as K. kingae, N. gonorrhoeae or N.\nmeningitidis\nReceipt of antibiotics prior to joint aspiration\nInhibition of bacterial growth by antimicrobial factors in purulent joint fluid",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 250,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_251",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Inhibition of bacterial growth by antimicrobial factors in purulent joint fluid\nMicrobial density below the level of detection for culture or PCR testing\nNon-infectious causes of arthritis: sterile inflammation from a reactive process mimicking ABA\nsuch as transient nonbacterial synovitis or reactive arthritis (including poststreptococcal\nreactive arthritis, or other post-infectious or rheumatologic/autoimmune disease [141])\nAn unknown portion of children with presumed ABA have bacterial etiologies. In a case series that\nincluded 89 such children with joint inflammation without associated osteomyelitis, 8 (9%) did not\nimprove clinically while receiving antimicrobial therapy, prompting care providers to change",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 251,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_252",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "improve clinically while receiving antimicrobial therapy, prompting care providers to change\nantimicrobials. None had long-term disability evident on evaluation six months after completion of\ntherapy [24]. Negative results of PCR testing do not exclude the presence of bacterial infection. A\nsmall proportion of culture negative cases will be caused by uncommon bacterial pathogens such\nas Borrelia or by mycobacteria or fungal pathogens (i.e., Histoplasma, Blastomyces and\nCoccidioides).\nIn children with suspected ABA and negative results of cultures after 48-72 hours of incubation (and\nnegative results of any molecular microbial tests obtained), reconsideration of the diagnosis with re-\nevaluation for historical and physical examination findings that may support alternative etiologies is",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 252,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_253",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "warranted. However, in the absence of alternative diagnoses, it is common practice to continue\nantimicrobial agents targeting the most common bacterial etiologies based on the child’s risk factors\n(e.g., age, geographic location, travel history, current local outbreaks of specific pathogens, co-\nmorbid conditions). The potential benefits of completing a treatment course (i.e., prevention of long-\nterm sequelae or relapse) may outweigh the risks of unnecessary antibiotic therapy. For those\nchildren who are improving while receiving initial empiric parenteral therapy (see Question V),\ntreatment may be continued on that regimen until ready for hospital discharge and then switched to\nappropriate oral agents (See also Question XI).\nAntimicrobial Management With Respect to Adverse Event Profile",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 253,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_254",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Antimicrobial Management With Respect to Adverse Event Profile\nTreatment regimens for ABA are generally shorter than those used for osteomyelitis, such that\nadverse events due to antimicrobial therapy may be less frequent with ABA than osteomyelitis.\nAntimicrobial agents used during hospitalization that have the potential for renal toxicity (e.g.,\nvancomycin and gentamicin) require laboratory monitoring of serum creatinine and serum antibiotic\nconcentrations [185].\nBeta-lactam agents may suppress the bone marrow at high doses given over a prolonged period;\nweekly or biweekly (every 2 weeks) assessments of marrow function (e.g., a complete blood count\nwith differential) have not been studied prospectively, but may be helpful, particularly for courses of",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 254,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_255",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "therapy of more than three weeks. The possible benefit of such monitoring can be weighed against\nthe burdens of pain, travel and cost for the child and family.\nMany antibiotics are associated with diarrhea. Probiotics may have a modest protective effect [249].\nClindamycin is notably associated with Clostridioides difficile-associated colitis in adults, requiring\neducation of care providers regarding symptoms of colitis and the need to notify healthcare\npractitioners if such symptoms develop. Prospective data on the risk of C. difficile colitis in\notherwise healthy children receiving clindamycin therapy for 2 to 3 weeks for ABA do not exist, but\nthe risk is likely lower than that documented in adults [250]. Colonization with C. difficile in children",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 255,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_256",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "under the age of 2 years is common and its detection in young children with diarrhea does not\nnecessarily indicate causation [251].\nIn prospective, pediatric, pre-licensure evaluations of linezolid, hematologic abnormalities occurred\nbut were no more frequent in those treated with linezolid compared with those receiving other\nantibiotics [252]. Long-term adverse events, such as optic and peripheral neuropathies, have been\ndescribed in both adults and children receiving more than 4 weeks of linezolid [253]; courses of\nsuch duration will be uncommon for children with primary ABA. Linezolid is a reversible,\nnonselective inhibitor of monoamine oxidase and should be used with caution in patients who are on\nan SSRI medication.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 256,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_257",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "an SSRI medication.\nFluoroquinolones are prescribed in adults for parenteral or oral therapy of osteoarticular infections\ncaused by enteric bacilli (including E. coli, Klebsiella spp, Enterobacter spp) or Pseudomonas\naeruginosa; for children, based on concerns for cartilage/tendon injury noted in animal toxicity\nstudies, non-fluoroquinolone oral antimicrobial agents (beta-lactams, TMP/SMX) are preferred if\nappropriate for the clinical scenario. However, for convalescent therapy, oral therapy with a\nfluoroquinolone is preferred over parenteral therapy with a non-fluoroquinolone agent (e.g., oral\nciprofloxacin rather than intravenous ceftazidime for a Pseudomonas infection) [254]. For children\nreceiving therapy with fluoroquinolones for ABA, attention is required for the development of",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 257,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_258",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "receiving therapy with fluoroquinolones for ABA, attention is required for the development of\narthritis/arthralgia, primarily in weight-bearing joints. This potential adverse event should be\ndiscussed with families, with instructions for the family to return for evaluation should symptoms\nconsistent with a persistent arthropathy or tendinopathy occur for more than 2-3 days during\ntherapy [254].\nTMP/SMX may cause drug-related rashes, including Stevens-Johnson syndrome, and drug rash\nwith eosinophilia and systemic symptoms (DRESS), as well as leukopenia and thrombocytopenia\n[255].\nRationale for Recommendation\nTreatment of children with presumed or documented ABA that is responding to empiric antibiotic",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 258,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_259",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Treatment of children with presumed or documented ABA that is responding to empiric antibiotic\ntherapy is best managed by selecting a definitive antimicrobial regimen with either parenteral or oral\nagents based on principles of selecting an effective agent with the narrowest spectrum agent with\nthe lowest adverse event profile and the best host tolerance. The benefits of selecting an agent\nbased on these principles are expected to be large and unequivocal.\nResearch Needs\nStudies of currently available parenteral and oral agents, particularly those with activity against CA-\nMRSA (e.g., ceftaroline, linezolid, TMP/SMX) are needed to evaluate safety and efficacy for ABA,\nincluding real-world comparative effectiveness studies. Studies that focus on children with primary",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 259,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_260",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "including real-world comparative effectiveness studies. Studies that focus on children with primary\nABA, distinct from those with ABA with adjacent osteomyelitis, would be helpful. Prospectively\ncollected data on the adverse drug events associated with the oral agents and treatment courses\nused for confirmed or presumed ABA would also be useful.\nX. In children with presumed or confirmed ABA, what clinical and laboratory criteria should be\nused to assess the response to therapy?\nRecommendation:\nIn children with presumed or confirmed ABA receiving antimicrobial therapy with or without surgical\nintervention, in addition to serial clinical evaluation, we suggest performing CRP at initial evaluation",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 260,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_261",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "followed by sequential monitoring of CRP to assess response to therapy, rather than relying solely\non clinical evaluation (conditional recommendation, low certainty of evidence). Comment: Serial\nclinical examinations that assess the febrile response, pain and musculoskeletal function remain the\nprimary means of monitoring response to treatment.\nSummary of Evidence\nGradual clinical improvement (resolution of fever over 2 to 4 days, reduction in joint pain, swelling,\nand other inflammatory signs, and increased mobility/range of motion of the affected joint) generally\nis expected as a response to administration of effective antimicrobial therapy with or without\ndrainage of the affected joint [256]. The clinical course may be influenced by the initial severity of",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 261,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_262",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "illness, adjacent osteomyelitis, the bacterial pathogen, and extent of required surgical\nintervention(s). Fever may be prolonged in children with ABA who have disseminated infection\nrather than joint infection alone [257]. ABA caused by some strains of S. aureus (e.g., USA\n300/CAMRSA) have been associated with more prolonged febrile courses than ABA caused by non-\nUSA 300 MSSA strains [92]. However, one study did not find a difference in febrile course between\nchildren with ABA caused by CA-MRSA versus MSSA, though CA-MRSA ABA required more surgical\ninterventions [258].\nABA is usually accompanied by a rapid rise in serum CRP concentration, typically with a peak on\nday 2-3 of treatment in uncomplicated infection [73, 259]. With appropriate therapy, this is followed",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 262,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_263",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "by a progressive decline, and the CRP typically returns to the normal range in about 9 to 12 days [73,\n141, 260]. In general, the fall in CRP parallels the resolution of fever and clinical improvement in local\nsigns of inflammation and return to normal function of the patient [141, 259, 261-263]. However,\nsituations may arise where persistent elevation of CRP alone may signal persistent disease that\nwarrants additional investigation and intervention. If serial CRPs fail to trend downward or resume an\nupward trend, particularly if patients have a recurrence of fever, pain or local symptoms, children\nshould be carefully evaluated for persistent ABA or adjacent osteomyelitis and may require\nadvanced imaging such as MRI [158]. Successful transition to oral therapy after good clinical",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 263,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_264",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "advanced imaging such as MRI [158]. Successful transition to oral therapy after good clinical\nresponse plus CRP decline by 50% or more has been described [178, 264].\nThere are no clear data as to how frequently inflammatory markers should be measured during\ntreatment or how specific values should affect treatment. The consensus of the Guideline Panel is\nthat CRP may be evaluated every 2 or 3 days until the concentration begins to drop consistently. A\ndeclining CRP concentration can be used to provide information supplementary to the clinical\ncourse (i.e., fever curve and physical examination) for determining when a child with confirmed or\nsuspected ABA may be transitioned to oral antimicrobial therapy and/or discharged home.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 264,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_265",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "suspected ABA may be transitioned to oral antimicrobial therapy and/or discharged home.\nOnce the CRP concentration has decreased substantially in the context of ongoing clinical\nimprovement, further measurement is not necessary. In one case series, CRP levels decreased\nconsistently during antibiotic therapy and the authors concluded that patients in whom CRP values\nreturn to normal earlier have better clinical and radiological outcomes than those who do not [265].\nFailure of the CRP to fall markedly during the first days of inpatient therapy could be due to 1) an\nunaddressed focus of infection; 2) inadequate antimicrobial regimen (e.g., inadequate dosing,\nnonadherence to the antibiotic regimen, or antimicrobial resistance to empiric therapy) or 3) a",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 265,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_266",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "nonadherence to the antibiotic regimen, or antimicrobial resistance to empiric therapy) or 3) a\nnoninfectious arthritis (e.g., autoimmune/inflammatory arthritis or malignancy). (See Question XIV)\nWith recurrence of clinical signs or symptoms, or a plateauing or rise in CRP, either failure to\naddress a persisting focus, or an unrelated, intercurrent viral or bacterial illness may be present; for\nfailure to respond after transition to oral outpatient therapy, also consider non-adherence to the\nantibiotic regimen.\nThe role of other inflammatory markers, such as serum PCT, in the assessment of response to\ntherapy or as a guide to duration of therapy for ABA in children has not been established.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 266,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_267",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "therapy or as a guide to duration of therapy for ABA in children has not been established.\nThe ESR has limited utility as an adjunctive factor in medical decision-making for treatment of ABA.\nIn contrast to the CRP, the ESR rises and declines more gradually and may continue to rise during\nthe acute phase of treatment, even with appropriate therapy [259]. In a study from Finland of\nchildren primarily infected by MSSA, the ESR took a mean of 18 days to normalize [73]. Some\nphysicians continue to follow the ESR until normalization as a marker of resolved inflammation in the\njoint, suggesting a good long-term outcome for the child [266].\nNormalization or substantial decline in blood WBC count (and proportion of neutrophils) over the",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 267,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_268",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Normalization or substantial decline in blood WBC count (and proportion of neutrophils) over the\nfirst few days of therapy is consistent with response to therapy but has not been prospectively\nevaluated adequately as a biomarker of recovery. Inflammation that may elevate the blood WBC\nduring the hospital treatment course, may not be caused by active infection (e.g., surgical trauma,\nnecrotic tissue) in children with ABA.\nImaging studies generally are not needed to confirm response to therapy but may be indicated when\nclinical findings and laboratory studies are not demonstrating the expected resolution or\nnormalization [158].\nRationale for Recommendation\nPhysical examination provides essential information for clinical decision making. Measurement of",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 268,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_269",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Physical examination provides essential information for clinical decision making. Measurement of\nserum CRP concentration is widely available in a timely manner, is relatively inexpensive, and can be\nan objective data point that supports clinical decision making. Pain, discomfort, and additional costs\ncan occur from venipuncture.\nThe relatively rapid normalization of CRP has been interpreted as providing useful clinical guidance\nfor early switch to oral therapy, discharge from the hospital, and avoidance of prolonged antibiotic\ntherapy for uncomplicated disease. Although higher CRP peaks and prolonged time to normalization\ncorrelate in general with various aspects of the extent and severity of infection in children with ABA,",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 269,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_270",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "no specific thresholds of CRP concentration have been well validated for specific pathogens or the\nvarious infected joints, with respect to the need to perform specific clinical/surgical interventions or,\nfor the purposes of making decisions on duration of therapy.\nAs the infection is appropriately treated, fever abates and local signs of inflammation begin to\nresolve, there usually is a concurrent fall in serum CRP concentration. Persistent elevation of CRP\nfrom what is expected in a typical uncomplicated course, especially when associated with slower\nthan expected clinical improvement, may prompt changes in management, including: 1) additional\nimaging to better define the extent of the infection and its complications; or 2) surgical",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 270,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_271",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "imaging to better define the extent of the infection and its complications; or 2) surgical\nintervention(s) that may optimize short- and long-term outcomes; and 3) reconsideration of the\netiology of arthritis (e.g., infection vs autoimmune disorder).\nThe interpretation of persistent elevation of the CRP in the face of apparent clinical improvement is\nuncertain. This discordance can raise concerns about the need for more evaluation or intervention\nbut acting on such data without regard to the clinical context of recovery could lead to unnecessary\nactions and procedures and their associated risks. Such discordance can be caused by intercurrent\ninfection or other issues unrelated to ABA.\nWithin the limitations outlined above, the Guideline Panel suggests sequential monitoring of CRP as",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 271,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_272",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Within the limitations outlined above, the Guideline Panel suggests sequential monitoring of CRP as\nan adjunctive measure in children with ABA that can be taken into account with other clinical factors\nin management decision-making. There are no data to support a particular frequency of CRP\nmonitoring during the course of ABA in children. Measurement every 2 to 3 days during the early\ntherapeutic course, rather than daily, followed by weekly or other periodic measurement until a clear\ntrend towards normalization is evident, is an acceptable approach [37].\nResearch Needs\nMore detailed analyses of the clinical utility of serial serum CRP concentrations and other\nbiomarkers of systemic inflammation, by pathogen and by joint involved would be useful.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 272,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_273",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "biomarkers of systemic inflammation, by pathogen and by joint involved would be useful.\nIdentification of specific CRP or other biomarker cutoff values would be helpful for specific\npathogens and for specific clinical situations, such as the need for additional surgery versus\nongoing observation. It is likely that multicenter studies using iterative protocols will be required to\ngain insight into some of these questions [37].\nXI. Should hospitalized children with presumed or confirmed ABA who are responding well to\ninitial intravenous therapy, no longer requiring skilled nursing care and deemed ready for\nhospital discharge be transitioned to a) oral therapy or b) outpatient parenteral antibiotic therapy\n(OPAT)?\nRecommendations:",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 273,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_274",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "(OPAT)?\nRecommendations:\n1. For children with presumed or confirmed ABA who respond to initial intravenous antibiotic\ntherapy, we recommend transition to an oral antibiotic regimen rather than OPAT when an\nappropriate, well-tolerated oral antibiotic option is available, and that antibiotic is active against\nthe confirmed or presumed pathogen(s) (strong recommendation; low certainty of evidence).\nComment: This recommendation places a high value on avoidance of harms and costs, as well\nas on considerations of patient’s values and preferences, feasibility, acceptability, and equity.\n2. For children with presumed or confirmed ABA who respond to initial parenteral antibiotic\ntherapy but for whom oral antimicrobial therapy is not feasible, we suggest transition from the",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 274,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_275",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "therapy but for whom oral antimicrobial therapy is not feasible, we suggest transition from the\nacute-care hospital to OPAT, rather than remaining in the hospital for the total duration of\ntherapy (conditional recommendation, very low certainty of evidence). Comment: This\nrecommendation places a high value on avoiding harms and costs associated with unnecessary\nand prolonged hospital stay. The decision to implement this recommendation and the selection\nof the type of OPAT (home, intermediate care facility, clinic) may be influenced by availability of\nlocal resources.\nBackground\nABA in children was once thought to require antimicrobial therapy for 21 to 28 days with at least 14\nto 21 days via the intravenous route [267, 268]. Variations in approach have occurred since the mid-",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 275,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_276",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "1970s when publications began to appear describing use of oral regimens after shorter durations of\ninitial IV therapy [3, 269-271]. Since the 1980s, practice in many centers has steadily evolved\ntowards routine use of oral antimicrobial switch therapy and shorter overall courses [12, 272-274].\nSummary of Evidence\nNo prospective, randomized clinical trials of early transition to oral therapy versus later transition or\nfull IV courses have been performed in children with ABA. Our systematic review of the literature\n2005 through 2022 identified a single retrospective study on this question among children with ABA\nhospitalized 1985 through 1995 [180] performed at two large, tertiary care children’s hospitals with",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 276,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_277",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "known local variation in practice between the hospitals (see Table 6). Data from 83 patients\nundergoing early transition (median of 7.4 days) were compared to 103 patients transitioned later\n(median of 18.6 days). Patients’ characteristics were similar at baseline, except for mean ESRs being\nsignificantly higher in the early vs. the late transition group (54.0 +/- 28.4 vs 45.4 +/- 30.1, p-value <\n0.05), suggesting the early transition group may have included children with more extensive or\nprolonged infection. Resolution of clinical symptoms was significantly more rapid in the early vs. the\nlate transition group (mean days until asymptomatic + S.D. (range) 11.8± 8.4 (1-55) vs. 16.0± 15.3 (1-",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 277,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_278",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "73), respectively, p-value <0.05). It is possible this observation of 4.2 days faster resolution (95%CI:\n0.5 to 7.9 days) may have reflected variations in surgical management strategy between the 2\nhospitals rather than simply the early versus late oral transition. Open drainage was more frequent in\nthe early transition group than the late transition group (83% vs 68% respectively; p-value=0.03); in\ncontrast both initial joint aspiration and multiple joint aspirations were more frequent in the late\ntransition group (32% vs 17% and 17% vs 0%, respectively). Still, outcomes were not worse in the\nearly transition group. The certainty of evidence was rated as very low due to the risk of bias\n(mainly due to analyses being unadjusted, and to differences in management strategy with possible",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 278,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_279",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "(mainly due to analyses being unadjusted, and to differences in management strategy with possible\nconfounding-by-indication) and due to imprecision being rated as serious (few events and small\nsample size) (see Table 6 ).\nA prospective, randomized clinical trial conducted in Finland (1983 to 2005) evaluated shorter total\ncourses (10 to 15 days) of antimicrobial therapy versus longer (30 days) after transition to oral\ntherapy following 2 to 4 days of parenteral therapy. There were no relapses or long-term sequelae\namong 130 children followed for 12 months [55]. One child in the longer course group had a\nrecurrence 17 months after initial infection. The hip was the most commonly infected joint (n=48,",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 279,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_280",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "recurrence 17 months after initial infection. The hip was the most commonly infected joint (n=48,\n37%) followed by the knee (n= 32, 25%) and ankle (n=30, 23%). MSSA was isolated from joints or\nblood in 76 (58%), H. Influenzae type b in 23 (18%), S. pyogenes in 16 (12%) and S. pneumoniae in\n11 (8.5%). The primary focus of this study was total duration of therapy. Serum CRP concentrations\nwere monitored serially (normal value considered < 20 mg/L). Based on the provided data, most of\nthe 130 children had CRP values above 90 to 100 mg/L on days 3 or 4 after initiation of therapy\n(approximately the time of oral switch), actually higher than the values on presentation. CRP values\nwere then observed to fall from their peak at 3 to 5 days. Almost all had CRP values fall below 20",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 280,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_281",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "were then observed to fall from their peak at 3 to 5 days. Almost all had CRP values fall below 20\nmg/L by 10 to 14 days. Of note, two-weeks after initiation of treatment, 31 (24%) of the children had\nvarying degrees of joint swelling, restricting mobility, and persisting pain. Three (2%) had minor\nresidual joint symptoms at 3 months and none at 12 months [55]. A subsequent analysis did not find\nany difference in outcomes with this early oral transition approach between children with\nosteoarticular infections with and without bacteremia [275]. None of the children had infection due\nto MRSA strains. Therefore, it is unclear if these data are generalizable to infections caused by the\nvirulent USA 300 pulsotypes that frequently characterize MRSA strains in the USA and are",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 281,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_282",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "virulent USA 300 pulsotypes that frequently characterize MRSA strains in the USA and are\noccasionally found in MSSA strains.\nA retrospective study in France from 2009 to 2014 followed 95 children with confirmed or\nsuspected ABA for at least 2 years [276]. Intravenous therapy was given for a median of 4.5 days\n(IQR: 4 to 7), with median total duration of 15 days (IQR: 15 to 17) and in 10 (11%) for >21 days. None\nhad long term sequelae. Etiology was confirmed in 40 (42%), with K. kingae in 18, S. aureus in 11\nand S. pyogenes in 5. Criteria for transition to oral therapy were receipt of 48 hours of IV therapy, 24\nhours without fever, improvement of clinical findings, and significant decrease in inflammatory\nmarkers, which included CRP <20 mg/L.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 282,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_283",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "markers, which included CRP <20 mg/L.\nA prospective, two-center study of acute pediatric bone and joint infections (N= 70, of which 33 had\nABA) conducted in Australia from 2001 to 2007 evaluated criteria for transition to oral therapy as\nearly as 3 days into IV therapy [56]. Transition criteria were clinical improvement (improved pain,\nrange of movement, and weight-bearing status), normalization of temperature and stabilizing CRP.\nS. aureus was isolated in 27% of those with ABA and streptococcal spp in 50%. Oral transition\noccurred in <4 days for 18 (54%) and <6 days for 27 (82%). Among the full group of 70 children\nwith osteoarticular infection, CRP >100 mg/L best predicted the use of IV antibiotics for > 5 days (p-\nvalue=0.03). There were no sequelae at 1 year of follow-up.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 283,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_284",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "value=0.03). There were no sequelae at 1 year of follow-up.\nA group of US investigators retrospectively reported on using clinical improvement plus CRP values\nhaving fallen to 20 to 30 mg/L (normal ≤ 9 mg/L) as criteria for transition to oral therapy in 194\npediatric osteoarticular infections (32 had ABA alone and 49 had osteomyelitis + ABA) from 2000 to\n2007 [178]. Among those with ABA alone, MSSA was documented as the etiology for 17 (53%) and\nK. kingae in 6 (19%), and none had MRSA. There were no microbiological failures or long-term\nsequelae among the children with ABA alone.\nA group from Singapore reported retrospective data on 37 overall osteoarticular infections (11 with\nABA alone) between 2007 and 2013 and used a 50% decline in CRP values plus clinical",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 284,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_285",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "ABA alone) between 2007 and 2013 and used a 50% decline in CRP values plus clinical\nimprovement to transition to oral therapy [264]. S aureus (not further identified as\nmethicillinsusceptible or -resistant) was isolated in 59% of these children. Within 4 days of\ntreatment, 34 (92%) had at least a 50% decline in CRP. One of these had subsequent complications\nbut none required switching back to IV therapy. No long-term complications were reported among\nthe 11 with ABA alone.\nThree retrospective studies provide additional experience with oral therapy for ABA. Among 94\nchildren with ABA alone and 61 with ABA and osteomyelitis who were transitioned to oral therapy\nafter ≤7 days of IV therapy between 2009 and 2015 in Nashville, TN, no treatment failures were",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 285,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_286",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "after ≤7 days of IV therapy between 2009 and 2015 in Nashville, TN, no treatment failures were\nassociated with oral therapy [67]. In a study of 47 children with ABA in Australia from 1998 to 2002,\noral switch was based on unspecified clinical improvement [59]. Median hospital LOS was 9.6 days\n(range 3 to 26 days). No other clinical or outcome data relevant to oral therapy were provided.\nAmong 42 children in Chile in 2003 and 2004, oral transition was provided for 35 (83%) after 7 days\nof IV therapy [277]. The other 7 (17%) had longer IV courses. None had complications on short term\nfollow-up.\nIndirect evidence from children with osteomyelitis also supports the effectiveness of early transition",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 286,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_287",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "to oral therapy for ABA without associated osteomyelitis. The pooled results of four retrospective\ncohort studies comparing outcomes in children with osteomyelitis who were transitioned to oral\ntherapy (n = 1,989) compared with those discharged home on OPAT (n = 2,237) found comparable\nrates of treatment failure among the two groups: 4.6% oral vs 6.2% OPAT (RR 0.79, 95% CI: 0.60 to\n1.02; RD -1.3%, 95% CI: -2.5 to 0.1) [37, 220, 278-280]. Treatment failure definitions included need\nfor surgical or other interventions during oral or outpatient treatment for ongoing aspects of acute or\nchronic osteomyelitis.\nNo studies have specifically compared the frequency of adverse events between children with ABA",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 287,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_288",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "No studies have specifically compared the frequency of adverse events between children with ABA\ntreated with prolonged courses of IV therapy versus early transition to oral therapy. Relevant indirect\nevidence is available from three retrospective cohort studies of children with osteomyelitis [278-\n280]. Two large studies with 4,049 subjects combined documented unscheduled medical visits and\nre-hospitalization in 6.5% of children (n = 1,953) transitioned to oral therapy compared with 16.2% of\nthose on OPAT (n = 2,076) with RR of 0.43 (95% CI: 0.23 to 0.79) [279, 280].\nAdverse drug reactions also were less common in children transitioned to oral therapy versus OPAT:\n1.3% versus 2.6% (RR: 0.49; 95% CI: 0.27 to 0.88) [279, 280]. Catheter-related complications",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 288,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_289",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "1.3% versus 2.6% (RR: 0.49; 95% CI: 0.27 to 0.88) [279, 280]. Catheter-related complications\noccurred in 9.7% of children on OPAT in three studies that reported these data for 2,161 children\ncombined [278-280].\nParenteral therapy may occasionally be deemed clinically necessary for the full course for a child\nwith ABA. Our systematic review of the literature 2005 through 2022 did not identify any\ncomparative studies regarding the benefits and harms of continuation of parenteral antibiotics as an\ninpatient versus outpatient parenteral antibiotic therapy (OPAT) in the specific setting for children\ntreated for ABA. A 2018 systematic review [281] of this question for a number of other pediatric\ninfections included one randomized controlled trial (RCT) and 18 observational studies. Despite the",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 289,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_290",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "infections included one randomized controlled trial (RCT) and 18 observational studies. Despite the\nlack of a pooled analysis in the 2018 systematic review, no differences were noted in treatment\nfailure rates, readmission rates or adverse event rates for the great majority of the included studies.\nChildren treated at home received longer total courses of treatment in half of the studies compared\nwith those treated in the hospital. Costs associated with home-based OPAT were substantially lower\nin most studies, and OPAT was deemed satisfactory by patients and their families.\nTransition to Oral Therapy for Presumed ABA\nOur systematic review of the literature identified only one study that focused on ABA with no",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 290,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_291",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Our systematic review of the literature identified only one study that focused on ABA with no\nidentified pathogen in 89 children [24]. Eight (9%) had a change of antimicrobial therapy during the\nearly hospital course due to lack of clinical improvement. This included 6 (11%) of 54 children who\nwere less than age 5 years. Sixty of the 89 (67%) were discharged on oral therapy, most commonly\n(85%) a single agent active against MRSA, with only 18% (10 of 55) of younger children receiving a\nregimen including an agent active against K. kingae. None of these children had evidence of\ndisability on follow-up at 6 months, and none had late evidence of osteomyelitis. Median hospital\nLOS was 4 days (IQR: 4 to 6) and total duration of antimicrobial therapy was 24 days (IQR: 22 to 26).",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 291,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_292",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Of the 29 discharged on OPAT, five (17%) had a complication requiring re-evaluation or readmission.\nA recent study of pathogen-positive cases by age supports decisions on selecting antibiotic therapy\nin presumed ABA and confirms the need for coverage for S. aureus throughout childhood and\nadolescence when treating ABA [66]. K. kingae occurs predominantly but not exclusively in children\n< 4 years old. S. pneumoniae most often infects children <10 years old. S. pyogenes most often\ninfects children between 4 and 10 years old but can occur in all age groups.\nRationale for Recommendation\nMost children with ABA show relatively rapid clinical improvement during appropriate initial inpatient\nantimicrobial IV therapy plus any necessary surgical intervention of the infected joint. Our",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 292,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_293",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "antimicrobial IV therapy plus any necessary surgical intervention of the infected joint. Our\nsystematic review demonstrated reasonable evidence that children transitioned to oral therapy after\nsuch responses have excellent outcomes comparable to those treated with longer parenteral\nantimicrobial courses. Indirect data from studies of children with AHO also document comparable\nmicrobiological and clinical outcomes with early transition to oral therapy and fewer adverse effects\nrelated to the antimicrobial regimen. Patient-important outcomes favor oral antibiotics over OPAT,\nespecially considering rates of catheter-related complications with their resulting need for\nunscheduled revisits and rehospitalizations.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 293,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_294",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "unscheduled revisits and rehospitalizations.\nFor situations in which two alternatives appear equivalent regarding treatment failures, that\ntransitioning to oral therapy clearly results in fewer harms, and that acceptability of oral transition is\nhigher for patients and their families, the Guideline Panel consensus is to make a strong\nrecommendation despite somewhat low certainty of evidence. This transition to oral therapy is\npreferred even when the microbial etiology is not confirmed by laboratory testing.\nAssessment of clinical improvement is the most important component of decision-making as to\nwhen to transition to oral therapy. Clinical improvement is indicated by the following:\nSubstantial improvement in fever if present (a clear downward trend in peak and frequency of",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 294,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_295",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Substantial improvement in fever if present (a clear downward trend in peak and frequency of\nfever spikes) over the first days of observation in hospital\nSubstantial improvement in local inflammatory signs, with partial if not complete return of\nmovement or function of the affected joint(s)\nImprovement of clinical signs and symptoms of sepsis (hypotension, tachycardia, poor\nperfusion, irritability in infants) if initially present\nImprovement in systemic inflammation as assessed by the serum CRP may be used as an adjunct in\ndecision-making. Definitive thresholds for the CRP in guiding the timing of transition to oral therapy\nfor children with ABA have not been established. Many studies combine results of patients with ABA",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 295,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_296",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "for children with ABA have not been established. Many studies combine results of patients with ABA\nwith those who have osteomyelitis. We suggest that substantial clinical improvement coupled with\nsome degree of decline in CRP are appropriate criteria for transition to oral therapy for children with\nABA.\nAdditional factors for oral transition beyond selecting therapy based on antimicrobial spectrum\ninclude 1) availability of an oral agent with good oral bioavailability, palatability, and tolerability; and\n2) assessment of the ability of the caregivers to comply with the treatment plan and follow up visits.\nDemonstration of the child’s ability to take the selected oral agent prior to hospital discharge is",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 296,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_297",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Demonstration of the child’s ability to take the selected oral agent prior to hospital discharge is\nuseful when feasible. Close outpatient follow-up is important to confirm adherence to and tolerance\nof the prescribed oral antibiotic regimen.\nSpecific oral agents are reviewed in Questions V and IX. Clinical follow-up and laboratory testing\nafter transition to oral therapy and discharge to home are discussed in Question X. Total duration of\nantimicrobial therapy is addressed in Question XII.\nIf oral antimicrobial therapy is not feasible, transitioning from an acute care hospital to OPAT rather\nthan the child remaining in the hospital to complete the needed course of therapy may reduce\nharms and costs associated with unnecessary and prolonged hospital stay.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 297,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_298",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "harms and costs associated with unnecessary and prolonged hospital stay.\nBased on limited data and the broad experience of many panel members, the Guideline Panel\nconsensus is that most children with presumed ABA, with no pathogen identified, and no alternative\nplausible etiology for arthritis, may successfully be transitioned to oral therapy using the same\ncriteria as for those with a pathogen identified, choosing an oral regimen with equivalent coverage\nto the intravenous regimen that led to improvement.\nResearch Needs\nThe consensus of the Guideline Panel is that the available pool of clinical data from comparative\neffectiveness and observational studies, inclusive of short term and long-term effectiveness and",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 298,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_299",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "effectiveness and observational studies, inclusive of short term and long-term effectiveness and\nadverse events, is substantial and supports routine transition to oral regimens for completion of\ntherapy for both osteomyelitis and ABA. Therefore, randomized controlled trials (RCTs) comparing a\nfull treatment course with parenteral therapy, compared with early switch to oral therapy, would not\nappear to meet current ethical standards concerning clinical equipoise (assumption that there is not\none “better” intervention), or not exceeding minimal risk within a randomized group (longer IV\ntherapy is likely to have a higher risk of adverse effects without added benefit), or justice (use of fair\nand equal medical treatment). However, data are needed to better understand whether and/or what",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 299,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_300",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "and equal medical treatment). However, data are needed to better understand whether and/or what\nprecise quantitative change in cytokine/chemokine profiles, or various types of biomarker panels,\ncould be useful as a reliable indicator for optimal timing of transition to oral therapy. Comparative\nstudies for oral switch can be conducted, particularly with newer oral antimicrobial agents. Such\nstudies would be most helpful if data are stratified by specific joints and by specific pathogens,\naddressing both short term and long-term outcomes. Multicenter collaboration with pre-specified\nmanagement protocols and data collection would likely be necessary. Studies that address\nscenarios for which oral therapy may be appropriate for the full course of treatment also are\nneeded.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 300,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_301",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "needed.\nXII. For children with presumed or confirmed ABA, what duration of therapy with antimicrobial\nagents is recommended?\nRecommendations:\n1. . In children with confirmed primary ABA without adjacent osteomyelitis with rapid clinical\nimprovement and consistent, progressive decrease in CRP by the end of the first week of\ntreatment, we suggest treating for a total duration of antimicrobial therapy (parenteral plus oral)\nas short as 10 to 14 days for common pathogens (S. aureus, S. pyogenes, S. pneumoniae, and\nH. influenzae type b), rather than for longer courses of 21 to 28 days (conditional\nrecommendation, low certainty of evidence). Comment: For children with slower clinical\nresponse, inadequate source control, or persistently elevated CRP, courses of therapy of 21 to",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 301,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_302",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "response, inadequate source control, or persistently elevated CRP, courses of therapy of 21 to\n28 days may be preferred. Such longer durations may be more commonly required when\ninfection is caused by pathogens with relatively less antibiotic susceptibility or greater\nvirulence, particularly enteric or non-fermenting Gram-negative bacilli and some S. aureus\nstrains (e.g., USA300 or similarly virulent strains, whether MSSA or MRSA). Children with ABA\nwith adjacent osteomyelitis should be treated according to the osteomyelitis guideline [37].\n2. In children with presumed primary ABA without adjacent osteomyelitis with rapid clinical\nimprovement and consistent, progressive decrease in CRP by the end of the first week of",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 302,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_303",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "improvement and consistent, progressive decrease in CRP by the end of the first week of\ntreatment, we suggest treating for a total duration of antimicrobial therapy (parenteral plus oral)\nas short as 10 to 14 days rather than for longer courses (conditional recommendation, very low\ncertainty of evidence). Comment: For children with slower clinical and laboratory responses,\nlonger courses of therapy may be preferred, as noted above.\nSummary of Evidence\nThese treatment recommendations apply to children with ABA (presumed or confirmed) who do not\nhave adjacent osteomyelitis. When osteomyelitis is present, treatment recommendations for it,\nwhich include longer treatment duration, supersede these recommendations [37].",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 303,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_304",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "which include longer treatment duration, supersede these recommendations [37].\nTraditional durations of antibiotic therapy for ABA without adjacent osteomyelitis in children were at\nleast 3 weeks for S. aureus, and 14 to 21 days for other common pathogens. Our literature review\nrevealed one prospective multicenter randomized controlled trial conducted in Finland 1983 through\n2005 which compared the efficacy of short (10 to 15 days) versus long (30 days) course\nantimicrobial treatment of culture-positive ABA in children without evidence of osteomyelitis (see\nTable 7 ). Both arms of this study included two to four days of parenteral antibiotics followed by\nhigh dose oral antibiotics for the rest of the assigned duration of treatment. Antibiotics were stopped",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 304,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_305",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "in the short-term group when there was evidence of clinical recovery and the CRP had declined to <\n20 mg/L (< 20 mg/L was considered normal). The outcomes of interest were full clinical recovery\n(having no signs or symptoms of ABA at the end of the follow up period, with no re-administration of\nantimicrobial therapy for an osteoarticular indication since treatment completion) and the absence\nof disease or sequelae after discontinuation of antibiotic treatment during follow up ranging from 2\nweeks to 12 months [55]. A total of 200 children aged 3 months to 15 years old presenting with\npresumed ABA were randomized, and outcomes for 130 were analyzed (47 were excluded due to\nthe lack of isolated organism and 23 due to adjacent osteomyelitis); 63 were assigned to the",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 305,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_306",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "the lack of isolated organism and 23 due to adjacent osteomyelitis); 63 were assigned to the\nshortterm treatment group (median 10 days total, IQR 10-15 days) and 67 to the long-term treatment\ngroup (all treated 30 days total). Children in both groups received IV antimicrobial therapy for a\nmean of 3 days prior to switching to oral therapy. Baseline characteristics appeared comparable\nbetween the groups with overall median age being 6.2 years old. The joints most frequently affected\nwere the hip (36.9%), knee (24.6%) and ankle (23.1%); the main causative agents were MSSA\n(58.5%; none were MRSA), Hib (17.7%), S. pyogenes (12.3%) and S. pneumoniae (8.5%). Invasive\nprocedures consisted of percutaneous aspiration in most children (n=110), and needle lavage (n=7).",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 306,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_307",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "procedures consisted of percutaneous aspiration in most children (n=110), and needle lavage (n=7).\nSixteen children underwent surgical procedures (arthrotomy (n=15) and arthroscopy (n=1)) [55].\nAfter initial joint aspiration and antimicrobial therapy, the sequential CRP levels of both groups\nfollowed similar curves and time to normalization, but more children in the short-term group\nexperienced full clinical recovery at 2 weeks compared with the long-term group (53/63 (84.1%) vs\n46/67 (68.7%), p-value 0.04), which could indicate a degree of failure of randomization or\ndifferences in surgical management between the 2 groups. At subsequent follow-up visits (3 months\nand 12 months), all 130 children experienced full recovery without evidence of recurrence of",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 307,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_308",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "and 12 months), all 130 children experienced full recovery without evidence of recurrence of\ninfection or sequelae. One patient in the long-term group experienced 2 late recurrences, with the\nfirst at 17 months after the initial episode. Ten days of antimicrobial therapy with evidence of clinical\nrecovery and CRP decline to <20 mcg/L resulted in equivalent outcomes (full recovery with no\nincrease of recurrence of infection and sequelae), compared with those treated for 30 days. The\ncertainty of evidence was rated as low due to the risk of bias (potential failure of randomization due\nto exclusion of 70 patients for culture-negative or adjacent osteomyelitis) and imprecision (very few\nadverse outcome events in either group and relatively small sample sizes) [55].",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 308,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_309",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "adverse outcome events in either group and relatively small sample sizes) [55].\nIn a prospective observational study of a shortened antimicrobial regimen with 33 children with ABA\nalone, 27 children were switched to oral therapy within 6 days. Thirty (91%) received total\nantimicrobial courses of 3 weeks, with 3 receiving longer total courses. Microbial etiologies were\nidentified in 26 (79%), of which 7 were S. aureus and 13 were streptococcal spp. None had sequelae\nevident one year after treatment [56].\nAmong 95 children with ABA alone in a retrospective observational study of transition to oral\ntherapy, the median duration of antimicrobial therapy was 15 days [IQR: 15 to 17] [276]. Ten (11%)",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 309,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_310",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "therapy, the median duration of antimicrobial therapy was 15 days [IQR: 15 to 17] [276]. Ten (11%)\nwere given total courses >21 days. Oral transition criteria were a minimum of 2 days of IV therapy,\n24 hours without fever, improvement in clinical findings, and CRP < 20 mg/L. A minimum total\ncourse of 15 days of antimicrobial therapy was specified, with longer durations at the discretion of\nthe treating clinicians based on clinical findings. On follow-up for at least two years, one (1%) had\nresidual pain from an arthrotomy scar with normal MRI results. No others had any sequelae.\nFollowing serial ESR values appears to have little value for determination of duration of therapy for\nchildren with ABA as it often remains elevated for 3 to 4 weeks or longer, even in children with rapid",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 310,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_311",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "clinical recovery [55, 56].\nPathogen-Specific Information\nABA caused by S. aureus, S. pyogenes, S. pneumoniae or Hib may be treated for 10 to 14 days if\nrapid clinical improvement and CRP decline (e.g., <20 mcg/L) are evident, based on the data from\nFinland as described above [55, 195, 262]. Treatment duration does not need to be prolonged for\nthose children with bacteremia at the time of diagnosis [275], when 1) bacteremia resolves quickly\nand is attributable to the infected joint as the source, and 2) there are no additional clinical findings\nthat raise concern for associated endovascular infection (septic thrombophlebitis) or endocarditis.\nThese shorter-course data may not apply when primary ABA is caused by more virulent, clinically",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 311,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_312",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "These shorter-course data may not apply when primary ABA is caused by more virulent, clinically\naggressive strains of S. aureus that may be associated with disseminated infection and poor\nresponse to surgical and antibiotic treatments. In the past two decades, such S. aureus strains have\noften been identified as belonging to the USA300 lineage (whether MRSA or MSSA) [282]; such\nstrains were not circulating in Finland at the time of the reports of these longitudinal multicenter\nstudies [55, 195, 275]. Determination of clonal designation of more virulent pathogens is primarily an\nepidemiologic and research endeavor and not part of routine clinical laboratory reporting available\nto treating clinicians. Ultimately, the clinical course (pace of response to interventions) plus",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 312,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_313",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "to treating clinicians. Ultimately, the clinical course (pace of response to interventions) plus\nsupporting laboratory data are the primary guides to duration of therapy for primary ABA caused by\nS. aureus rather than a specific antimicrobial susceptibility phenotype.\nDefinitions of “uncomplicated” vs “complicated” cases of primary ABA have not been standardized.\nTherefore, no prospective controlled studies have been conducted to determine the appropriate\nduration of therapy in “complicated” cases caused by specific pathogens at specific joints. Without\nevidence for benefits and risks of short vs long duration of therapy in “complicated” ABA, longer\ntreatment courses of at least 21 to 28 days are considered reasonable, particularly for those cases",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 313,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_314",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "treatment courses of at least 21 to 28 days are considered reasonable, particularly for those cases\ncaused by more resistant pathogens with a slow clinical and laboratory response to surgical and\nmedical therapy.\nK. kingae has been increasingly reported as an etiology of ABA, most commonly in children 6 to 48\nmonths of age [191, 283, 284]. These infections usually are not severe and are characterized by\nlower fever (even afebrile), with fewer local signs of inflammation, and lower peak CRP values [95,\n105] than those caused by the other common ABA pathogens. Response to treatment tends to be\nrapid. Specific prospective studies have not been conducted to determine the appropriate duration\nof therapy with antibiotics that demonstrate in vitro efficacy for K. kingae, but antibiotic treatment",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 314,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_315",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "courses reported for other common ABA pathogens (IV plus oral) appear to be effective based on\nlack of data on reports of antibiotic failure and the fact that resolution of disease may occur\nfollowing surgical management, without specific antibiotic therapy [24]. Approximately 5% of strains\nof K. kingae produce beta-lactamase and may not be susceptible to ampicillin or first generation\ncephalosporins, but we are not aware of reports of treatment-failure with these antibiotics [285].\nInvasive N. meningitidis infections, including meningitis, have been successfully treated with short\ncourses (4 days) of parenteral ceftriaxone [239, 286-288]. Data on the effectiveness of a specified\ntreatment course of antibiotics for meningococcal ABA is complicated by the different clinical",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 315,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_316",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "treatment course of antibiotics for meningococcal ABA is complicated by the different clinical\npresentations (primary ABA vs a manifestation of disseminated meningococcal disease) and the\noccurrence of noninfectious inflammatory complications, e.g., reactive arthritis, which may\ncomplicate the decision regarding surgical and medical management of these infections [8].\nPublished data do not specifically address pediatric primary meningococcal ABA. Administration of\na 4-day course of parenteral penicillin or ceftriaxone was successful for treatment of 8 patients\n(mostly adults) with primary meningococcal ABA without meningitis, out of 522 reported with\ninvasive meningococcal infection. None of these patients required surgical drainage [239].",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 316,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_317",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "invasive meningococcal infection. None of these patients required surgical drainage [239].\nHowever, some studies have used 14-day courses [238, 240]. Some experts will transition children\nto oral antibiotics using clinical and laboratory parameters described for other pathogens, but\nlimited published data exist.\nPrimary gonococcal arthritis is common in sexually active adolescents; it is typically monoarticular\nand associated with positive synovial cultures and negative blood cultures. When associated with\nbacteremia, there may be involvement of multiple small joints. Higher doses of ceftriaxone are now\nrecommended for initial treatment until results of susceptibility testing are available [244]. For fully",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 317,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_318",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "susceptible strains, treatment may be completed with oral antibiotics, usually cefixime or\nfluoroquinolones, for a total course of 7 to 10 days. More data are needed on the duration of therapy\nand feasibility of oral treatment of antibiotic resistant organisms [243, 244].\nABA due to non-typhoidal Salmonella spp, is seen primarily in developing countries and is typically\nfood- or water-borne [131, 289]. Underlying hemoglobinopathy including sickle cell disease is also a\nrisk factor. Reptile pet-associated Salmonella infections have also been reported in the United\nStates [246]. These very limited data suggest these infections may need to be treated for 4 – 6\nweeks. ABA can also be a manifestation of Brucella infections. Treatment for at least 45 days is",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 318,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_319",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "weeks. ABA can also be a manifestation of Brucella infections. Treatment for at least 45 days is\nrecommended for pediatric brucellosis [248, 290].\nPresumed ABA\nIn a retrospective study of 89 children 2002 through 2014 in Philadelphia, PA, with presumed ABA\nbut no identified pathogen, without adjacent osteomyelitis, various antimicrobial regimens were\nused with median duration of 24 days [IQR 22 to 26] [24]. Sixty (67%) were transitioned to oral\ntherapy, with 51 (85%) receiving an agent active against MRSA. Younger children, recognized to be\nat risk for K. kingae, only received an agent active against this microbe 18% of the time. There were\nno relapses after hospital discharge or disability evident at 6-month follow-up.\nRationale for Recommendation",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 319,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_320",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Rationale for Recommendation\nThe available data indicate that the outcome of previously healthy children older than 3 months of\nage with culture proven ABA due to common pathogens treated for a total duration of 10 days is not\ndifferent to those treated for 30 days, if clinical and CRP improvement is documented. This is\ntypically accomplished by 2 to 4 days of initial parenteral antibiotic therapy followed by transition to\noral therapy. Use of shorter course antibiotics is anticipated to be safer and result in less impact on\nantibiotic resistance and microbiome diversity. It is also likely to be less expensive, allow for care\nproviders to return to work earlier and facilitate the child’s return to school and other daily activities.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 320,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_321",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "There are very limited data on the management of ABA caused by: 1) more virulent S. aureus strains,\nsuch as the USA 300 strain, whether MRSA or MSSA; for less common pathogens; and 2)\npathogens with decreased susceptibility (higher minimum inhibitory concentrations, in vitro) to\nantibiotics (including Enterobacterales, and oxidase-positive Gram-negative pathogens). For more\nsevere infections (e.g., “complicated ABA”) as determined based on initial clinical and laboratory\nparameters and on the clinical course on therapy, a total duration of at least 3 to 4 weeks,\ndetermined on a case-by-case basis, is reasonable until additional data are available.\nThere are no data specific to shorter versus longer courses of treatment of children with presumed",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 321,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_322",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "There are no data specific to shorter versus longer courses of treatment of children with presumed\nABA with no pathogen identified. The Guideline Panel consensus is that total duration of therapy\nmay be based on the observed response from clinical and laboratory data, with treatment durations\nas short as 10 days.\nResearch Needs\nThere is an ongoing need for prospective studies of duration of therapy stratified by pathogen\n(including susceptibilities to particular antimicrobial agents) and involved joint. Multicenter\ncollaborations with pre-specified management protocols and data collection will likely be necessary.\nPathogens for which it may be more difficult to achieve microbiologic cure, such as Salmonella spp,",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 322,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_323",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Pathogens for which it may be more difficult to achieve microbiologic cure, such as Salmonella spp,\nshould be investigated for the appropriate duration of therapy. Collaborative efforts to develop\ndefinitions of uncomplicated and complicated primary ABA may help guide future design of clinical\ntrials that may better inform clinical decision-making about duration of therapy with specific\nparenteral and oral antibiotics.\nXIII. Are follow-up imaging studies needed to assess the response to and duration of therapy for\nprimary ABA?\nRecommendation:\nIn children with primary ABA with expected improvement during medical management with or\nwithout surgical intervention, associated with full clinical recovery, we suggest against routine",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 323,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_324",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "without surgical intervention, associated with full clinical recovery, we suggest against routine\nfollow-up imaging (conditional recommendation, very low certainty of evidence). Comment: In\nsituations where there is any clinical concern for previously undetected adjacent osteomyelitis, a\nplain film may be considered just prior to cessation of antimicrobial therapy if osteomyelitis was not\nreasonably excluded by advanced imaging studies (e.g., MRI) earlier in the course.\nSummary of Evidence\nA small proportion of children initially diagnosed with primary ABA without signs suggestive of\nadjacent osteomyelitis may actually have adjacent osteomyelitis or subsequent development of\nosteomyelitis that may not be clinically apparent at the time of presentation [62, 88, 291]. Our review",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 324,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_325",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "of the literature did not identify any prospective systematic studies evaluating the utility or\ncomparison of outcomes of routine end of therapy follow-up imaging, whether using plain films or\nadvanced imaging studies, among children with primary ABA for whom adjacent osteomyelitis had\nnot been identified earlier in the therapeutic course.\nIn a series of 96 children ages 1 month to 12 years old with ABA and follow-up plain films at two\nweeks and six weeks after presentation, 21 had radiographic changes in an adjacent bone at 2\nweeks and 10 others developed changes by six weeks [291]. Among 91 who returned for a 12-week\nevaluation, none had new findings indicative of associated osteomyelitis. MRI was not available in\nthis study and Salmonella spp were the dominant pathogens.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 325,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_326",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "this study and Salmonella spp were the dominant pathogens.\nOne study provided follow-up plain film data on 42 children identified as having confirmed ABA with\nadjacent osteomyelitis by clinical and imaging findings during initial evaluation [62]. Of these, 33\n(79%) had follow-up plain films that showed evidence of osteomyelitis. Follow-up plain radiographs\nin one (11%) of 9 with confirmed ABA without evidence of adjacent osteomyelitis on initial\nevaluations showed features consistent with presence of osteomyelitis on follow-up radiograph.\nMRI has high but imperfect sensitivity (81 to 100%) for the presence of osteomyelitis but is superior\nto CT scan for detection of changes suggestive of osteomyelitis. MRI results that are negative for",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 326,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_327",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "to CT scan for detection of changes suggestive of osteomyelitis. MRI results that are negative for\nosteomyelitis obtained early in the course of suspected ABA may not fully exclude the presence of\nadjacent osteomyelitis [37]. For review of imaging considerations for children with ABA when there\nare concerns for adjacent osteomyelitis, see Question II.\nRationale for Recommendation\nIn circumstances where an MRI was obtained early in the clinical course and demonstrated no\nevidence of osteomyelitis adjacent to the infected joint, with a clinical course demonstrating an\nexpected, rapid improvement without complications, adjacent osteomyelitis is very unlikely.\nIn circumstances where an MRI was not obtained during the treatment course and initial plain",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 327,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_328",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "In circumstances where an MRI was not obtained during the treatment course and initial plain\nradiographs showed no evidence of osteomyelitis, a low risk of osteomyelitis still exists, even in\nclinical courses with rapid responses to therapy. Plain radiographs of the bones adjacent to the\ninfected joint for children with full recovery are not routinely necessary. However, the risks of\nadjacent osteomyelitis for ABA caused by certain pathogens (MRSA) in certain joints (hips, knees)\nhave not been prospectively defined, and may be greater than expected for less virulent pathogens\n(K. kingae).\nThe collective clinical experience of the Guideline Panel supports this conditional recommendation\nagainst routine follow-up imaging, but the Guideline Panel recognizes that the evidence base for",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 328,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_329",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "against routine follow-up imaging, but the Guideline Panel recognizes that the evidence base for\nmaking a recommendation for or against obtaining plain radiographs at end of therapy is very weak.\nOur literature review also did not find reports of cases of relapse of infection after standard\ntreatment courses for primary ABA due to the inadequacy of these regimens for occult adjacent\nosteomyelitis. It is also possible that early osteomyelitis, not clinically suspected or detected by\nimaging, may have been treated adequately with the 3-week duration previously recommended for\nABA.\nOn rare occasions MRI imaging is reasonable, based on considerations of underlying comorbid\nconditions, or concerning clinical or laboratory findings for a particular child.\nResearch Needs",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 329,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_330",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "conditions, or concerning clinical or laboratory findings for a particular child.\nResearch Needs\nAdditional controlled, prospective studies of factors are needed to assess and quantify the risk of\nadjacent osteomyelitis, by pathogen and by involved joint, when the initial presentation is consistent\nwith primary ABA. Additional data on long term sequelae from primary ABA are needed, also\nstratified by pathogen, and involved joint. Multicenter collaborations likely will be required for such\nstudies.\nXIV. For children with presumed or confirmed ABA who do not respond to therapy, or relapse\nfollowing completion of therapy, which interventions are appropriate to optimize outcomes?\nRecommendations:\n1. For children with presumed or confirmed ABA either experiencing primary treatment failure, or",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 330,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_331",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "1. For children with presumed or confirmed ABA either experiencing primary treatment failure, or\nearly or late recurrence:\nClinicians should assess adequacy of the antimicrobial regimen (spectrum of activity,\ndosage, and antibiotic exposure at the site of infection, adherence) and of joint\ndebridement and irrigation before deciding on the need to broaden the spectrum or to\nrestart antimicrobials (Good Practice Statement)\nClinicians should assess the need for additional diagnostic evaluation for possible adjacent\nosteomyelitis, along with any need for surgical intervention for therapeutic and/or\ndiagnostic purposes (Good Practice Statement). Comment: The initial diagnosis of primary\nABA may need to be reconsidered\nSummary of Evidence",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 331,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_332",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "ABA may need to be reconsidered\nSummary of Evidence\nFailure to ultimately achieve clinical and microbiologic cure is rare among children with ABA, and\nespecially primary ABA [55, 67, 87, 230, 292]. When failure does occur, clinical patterns include: 1)\nfailure to respond to initial therapy (primary failure); 2) a good clinical response to initial therapy but\nrecrudescence during therapy (secondary failure); or 3) relapse/recurrence of infection weeks to\nmonths after completion of therapy. This aspect of management has not been systematically\nstudied, likely due to its relative infrequency at any given center.\nPrimary treatment failure in a child with confirmed or suspected ABA is defined by lack of",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 332,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_333",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Primary treatment failure in a child with confirmed or suspected ABA is defined by lack of\nimprovement of local (i.e., overlying erythema or edema, tenderness, limitation of range of motion)\nand/or systemic signs of infection (i.e., persistent fever that is not trending downward, or ongoing\nclinical signs of sepsis) two to four days after initiation of presumed adequate antimicrobial therapy,\nwith or without definitive surgical/procedural intervention. Lack of expected improvement of\ninflammatory markers (e.g., reduction in serum CRP concentration), particularly in the context of\nlack of clinical improvement, may also indicate primary treatment failure. Secondary treatment\nfailure may occur early in the course after a few days of apparent clinical improvement or after",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 333,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_334",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "failure may occur early in the course after a few days of apparent clinical improvement or after\nhospital discharge while on the selected outpatient antimicrobial regimen.\nThe presence of unrecognized adjacent osteomyelitis may be an important risk factor for relapse of\nABA after an apparently successful treatment course. This has been described for multiple joints\nand multiple microbial etiologies [293-295]. Data on other risk factors for treatment failure or\nrelapse are very limited.\nAmong 89 children with culture negative arthritis of presumptive bacterial etiology, without adjacent\nosteomyelitis, 8 (9%) required a change in antimicrobial therapy for clinical worsening or failure to\nimprove within 48 hours of starting the initial regimen. Two required a repeat drainage procedure.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 334,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_335",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "improve within 48 hours of starting the initial regimen. Two required a repeat drainage procedure.\nNo risk factors for failure were identified. There were no relapses after hospital discharge and no\ndisability evident at 6-month follow-up [24].\nRisk of treatment failure in a series of 74 children with ABA of the knee treated with antibiotics and\nneedle aspiration alone was higher in children >3 years old and in children of any age with serum\nCRP concentration >20 mg/L [125]. Nine (21%) in a series of 42 children with ABA of the hip treated\nwith single or multiple needle aspirations required subsequent open procedures due to failure to\nimprove. Increasing age, especially >10 years old, was a risk factor for failure of joint aspiration\nalone (with no other invasive procedures) [199].",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 335,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_336",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "alone (with no other invasive procedures) [199].\nTwo uncommon bacterial etiologies are particularly prone to relapse or delayed recovery, Brucella\nand Borrelia. Relapse was observed in 12 (14%) of 87 children with brucellosis with osteoarticular\ninvolvement after various 6-week courses of therapy. Relapses sometimes occurred in different\njoints from the initial infection [296]. Lyme arthritis in children can be slow to resolve and may\nrequire more intensive anti-inflammatory treatments than nonsteroidal agents in a small minority of\ncases [111, 297].\nPrimary and secondary failure that is not due to unrecognized adjacent osteomyelitis can have\nmultiple causes, including:\nDosage (and resulting antibiotic exposure) of the prescribed antimicrobial regimen is inadequate",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 336,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_337",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Dosage (and resulting antibiotic exposure) of the prescribed antimicrobial regimen is inadequate\nfor the infection being treated\nThe prescribed antimicrobial regimen is not being administered appropriately (e.g.,\nadministration errors, non-adherence)\nThe pathogen is resistant to the current antibiotic regimen\nEmergence of resistant organisms during therapy\nThe involved joint space has not been adequately drained\nThere is an undrained soft tissue focus of infection (e.g., pyomyositis) adjacent to the joint\nThere is a remote/metastatic focus of infection that requires surgical intervention\nThere is a new, unrelated infection (e.g., intercurrent viral infection or new bacterial wound\ninfection)\nThe etiology of joint inflammation is non-infectious (e.g., reactive, auto immune)",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 337,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_338",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "infection)\nThe etiology of joint inflammation is non-infectious (e.g., reactive, auto immune)\nReconsideration of the spectrum of the empiric antibiotic regimen may be necessary for children\nwith primary or secondary treatment failure. once the microbial etiology and its antibiotic\nsusceptibilities are known, inappropriate antibiotic selection or dosage should be corrected. If the\nregimen is deemed appropriate, then additional imaging (e.g., MRI) may be warranted, to diagnose\npossible adjacent osteomyelitis, or secondary sites of infection. [37].\nIf no pathogen has been initially identified, obtaining additional cultures and tissue for\nhistopathology and molecular pathogen detection from the involved joint(s), should be strongly",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 338,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_339",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "histopathology and molecular pathogen detection from the involved joint(s), should be strongly\nconsidered, particularly if imaging documents persisting collections of fluid within the joint.\nObtaining specimens for testing prior to changing the antibiotic regimen is suggested when clinically\nfeasible.\nFor children with secondary failure following hospital discharge, assessment of adherence is\nnecessary, whether the route of administration of the prescribed regimen is oral or IV. For\noutpatients on oral therapy, other factors may impact absorption of antibiotics, such as viral\ngastroenteritis. Repeat imaging studies may be necessary in these cases as well.\nPersistent bacteremia is often due to occult secondary foci of infection (e.g., pyomyositis,",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 339,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_340",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Persistent bacteremia is often due to occult secondary foci of infection (e.g., pyomyositis,\nsubperiosteal abscess) or an associated deep vein thrombosis. Persistent bacteremia can be the\nresult of or lead to complications and metastatic spread of infection [298]. Evaluation for\nuncontrolled sources of infection (e.g., the involved joint(s), adjacent bones and soft tissues,\npotential remote sites) should be considered. When bacteremia persists 48 to 72 hours into the\ncourse of antimicrobial therapy (particularly in the child with poor clinical response), the panel\nsuggests obtaining MRI of the site(s) of infection to detect any foci of infection that may be\namenable to surgical drainage. Detection of deep vein thrombosis as a risk for bacterial",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 340,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_341",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "amenable to surgical drainage. Detection of deep vein thrombosis as a risk for bacterial\nthrombophlebitis may require specialized imaging and may impact choice of antibiotic regimens as\nwell as route and duration of therapy.\nLate relapse following appropriate antibiotic and surgical therapy for ABA is uncommon in the\nabsence of adjacent osteomyelitis, and evidence to support recommendations are not available. The\npotential for chronic osteomyelitis or misdiagnosis of an underlying rheumatologic condition as ABA\nshould be considered. Investigations similar to those outlined for primary and secondary failure as\ndetailed above may also be helpful, including new infection, or alternative, non-infectious\ndiagnoses.\nRationale for Recommendation",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 341,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_342",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "diagnoses.\nRationale for Recommendation\nA clinician may be challenged by a child who is not responding to what is believed to be the best\nantimicrobial and surgical therapy, regardless of the timing of onset of the new signs, symptoms,\nand laboratory values. This situation may occur in cases for which a definitive pathogen has been\ndetected. Potential causes that may be responsible for failure to respond include inadequate\nmedical or surgical therapy, presence of adjacent osteomyelitis that has not been detected, and/or\nerrors in diagnosis of a bacterial etiology of joint inflammation. Re-evaluation of the child should be\nconsidered, especially in scenarios of presumed ABA with no pathogen identified and without bone",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 342,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_343",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "considered, especially in scenarios of presumed ABA with no pathogen identified and without bone\ninvolvement, rather than empirically broadening antibacterial coverage or restarting antibiotics,\nwhich could place the child at unnecessary risk of additional antibiotic exposure and missed\nopportunities for appropriate management. Benefits of such reassessment are believed to be large\nand unequivocal.\nResearch Needs\nProspective studies that assess response to medical and surgical therapies, with stratification of\noutcomes by pathogen (including virulence factors and antibiotic susceptibilities), antibiotic dosing\nexposure, involved joints, severity of infection at presentation and complications during the clinical",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 343,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_344",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "course need to be performed to provide insights into rates of failure attributable to each component\nof management. The rarity of such events requires multicenter collaborations, with efforts required\nfor standardization of antibiotic therapy and approach to surgical management for both\n“uncomplicated” and “complicated” ABA. Better diagnostic methods for non-infectious causes of\narthritis (e.g., JIA) may allow alternative diagnoses to be made, without a need for additional imaging\nor surgical procedures.\nXV. How long do children with primary ABA require follow-up examinations to address sequelae\n(e.g., joint contractures, potential growth arrest) due to the infection?\nRecommendation:\nIn children with primary ABA, we suggest close follow-up by providers with expertise in",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 344,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_345",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "In children with primary ABA, we suggest close follow-up by providers with expertise in\nmanagement of musculoskeletal infections until the completion of antibiotic therapy and return of\nfunction in the infected joint (conditional recommendation, very low certainty of evidence).\nComment: For primary ABA that responds promptly to treatment, follow-up is not routinely required\nbeyond 2-3 weeks from the start of treatment. For children with ABA with adjacent osteomyelitis,\nsee 2021 PIDS/IDSA Guideline on Diagnosis and Management of Acute Hematogenous\nOsteomyelitis in Pediatrics [37].\nSummary of Evidence\nChildren with primary ABA should be followed during their therapy by those experienced in the",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 345,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_346",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Children with primary ABA should be followed during their therapy by those experienced in the\nmanagement of this disease. While direct consultation for follow-up needs with Pediatric Infectious\nDiseases and/or Pediatric Orthopedic specialists is preferred, indirect consultation with such\nexperts or others with experience managing joint infections (including by telephone) is\nrecommended when logistical and practical matters preclude direct consultation.\nSeveral studies provide long term outcome data that can partially inform follow-up needs after\npediatric ABA. The majority of children with ABA have excellent outcomes. Some have poor\nfunctional and/or radiologic outcomes but it is rare that these are severe [229, 230, 299]. Significant",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 346,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_347",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "complications that can arise include joint contractures and dysfunction, as well as bone growth\narrest. The rate of complications following ABA is approximately 10% overall [300, 301] among\nchildren with adjacent osteomyelitis [67, 87, 230, 292]. This may be due to more extensive tissue\ninjury from infection spreading into a joint from an adjacent epiphyseal osteomyelitis or as a\nconsequence of infection eroding through the physis into the joint from an initial metaphyseal site.\nLong term sequelae are uncommon in children with primary ABA. In a recent study, only 1 (0.7%) of\n134 children with primary ABA had an abnormality with a median of 36 days of follow-up after the\nend of therapy [87]. This child suffered physeal injury from hip infection caused by MSSA that led to",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 347,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_348",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "separation of the femoral epiphysis from the metaphysis two years later. A retrospective cohort\nstudy documenting various outcomes at the end of therapy found that, among 109 children with\nprimary ABA, 103 (95%) had full range of motion (FROM) and 93 (85%) had no pain at the end of\ntherapy (median of 25 days) [67]. Another retrospective study evaluating long term follow-up of 52\nchildren with primary ABA (32 children with ABA of the hip and 19 of the knee, with a mean follow-\nup of 8.5 and 7.7 years respectively) showed that no children had sequelae considered to be severe,\nbut 10 (31%) of those with hip infections and 9 (47%) with knee infections had findings considered\nto be of mild to moderate severity [299].",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 348,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_349",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "to be of mild to moderate severity [299].\nAmong children with ABA with adjacent osteomyelitis, long-term sequelae were evident in 40 (38%)\nof 105 with a median of 139 days of follow-up [87].\nChildren with primary ABA who have had a careful physical examination documenting their\nsubstantial improvement at the end of acute treatment for uncomplicated ABA at 10-14 days (i.e.,\nlacking pain, decreased swelling, substantially improved range of motion and function, and\ndecreased laboratory markers of inflammation if obtained) are likely at very low risk of sequelae\nduring childhood. Based on the limited literature and clinical experience, longer follow-up is not\nnecessary as the efforts, costs, and risks associated with ongoing follow up (including clinic visits,",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 349,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_350",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "laboratory investigations, and radiographs) appear to outweigh any potential benefits for detecting\nlong term sequelae for this group of children.\nComplications are more likely among certain subgroups with ABA and are usually clinically present\nand recognized at the end of antibiotic therapy. These include premature infants during the first\nmonths of life [302] and infants less than 6 months of age [303], as well as those with ABA of the\nhip or shoulder, and those with delay of diagnosis or definitive surgical management beyond 4 days\ninto treatment [69, 139, 304-306] or other delays in antibiotic therapy or sterilization of synovial\nfluid. Infection caused by resistant organisms, such as CA-MRSA, have been associated with",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 350,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_351",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "fluid. Infection caused by resistant organisms, such as CA-MRSA, have been associated with\nincreased risk of growth arrest of the femur in some series. It is unclear whether this finding is\nrelated primarily to delay in receipt of effective antimicrobial therapy or the presence of a more\nvirulent microbe (e.g., USA 300 S. aureus) in the hip joint [307]. Avascular necrosis of the femoral\nhead as a consequence of ABA of the hip was recognized way before the global spread of USA 300\nS. aureus during the past two decades.\nChildren with any limitation in joint function at the end of acute therapy (such as decreased joint\nrange of motion) should be followed closely by orthopedic specialists for complications or the need",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 351,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_352",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "range of motion) should be followed closely by orthopedic specialists for complications or the need\nfor ongoing management. Growth arrest can be typically detected within months from the initial\ninfection; monitoring for growth arrest may be performed as part of ongoing routine wellchildcare by\nprimary care providers as well as by orthopedic specialists. There are no data describing what can\nbe done to prevent growth arrest, but orthopedic procedures to manage growth arrest can be\nperformed if needed.\nRationale for Recommendation\nThis conditional recommendation is based on very low certainty of evidence, and places high value\non considerations of patient’s values and preferences, feasibility, acceptability, equity, and cost in",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 352,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_353",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "recommending that children with either presumed or confirmed primary ABA who have substantial\nrecovery at the end of acute management will not routinely require either orthopedic or infectious\ndiseases follow-up. The recommendation for ongoing orthopedic specialist follow-up for ABA in\nchildren who appear to have higher risk of long-term complications with joint or bone growth or\nfunction as outlined above, places high value on identifying complications early to allow for early\nintervention.\nResearch needs\nFuture research needs include comprehensive controlled prospective studies to identify which\nclinical and laboratory parameters will help identify children at risk of developing long-term\nsequelae of ABA, stratified by joint and causative pathogen.\nSupplementary Data",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 353,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_354",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "sequelae of ABA, stratified by joint and causative pathogen.\nSupplementary Data\nSupplementary materials (e.g., tables and figures) are available at the Journal of the Pediatric\nInfectious Diseases Society  online.\nNotes\nAcknowledgments: The expert panel expressed its gratitude for thoughtful reviews of an earlier\nversion by Drs. Sheldon Kaplan, Paul Krogstad, and Nicole Le Saux. The panel would also like to\nthank Drs. Theoklis Zaoutis and David Feldman for their contribution to the guideline. The panel\nthanks Genet Demisashi and Hannah Rehm for their continued support throughout the guideline\nprocess. The panel also expresses gratitude to librarian Elena Guadagno for her continued literature\nsupport throughout the development of the guideline.",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 354,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_355",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "support throughout the development of the guideline.\nFinancial Support: This work was supported by the Infectious Diseases Society of America and the\nPediatric Infectious Disease Society.\nPotential Conflicts of Interest: To provide thorough transparency, IDSA requires full disclosure of all\nrelationships, regardless of relevancy to the guideline topic. Evaluation of such relationships as\npotential conflicts of interest is determined by a review process, which includes assessment by the\nStandard and Practice Guidelines Committee (SPGC) Chair, and the Board of Directors liaison to the\nSPGC and, if necessary, the Conflict of Interest (COI) Ethics Committee. The assessment of\ndisclosed relationships for possible COIs is based on the relative weight of the financial relationship",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 355,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_356",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "(ie, monetary amount) and the relevance of the relationship (ie, the degree to which an association\nmight reasonably be interpreted by an independent observer as related to the topic or\nrecommendation of consideration). The reader of these guidelines should be mindful of this when\nthe list of disclosures is reviewed. C. H. A. serves as an advisory/consultant for Emergency Medicine\nand Halozyme; receives research funding from Merk and Co, AstraZeneca, and Theravance\nBiopharma; served as speakers bureau for Halozyme and Sanofi; held ownership interests in\nEmergency Medicine; and received research funding from Baxter International. S. R. A. served as an\nadvisory/consultant for Cubist Pharmaceuticals; received research funding from Pfizer, Enanta,",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 356,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_357",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "advisory/consultant for Cubist Pharmaceuticals; received research funding from Pfizer, Enanta,\nModerna, Regeneron and Contrafect, the Centers for Diseases Control and Prevention, Cubist\nPharmaceuticals, Pfizer, and the Urban Child Institute. A. A. receives research funding from Astellas\nPharmaceuticals, Melina Therapeutics, Merck and Co., Nabriva Therapeutics, Pfizer, and Rempex\nPharmaceuticals Inc.; receives organizational benefit from the Lon V. Smith Foundation; and served\nas an advisory/consultant for Astellas Pharmaceuticals and AstraZeneca. J. S. B. employer receives\nresearch funding from Merck and Co.; received research funding from Bayer, Cerexa Inc., Cubist\nPharmaceuticals, Astra-Zeneca, Pfizer, Allergan, and Trius; receives research funding from the",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 357,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_358",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Pharmaceuticals, Astra-Zeneca, Pfizer, Allergan, and Trius; receives research funding from the\nNational Institutes of Health (NIH); received organizational benefits from AstraZeneca, Cerexa Inc.,\nCubist Pharmaceuticals, and Trius; and served as a member on the HHS National Biodefence\nScience Board. M. A. C. M. served in an advisory/ consultant role for Karius, Inc. and Avalere Health;\nreceived research funding from BioCryst Pharmaceuticals, the Sanford Health Research Foundation,\nNIAID, Pfizer, Moderna, and ContraFect Corporation. A. C. served in an advisory/consultant role for\nCerexa, Inc., Merck and Co., the Cochran and Heidman Law Firms, GlaxoSmithKline, Insmed, for\nLamson, Dugan, and Murray Law Firm, Moderna Therapeutics, Seqirus, Inc., Novartis, and",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 358,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_359",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Lamson, Dugan, and Murray Law Firm, Moderna Therapeutics, Seqirus, Inc., Novartis, and\nSanofiPasteur; served in a promotional role for AstraZeneca, Merck and Co., GlaxoSmithKline,\nNovartis, Sobi, Inc., and Medimmune; has given expert testimony to the Cochran and Heidman Law\nFirms; received research funding from GlaxoSmithKline, Sanofi Pasteur, Merck and Co., Novartis,\nPfizer, and Hoffman and LaRoche, Inc.; and received organizational benefit from InterHealth\nNutraceuticals, Inc. L. A. C. received research funding from the Texas Scottish Rite Hospital. C. B. C.\nserves in an advisory/consultant role for Astellas Pharmaceuticals, Karius Diagnostics, Altimmune,\nNabriva, Horizon Therapeutics, and Premier Inc; served in an advisory/consultant role for Cerexa",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 359,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_360",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Nabriva, Horizon Therapeutics, and Premier Inc; served in an advisory/consultant role for Cerexa\nInc., Cubist Pharmaceuticals, GlaxoSmithKline, and Novartis; receives honoraria from UpToDate; and\nreceives or has received research funding from the Centers for Disease Control and Prevention,\nMerck and Co., the National Institutes of Health, Cerexa Inc., GlaxoSmithKline, and Pfizer. S. C. E.\nreceived research funding Pfizer and Roche. S. L. F. receives other remuneration from Shionogi;\nreceives research funding from the National Institutes of Health (NIH); and received research\nfunding from Cerexa Inc. and Roche. C. H. receives research funding from GlaxoSmithKline, Pfizer,\nand Merck and Co. and received research funding from Astellas Pharmaceuticals, GlaxoSmithKline,",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 360,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_361",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "and Merck and Co. and received research funding from Astellas Pharmaceuticals, GlaxoSmithKline,\nJohnson & Johnson, and Merck and Co. M. P. K. receives research funding from the National\nInstitutes of Health; serves on the Pediatric Infectious Diseases Society on their Board of Directors\nand pediatric committee on antimicrobial stewardship; and received research funding from the\nAcademic Pediatric Association, the Agency for Healthcare Research and Quality, and the National\nInstitutes of Health. V. L. has received past research funding from the Fonds de recherche du\nQuébec Research (FRQ-S). L. J. M. received research funding from the National Environmental\nEducation Foundation. J. R. serves in an advisory/consultant role for Westat; receives or has",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 361,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_362",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Education Foundation. J. R. serves in an advisory/consultant role for Westat; receives or has\nreceived past research funding from the Canadian Institute for Health Research; received\nrenumeration from Pfizer; and received research funding from Alberta Innovates and the\nCollaborative Antiviral Study Group. S. S. S. receives remuneration from McGraw-Hill Medical\nLippincott Williams and Wilkins and Elsevier Publishing; receives or has received past research\nfunding from Agency for Healthcare Research and Quality, the National Heart Lung Blood Institute,\nand the Children’s Hospital Association (formerly known as the Child Health Corporation of\nPhone: (703) 299-0200\nAmerica); and received research funding from the National Institute of Allergy and Infectious",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 362,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_363",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "America); and received research funding from the National Institute of Allergy and Infectious\nDiseases, the Patients Center Outcomes Research Institute, and the Robert Wood Johnson\nFoundation. C. R. W. receives honoraria from Up To Date, Inc.; served in an advisory/consultant role\nfor Cerexa, Inc., Wyeth, and Pfizer; received research funding from Pfizer and Wyeth; serves on the\nCommittee on Guideline Development for the American Academy of Pediatrics (AAP); was a\nmember of the editorial board for the AAP Grand Rounds; was Chair of the AAP Section on\nEpidemiology, Public Health and Evidence; served on the AAP Task Force on Policy Development\nProcess Improvement; and served on Board of Directors and as Treasurer and was an Associate",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 363,
      "total_chunks": 365
    }
  },
  {
    "chunk_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics_chunk_364",
    "document_id": "PIDS_IDSA 2023 Guidelines for Diagnosing and Managing Acute Bacterial Arthritis in Pediatrics",
    "text": "Process Improvement; and served on Board of Directors and as Treasurer and was an Associate\nEditor on the editorial board for the Journal of the Pediatric Infectious Diseases Society (JPIDS) for\nthe Pediatric Infectious Diseases Society (PIDS). All other no disclosures reported. All authors have\nsubmitted the ICMJE Form for Potential Conflicts of Interest. Conflicts that the editors consider\nrelevant to the content of the manuscript have been disclosed.\nReferences\nFor the full list of references, please visit the Journal of the Pediatric Infectious Diseases Society \nonline.\nBack to top\nAbout IDSA\n\nNews & Insights\n\nMembership & Community\n\n©2026 Infectious Diseases Society of America\n\n\n\n\n\n\nTerms of Use\nPrivacy Policy",
    "metadata": {
      "disease_type": "bacterial_arthritis",
      "year": 2023,
      "guideline_name": "PIDS/IDSA Acute Bacterial Arthritis Guidelines 2023",
      "section_header": "General",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 364,
      "total_chunks": 365
    }
  }
]